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DEFINITIONS
DEFINITIONS
ALLERGIC RHINITIS  is a symptomatic disorder of the nose, resulting from an IgE-
mediated inflammation of the membranes lining the nose, induced by allergen 
exposure.1 
INTERMITTENT ALLERGIC RHINITIS (IN UNTREATED PATIENTS):  allergic rhinitis 
with symptoms being present for less than 4 days a week or for less than 4 weeks.2
PERSISTENT ALLERGIC RHINITIS (IN UNTREATED PATIENTS):  allergic rhinitis with 
symptoms being present for more than 4 days a week and for more than 4 weeks.2
MILD ALLERGIC RHINITIS (IN UNTREATED PATIENTS):  allergic rhinitis with none of 
the following items being present:
• Sleep disturbance
• Impairment of daily activities, leisure and/or sport
• Impairment of school or work
• Troublesome symptoms.2
MODERATE-SEVERE ALLERGIC RHINITIS (IN UNTREATED PATIENTS):  allergic rhinitis 
with one or more of the following items being present:
• Sleep disturbance
• Impairment of daily activities, leisure and/or sport
• Impairment of school or work
• Troublesome symptoms.2
EVIDENCE-BASED MEDICINE  is the conscientious, explicit and judicious use of 
current best evidence in making decisions about the care of individual patients. 
It means integrating individual clinical expertise with the best available external 
clinical evidence from systematic research.3
OPINION-BASED MEDICINE  is medicine conducted based on unsystematically-
compiled opinions of experts, based on clinical trails and mechanistic approaches.
CLINICAL GUIDELINES  are systematically developed statements to assist 
practitioners and patients in making decisions about appropriate and effective 
healthcare in specific circumstances.4
DEFINITIONS
DISSEMINATION  is the targeted distribution of information and intervention 
materials to a specific public health or clinical practice audience. The intent is to 
spread knowledge and the associated (evidence-based) interventions.5 
IMPLEMENTATION  is the use of strategies to adopt and integrate (evidence-based) 
health interventions and change practice patterns within specific settings.5
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ALLERGIC RHINITIS: BURDEN 
OF DISEASE, DIAGNOSTIC AND 
THERAPEUTIC CHALLENGES AND 
THE NEED FOR GUIDANCE
13
INTRODUCTION
Allergic rhinitis (AR) is defined a symptomatic disorder of the nose, resulting 
from an IgE-mediated inflammation of the mucosal lining of the nose, induced 
by allergen exposure.1 The burden of disease for both the patient and the society 
goes far beyond the nasal symptoms of rhinorrhea, nasal congestion, sneezing and 
pruritus. Nevertheless, the condition often remains regarded as trivial, un(der)-
diagnosed and inadequately treated. Clinical practice guidelines aim to increase 
the awareness of AR and to optimize the diagnostic and treatment practices in 
order to improve the quality of patient care and healthcare outcomes. 
ALLERGIC RHINITIS PREVALENCE 
HAS RISEN TO EPIDEMIC PROPORTIONS
Whereas the world health is generally improving, the prevalence of chronic 
respiratory disorders (CRDs) is still increasing. CRDs involve asthma, chronic 
obstructive pulmonary disease, respiratory allergies, occupational airway diseases 
and pulmonary hypertension, and represent the epidemic challenge of the 3rd 
millenium. AR is the most common CRD and affects an estimated 600 million 
of people worldwide.2 Many large national and international studies3-7 have 
increased our knowledge on the epidemiology of AR. It is important to remark, 
however, that heterogeneous definitions and diagnostic criteria for AR have been 
used throughout these different studies, which complicates the interpretation 
and comparison of results.
Monocentric studies have reported a prevalence of AR ranging from 1 up to 
40 %.8 Large multicentric surveys have confirmed this tremendous variation in the 
prevalence of AR symptoms among children and adults throughout the world, 
and reported the highest prevalence rates of AR (between 15 and 40%) in Western 
lifestyle countries: Western Europe, Australia, New Zealand and the USA.3-4 
Prevalence figures for AR in Belgium from various epidemiological surveys are 
represented in TABLE 1 .
Although AR can occur at any age, most individuals develop the condition 
before the age of 20 years old9 and the disease is usually clinically most active 
in young adults.10 At child age, boys are more frequently affected than girls, at 
puberty this tendency reverses, and at adulthood men and women are equally 
affected.11
The prevalence of AR not only varies between regions and populations, but 
has also shown to vary over time. Over the last 40 years of the past millennium 
a steeply increasing trend in the prevalence of AR and other allergic diseases 
has been observed.12 In recent years, there are some signs that this increase has 
leveled off, as the prevalence seems to be stabilizing or even slightly decreasing 
in high prevalence areas,13-14 but still, a substantial rise in AR prevalence is noted 
in many countries undergoing rapid socio-economic development, where AR was 
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previously less common.5 Although it is well-established that allergic diseases tend 
to occur within families and have a genetic basis, changes in gene pool require 
numerous generations and can not explain the observed prevalence gradients 
and time trends. The recent increase in prevalence of AR and other allergic 
diseases is largely attributed to changes in environmental en lifestyle factors such 
as higher socio-economic status, urbanization, reduced family size, increased 
allergen exposure, reduced early life microbial exposure, diet changes such as 
early introduction of foods or formula and possibly also alcohol consumption, 
tobacco smoke exposure, indoor and outdoor pollution. To meet the challenge 
of the growing impact of allergy and to allow the introduction of individualized 
prevention strategies, further assessment of the complex interactions between 
risk factors, including gene-environment interactions, is required.18
TABLE 1.  Prevalence of  AR in Belgium as reported in dif ferent national 
and international  studies.  N= number of  (Belgian)  individuals recruited
Author/ 
Study Group
Year Study population AR diagnosis n Prevalence 
AR
ISAAC Children from 
randomly selected 
schools Antwerp area
Allergic 
rhinoconjunctivitis
ISAAC I4 1992-98 1515
5-7 years old
 
13-14 years old
Questionnaire for 
parents
Questionnaire for child
4.9%
 
14.5%
ISAAC III5 1999-04 5645
5-7 years old
 
13-14 years old
Questionnaire for 
parents
Questionnaire for child
5.8%
 
16.9%
Bauchau15 2001 Random general 
population sample 
≥ 18 years olds
1) Telephone interview
2) Clinical diagnosis and 
sIgE measurement
1) 1602
2) 187
28.5%
Bachert16 2003 Random general 
population sample 
≥ 15 years olds
1) Screening 
questionnaire
2) Detailed 
questionnaire
1) 4959
 
2) 754
29.8%
Blomme17 2008 Public fair visitors
3-88 years old
Skin prick test and 
clinical history
2320 30.9%
ALLERGIC RHINITIS IS ACCOCIATED WITH 
COMORBIDITIES AND UNDERLIES COMPLICATIONS
AR is not an isolated disease. Findings from basic science and epidemiological 
studies have demonstrated that AR is not restricted to the nasal airway, but 
is associated with multiple comorbidities including asthma, rhinosinusitis, 
conjunctivitis and probably also otitis media. At a local level, nasal inflammation, 
congestion and dysfynction predisposes to inflammation and infection in the 
adjacent anatomical areas, but over the last years, it has also become clear that AR 
is part of a systemic inflammatory process and that common causal pathways and 
interactions result in allergic inflammatory disorders at different mucosal levels 
throughout the body.8 
It is estimated that 42% of the patients with AR experience symptoms of allergic 
conjunctivitis and that 33-56% of the cases of allergic conjunctivitis occur in 
association with AR. This co-existence, referred to as ‘allergic rhinoconjunctivitis’, 
is a typical feature in patients with pollen allergy, where eye symptoms are 
present in up to 80% of the patients.19 There is also good evidence to support a 
link between sinus disease and AR, as underlying AR can be found in 25-30% of 
individuals with acute rhinosinusitis, 40-60% with unilateral chronic rhinosinusitis 
and up to 80% with bilateral chronic rhinosinusitis.20 Most epidemiological data 
also suggest an association between AR and otitis media, but controversy remains, 
as the available evidence is compromised by a possible patient referral bias and 
by a lack of prospective, controlled studies.21
Although the clinical association between AR and asthma was already 
described many centuries ago,22  the comorbid relationship between both 
diseases was misregarded until the end of the previous century. Since then, 
repeated epidemiological, histological, physiological and immunopathological 
links have been reported and the concept of (allergic) rhinitis and asthma as part 
of a united airway disease is now well-established.23 FIGURE 1 represents potential 
pathophysiological interactions between the nose and the lower airways.
20-40% of the patients with AR have clinical asthma, whereas up to 80% of 
the patients with asthma demonstrate symptoms of rhinitis.24 Both allergic and 
nonallergic rhinitis are risk factors for the development of asthma,25 but patients 
with sensitization to indoor or outdoor allergens,26 and patients with persistent 
and severe rhinitis27 are most prone to have asthma as a comorbidity. In addition, 
moderate-severe rhinitis is related to poor asthma control.28 Furthermore, 
it is important to consider that in patients with AR, even in case of subliminal 
exposure to the allergen(s) and in the absence of AR symptoms, a certain degree 
of inflammatory infiltration at the mucosal level persists. This ‘minimal persistent 
inflammation’29 synergizes with infective disease and explains why individuals 
with AR experience additional problems with viral colds, and with a higher rate 
and prolonged duration of respiratory symptoms.30 In children and adults the 
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combination of a respiratory viral infection, allergic sensitization and allergen 
exposure have shown to significantly increase the risk (odds ratio of respectively 
19 and 9) for hospital admisson for asthma exacerbation.11, 31, 32
FIGURE 1.  Potential pathophysiological interactions between the nose and the 
lower airways include the loss of nasal protective function, postnasal drip with 
pulmonary aspiration of nasal contents, the still contradictory presence of a 
nasal-bronchial reflex and probably most important: the systemic progression 
of local allergic inflammation. This bidirectional systemic inflammation is 
produced after local allergen provocation (in the nose or lower airways) leading 
to up-regulation and release of haemopoietic eosinophil/basophil progenitor 
cells from the bone marrow, which subsequently migrate to both nose and lungs 
and can undergo differentiation and activation. Adapted from Togias et al33.
Bone marrow
Systemic propagation
of local inflammation
Postnasal 
drainage of 
inflammatory 
material
Nasopharyngobronchial
reflexes (?)
Decreased nasal function
↑ Mouth Breathing
↓ Air warming and humidification
↑ Particle/irritant trapping
ALLERGIC RHINITIS IMPAIRS
THE QUALITY OF LIFE
AR comprises more than the classical symptoms of rhinorrhea, sneezing, nasal 
obstruction, itching and frequently associated non-nasal symptoms involving eye 
symptoms, sore throat, headache and cough. Both generic and disease-specific 
health-related quality of life (HRQOL) questionnaires have demonstrated that the 
disease causes a significant impairment of the physical, mental and psychosocial 
well-being in adults and children.34-35 Furthermore, AR has shown to be at least 
as bothering as asthma in the patient’s everyday life for concepts related to 
mental and social health, whereas asthma provides more physical limitations.36 
Poorly controlled symptoms of AR, especially nasal congestion, lead to sleep loss 
or disturbances and daytime fatigue and somnolence.37 
In the US, symptoms of AR are estimated to be responsible for a loss of about 4 
million  work and school days a year.38 Probably even more important than school 
and work absenteeism is presenteeism (being present, but not fully functioning), 
as it has well been demontrated that AR adversely affects the cognitive function,39 
learning and school performance40-41 and work productivity42. Participation in 
leisure, sport and social activities can also be compromised, which especially in 
children can lead to emotional disturbances inluding frustration, sadness and 
anger.43
Comorbid diseases associated with AR add to the impact on the patient’s 
quality of life. Adequate medical interventions have shown not only to improve the 
control of symptoms but also the health-related quality of life. However, certain 
treatments have also been found to provide increased functional impairments 
due to troublesome adverse events e.g. first-generation antihistamine-induced 
sedative effects.43
THE ECONOMIC CONSEQUENCES 
OF ALLERGIC RHINITIS ARE SUBSTANTIAL
Although the annual cost to manage AR might seem low relative to other chronic 
conditions, due to its high prevalence, AR poses a significant economic burden on 
the society. The overall healthcare costs, resulting from AR, comprise both direct 
and indirect costs. Direct costs are related to patient-care and include medical 
(e.g. medication, physician and hospital visits, diagnostic tests and medical 
procedures) and non-medical costs (e.g. transportation to and from healthcare 
provider, household modifications, special diets). Indirect costs are related to 
disease consequences, such as absenteeism and reduced productivity at work.44 
Estimates of the annual costs resulting from AR vary widely from study to study. 
This large variation is attributed to differences in identifying patients with AR, 
differences in cost calculations, limitations associated with available data (e.g. 
use of over-the-counter medications, complementary and alternative treatments) 
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and difficulties in assigning indirect costs of AR.45 The majority of studies, 
however, agree that especially the indirect costs of AR are tremendous, which 
can be explained by the fact that AR peaks during the highly productive years of 
individuals (20-40 years old).
In Europe, the direct yearly costs for AR were reported to approximate 1.286 
billion Euro, the indirect yearly costs 1.723 billion Euro.45 Most economic analyses 
of AR were performed in the US with annual estimates of the direct cost varying 
from $US1.6 billion to $US4.9 billion and estimates of indirect costs ranging from 
$US0.1 billion to more than $US9.7 billion.46 A large prevalence-based cost-of-illness 
study to estimate the direct healthcare costs for treating allergic rhinoconjunctivitis 
(as primary diagnosis) and/or associated comorbidities for all persons in the US in 
1996 has demonstrated that the cost of allergic rhinoconjunctivitis was increased 
by 3.7 to 4.9 times when the costs attributable to the comorbid conditions were 
included.44, 47
THE DIAGNOSTIC CHALLENGE
IN ALLERGIC RHINITIS
Rhinitis is characterized clinically by one or more of the following sympoms: 
rhinorrhea, nasal obstruction, nasal itch and sneezing. Additional nasal symptoms, 
including loss of smell, snoring and postnasal drip, are also frequently present. 
These symptoms, however, do not necessarily have an allergic origin. In about 
50% of the cases, rhinitis is caused by allergy. In the differential diagnosis, AR 
must be differentiated from several types of non-allergic rhinitis and other nasal 
conditions (TABLE 2) .
CLINICAL HISTORY
A comprehensive clinical history, not only assessing the nasal symptomatology, 
but also associated and comorbid symptoms, such as eye symptoms (which have 
shown to have a high predictive value for differentiating AR from other types of 
rhinitis), oral and pharyngeal hypersensitivity symptoms after contact with fresh 
fruits or vegetables (suggestive for oral allergy syndrome in patients with pollen-
induced AR) and lower airway symptoms is the first step in the (differential) 
diagnosis of AR. Special attention must be paid to symptoms not suggestive for AR 
and warranting specialist referral, such as unilateral nasal symptoms and recurrent 
epistaxis.  A thorough history documents allergic and non-allergic triggers, family 
and occupational history, the severity and duration of the problem, the impact on 
the quality of life and response to treatment.8, 11, 18
CLINICAL EXAMINATION
Clinical examination should include a thorough nasal examination. Anterior 
rhinoscopy can reveal typical changes in the nasal mucosa.  During allergen 
exposure, the nasal mucosa of patients with AR can demonstrate swelling, and 
often changes in colour, from a purplish to a more common pale coloration, and 
an increase in vascularity are seen (FIGURE 2) . In absence of allergen exposure, 
the nasal mucosa may appear completely normal, but in patients who have 
suffered from AR for several years, irreversible mucosal hyperplasia and/or 
viscous hypersecretion may also occur. Nasal endoscopy, usually performed 
by specialists, allows a more thorough examination of the nose, including the 
TABLE 2.  Differential  diagnosis  of  al lergic  rhinit is .  Adapted from Greiner 
et  al11 and International  Rhinit is  Management Working Group 48.
Allergic rhinitis 
Infectious rhinitis, acute and chronic rhinosinusitis 
Occupational rhinitis: allergic and non-allergic  
Drug-induced rhinitis: e.g. aspirin, nasal decongestants, cocain  
Hormonal rhinitis: puberty, pregnancy, menstruation, endocrine disorders 
Emotional rhinitis 
Atrophic rhinitis 
Irritants-induced rhinitis  
Food-induced rhinitis e.g. red pepper 
NARES: non-allergic rhinitis with eosinophilic syndrome 
Rhinitis associated with gastro-esophageal reflux 
Idiopathic rhinitis 
Mechanical factors 
 Deviated septum 
 Adenoid hyperplasia 
 Hypertrophic turbinates 
 Foreign bodies 
 Choanal atresia 
 Nasal valve dysfunction 
Nasal or central nerve system tumours 
 Benign 
 Malignant 
Multisystem diseases 
 Wegener’s granulomatosis 
 Sarcoidosis 
 Churg-Strauss syndrome 
Relapsing polychondritis 
 Systemic lupus erythematosus 
Ciliary defects 
Cerebrospinal rhinorrhea
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posterior nasal cavity and the middle meatus, which is not necessary to confirm 
AR, but to exclude other conditions, such as polyps, foreign bodies, tumours and 
septal deformations.8, 18
FIGURE 2.  Naso-endoscopic visualisation (right nasal cavity: Hopkins 30°) of 
nasal mucosa before and after allergen challenge in an allergic rhinitis patient. 
Image courtesy of Jean-Baptiste Watelet, MD, PhD.
Before allergen challenge After allergen challenge
ALLERGY TESTING
To confirm the allergic origin of rhinitis symptoms, specific IgE reactivity to 
airborne allergens needs to be recorded, via either skin-prick testing or by 
measuring specific IgE in serum. Both tests are of similar value, with a good 
sensitivity and specificity. Skin prick tests allow a wider selection of allergens, 
provide results within 20 minutes (whereas specific serum IgE measurements 
can take several days) and are more cost-effective than serum specific IgE testing. 
Specific serum IgE measurement, however, is the test of choice when the patient 
has dermographism or widespread dermatitis, when the patient is non compliant 
for skin testing or did not discontinue oral antihistamine treatment. The results of 
the allergy tests, however, must always be interpreted with the patient’s history 
and clinical examination in mind. False positive and false negative allergy tests can 
occur, individuals can demonstrate sensitization without clinical symptoms of AR 
and some sensitizations can be irrelevant.11
Total serum IgE measurement lacks of specificity and has a poor predictive 
value for underlying allergy in rhinitis patients.
Nasal challenge tests are especially used for research purposes and are 
important in the diagnosis of occupational rhinitis.
DIAGNOSTIC ASSESSMENT OF COMORBIDITIES
The presence of comorbidities should also be assessed throughout the clinical 
history and clinical examination and if necessary additional investigations have to 
be performed (e.g. imaging of the paranasal sinuses, lung function measurement).
THE THERAPEUTIC CHALLENGE 
IN ALLERGIC RHINITIS
The therapeutic approach to AR includes patient education, environmental 
measures, pharmacotherapy and consideration of immunotherapy. Surgery 
is rarely needed. Optimal treatment is important, not only  to obtain symptom 
control, but also to improve the quality of life, the academic and work performance 
and to minimize the risk of the development or exacerbation of comorbidities. 
Cost-effectiveness is also an important treament attribute, but, to date, there 
still is a lack of comprehensive cost-effectiveness analyses for many standard 
treatments for AR. 
PATIENT EDUCATION
Education of the patient is critical in the management of any disease. Patients who 
understand their disease, treatment options and likelihood of treatment success 
are more likely to be compliant with their physicians’ recommendations. As 
successful treatment of AR requires good long-term patient adherence, adequate 
patient education is also required to optimize treatment outcomes. To improve 
adherence, healthcare providers should educate, communicate and partnership 
with their patients about the nature of their disease and the likelihood of disease 
progression, the need for, aims, regimen and costs of treatment, the expected 
benefits and possible side-effects. Furthermore, it is very important to demonstrate 
and teach patients the proper technique using medicines. A correct technique 
for nasal delivery of corticosteroids for instance, enables effective treatment and 
reduction of adverse events. To opimize the partnership between healthcare 
provider and patient in the management of AR, patients should receive a written 
management plan and patients should give feedback about the control of their 
disease and compliance with the suggested management plan, preferentially by 
reporting in a diary.11, 49
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ENVIRONMENTAL MEASURES
As symptoms of AR are clearly triggered by allergen exposure, the rationale of 
allergen avoidance is obvious. Significant reduction of allergen load can be 
achieved by physical and chemical means, but to date, there is little evidence that 
these reductions are sufficient to translate into clinical improvements of AR.50
Avoidance measures for house dust mite are the most investigated. They 
involve regular washing of bedding, pillows and duvets at 55-60°, encasing pillows 
and mattresses with protective coverings, reducing indoor humidity below 50°C, 
removing/reducing carpets, curtains and soft furnishings, removing, hot washing 
or freezing soft toys and use of vacuum cleaners with High Efficiency Particulate 
Air (HEPA) filters. At present there is no evidence to support the single use of one 
of these measures, but a multifaceted avoidance strategy might be beneficial in 
selected patients.8, 50-52
The only effective measure to avoid animal dander allergens in the home is 
to remove the pet and to subsequently and carefully vacuum-clean all carpets, 
mattresses and upholstered furniture.8, 50, 52
Although some methods have been developed to decrease the exposure to 
outdoor allergens (including filters and ventilation systems), avoidance of pollen 
and fungal spores is often impossible and impractical due to its ubiquitous 
nature.8, 52
Next to allergens, non-specific stimuli and irritants e.g. temperature changes, 
air conditioning and tobacco smoke, can lead to aggravation of symptoms in 
patients with AR. Although avoidance of these exposures seems logical, there is a 
lack of good evidence to support such environmental control measures.8, 11
PHARMACOTHERAPY
Pharmacological treatment of AR should take into account the spectrum of 
symptoms, the  severity and duration of disease, the presence of comorbidities, 
the efficacy, safety and cost-effectiveness of the medications, the patient’s 
preferences and the objective of treatment.
Pharmacological agents for AR or allergic rhinoconjunctivitis can be administered 
locally or systemically. Often agents are combined and some combined treatments 
e.g. an oral antihistamine and oral decongestant are commercially available.
A brief overview of the current standard pharmacotherapeutical treatments 
available for AR, their clinical effects, and advantages and disadvantages is 
provided in TABLE 3 . The strength of evidence of these different AR treatments is 
represented in TABLE 3 of Chapter 3.
TABLE 3.  Overview of  pharmacological  agents for the treatment of 
al lergic  rhinit is 11, 53,  54
Class name Mechanism of action Clinical effects and 
advantages
Side effects and 
disadvantages
Oral H1-antihistamines Blockage of 
H1-receptor
Inhibition of autacoid 
release in some new 
agents
Rapid (<1h) onset of 
action 
Effect on nasal 
symptoms of itch, 
sneezing, rhinorrhea; 
reduction of conjunc-
tival, oral, and skin 
symptoms
Second generation: 
favorable risk/benefit 
ratio
Poor effect on nasal 
congestion
‘On demand’ treat-
ment less effective 
than regular therapy
First generation: 
- anticholinergic effects 
- sedative effects 
with risk of behavior 
changes and reduced 
psychomotor perfor-
mance
Second generation: 
- mild sedative and 
anticholinergic effects 
in minority of patients
Local H1-antihistamines
Nasal
Ocular
Blockage of H1-
receptor
Inhibition of autacoid 
release in some new 
agents
Very rapid (<15min) 
effect on nasal 
itch, sneezing, 
rhinorrhea (nasal 
H1-antihistamine) 
or ocular symptoms 
(ocular antihistamine)
Safe treatment
Only local beneficial 
effects
Minor local side effects
Nasal anticholinergics Blockage of acetyl-
choline receptor
Effective reduction of 
watery rhinorrhea
Rare local or systemic 
side effects
Effective for reduction 
of watery rhinorrhea 
only
Three applications a 
day
Local dryness
Occasional systemic 
anticholinergic effects
Nasal corticosteroids Inhibits influx of 
inflammatory cells
Improvement of all 
nasal symptoms, 
some effects on eye 
symptoms
Superior effect 
compared to other 
pharmacological 
treatments for AR
Low bioavailability with 
new molecules
Effect starts after 
several hours, maximal 
effects only after 2 
weeks
Local side effects 
(5-10%): epistaxis, 
dryness
Concerns about 
growth in children with 
prolonged use and/
or  combined inhaled 
corticosteroids
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Nasal saline irrigation is most commonly used in rhinosinusitis, but may also prove 
useful in AR, allowing a reduction in the amount of pharmacotherapy needed to 
control symptoms.11
Furthermore, increasing insights in the pathophysiology of AR, the roles of 
diverse cells and their cytokine products, receptors and mediators involved in 
allergic inflammation has provided new (potential) targets for pharmacotherapy. 
Class name Mechanism of action Clinical effects and 
advantages
Side effects and 
disadvantages
Oral corticosteroids Inhibits influx of 
inflammatory cells
Rescue treatment for 
all AR symptoms
Adverse events related 
to oral corticosteroid 
use, only for rare 
and short-term use; 
not recommended in 
children
Nasal decongestants Sympathicomimetic 
Vasoconstrictive
Potent effect on nasal 
obstruction
Very rapid onset of 
action (<10 minutes)
Beneficial effects on 
nasal congestion only
Overuse and addiction 
is common 
Risk of rhinitis 
medicamentosa with 
prolonged use 
(>10 days)
Oral decongestants Sympathicomimetic 
Vasoconstrictive
Reduction of nasal 
obstruction
Rapid onset of action 
(<30 minutes)
Beneficial effects on 
nasal congestion only
Important risk of 
systemic side effects: 
hypertension,  
tachycardia, dry 
mouth, cental nerve 
stimulation with 
insomnia, tremor, 
agitation
Mastcell stabilizers
Nasal
Ocular
Inhibition of 
degranulation of 
sensitized mast cells 
Nasal: Modest effect 
on nasal symptoms 
of AR
Ocular: More effective 
relief of ocular 
symptoms
Safe treatment
Nasal: Less effective 
than other treatments
Several applications a 
day required
Rare and mild local 
side effects
Antileukotrienes (oral) Blockage of 
leukotriene receptor
Inhibition of 
leukotriene synthesis
Effective for nasal 
obstruction, 
rhinorrhea, and 
conjunctival 
symptoms; effective 
for bronchial 
symptoms in patients 
with asthma
Generally well 
tolerated
Less effective for nasal 
itch and sneezing
Not consistently 
effective
Occasional local or 
systemic side effects
Modulation of allergic response through anti-mediators and anti-receptors has 
gained much interest (e.g. anti-IgE, anti-IL-5, anti-CCR3). Omalizumab (anti-IgE) 
is a “humanized” monoclonal antibody that effectively hinders the interaction 
between IgEs and the high-affinity IgE receptor present on mast cells, basophils, 
and dendritic cells. At present this costly treatment is only licenced for the 
treatment of severe asthma, but placebo-controlled studies have shown benefits 
in the treatment of AR.55, 56 
Two pharmacological treatments are not advised for patients with AR: first-
generation antihistamines, that cause sedation, impair academic and work 
performance and are associated with traffic and industrial accidents, and 
intramuscular corticosteroid injections, that are associated with potentially severe 
systemic side-effects and subcutaneous and muscular necrosis.11
IMMUNOTHERAPY
Immunotherapy is the practice of administering gradually increasing doses of 
standardized allergen extract to an allergic patient. The treatment consists of 
a build-up and a maintenance phase, which is continued for at least 3 years. 
Where pharmacotherapy aims to suppress symptoms, immunotherapy aims 
to alter the immune system (inducing a shift away from a Th2 type response 
and generating regulatory T cells) and the natural disease course. Traditionally, 
allergen-specific immunotherapy is administrated subcutaneously (SCIT). There 
now is good evidence that SCIT with seasonal and perennial allergens is clinically 
effective for the treatment of AR in adults and children (over 5 years old) with 
long-term reduction of symptoms and medication requirements after treatment 
stop.57 In addition, SCIT, when administrated early in the disease process, has also 
demonstrated to modify the long term progress of the allergic inflammation and 
disease, by preventing the development of new sensitizations58 and by preventing 
the development of asthma.59 As SCIT holds a small (<0.1% of treated patients) 
but definite risk of inducing systemic reactions (including severe asthma attacks 
and potentially fatal anaphylaxis), patients must be closely observed for at least 
30 minutes after injection and SCIT can only be carried out in medical settings 
where the necessary expertise is avaible with direct access to rescue medication 
and equipment. As SCIT is a highly-demanding long-term treatment with potential 
serious side effects, it should only be considered in patients with severe symptoms 
of AR, when allergen avoidance and pharmacotherapy have failed to reduce 
symptoms or when pharmacotherapy has been associated with unacceptable 
side effects.8 
More recently local administration routes for immunotherapy have been 
introduced. Sublingual immunotherapy (SLIT) has shown to be effective for 
children and adults with AR with clinical and immunological benefits persisting 
after 3 years of follow-up.60, 61 SLIT appears to be safer than SCIT with merely 
local adverse effects and very rare systemic side effects, but no reported fatal 
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incidents. SLIT is a more patient-friendly treatment as only the first dosing requires 
medical supervision. Also promising and safe results have been reported with oral 
immunotherapy tablets containing grass pollen.62 For the locally administered 
immunotherapy, however, further studies on the longevity and concordance, 
especially in children, and on the potential beneficial effects on subsequent 
sensitizations and development of asthma are required.11
SURGERY
Surgery does not relief allergic inflammation and is rarely indicated for the 
treatment of AR. It can, however, be considered to improve the nasal patency 
(and route for nasal treatment application) in case of turbinate hypertrophy, 
anatomical cartilaginous or bony obstruction. In these cases, a conchotomy, nasal 
valve surgery and/or septo(rhino)plasty is recommended. In case of secondary 
chronic rhinosinusitis disease, unresponsive to medical treatment, functional 
endoscopic sinus surgery can be performed.
ALLERGIC RHINITIS: 
THE NEED FOR GUIDANCE
Due to its high prevalence, impairment of the quality of life, important economic 
consequences and risk for comorbidities, AR represents a considerable 
burden for the patient and society as a whole. Consequently, early detection 
and optimal treatment of AR should be a priority. AR, however, often remains 
unrecognized and/or trivialized. A large study conducted in 6 European countries 
demonstrated that 45% of AR patients were previously undiagnosed15. This high 
rate of undiagnosed cases of AR can partly be explained by a high proportion 
of patients either neglecting or trivializing their symptoms and not seeking help 
(often patients with mild symptoms) and a high rate of patients not consulting 
a physician, but self-treating, using over-the-counter medication or alternative 
treatments.63 On the other hand, there remains a significant proportion of AR 
patients undiagnosed in clinical practice, which might be explained by inadequate 
doctor-patient dialogue, insufficient attention or awareness of physicians about 
the condition or inadequate diagnostic skills.64 Furthermore, several studies 
have demonstrated that, even in case of a diagnosis of AR, physicians tend to 
underestimate the severity and impact of disease and to overestimate the control 
of disease.65-66 Although no studies have linked physician’s perspectives on AR 
to their prescribing behavior, it is to be expected that physicians who consider 
AR a low priority disease, who do not acknowledge or underestimate the impact 
of the disease, also inadequately treat the condition.67 In addition, clinicians are 
confronted with various treatment options for AR and are often not fully aware of 
their relative downsides and merits, leading to considerable variation in treatment 
practice for AR68 and resulting in insufficient patient outcomes.69
To raise awareness and to optimize the diagnostic and treatment practices of 
AR guidelines have been developed. The main goal of clinical practice guidelines is 
to improve the quality of patient care and healthcare outcomes, but additionally, 
the scope of clinical guidelines is to summarize research findings and make 
clinical decisions more transparent, to reduce inappropriate variation in practice, 
to promote efficient use of resources, to identify gaps in knowledge and prioritize 
research activities, to provide guidance for consumers and inform and empower 
patients, to inform public policy and to support quality control.70
In 2001 the first evidence-based guidelines for AR, the Allergic Rhinitis and its 
Impact on Asthma (ARIA) guidelines,8 were published. The ARIA guidelines propose 
diagnostic recommendations and a stepwise treatment algorithm, based on a new 
classification for AR in terms of the duration of disease and its impact on quality 
of life. Limited information, however, is available on the impact of guidelines 
on clinical practice and, more specifically, the applicability, dissemination and 
implementation of the ARIA guidelines in general and specialist practice warrants 
further research.
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CHAPTER I
AIMS OF THE STUDY AND THESIS OUTLINE
The general aim of this thesis is to better understand the impact of guidelines 
on clinical practice. The impact of “the Allergic Rhinitis and its Impact on Asthma” 
(ARIA) guidelines for allergic rhinitis (AR) was studied in order to meet this goal.
AR represents a serious health problem and a social and economic burden to the 
patient and society. To raise awareness about the disease, to assist healthcare 
providers in the management of their patients and to improve the quality of 
healthcare, clinical practice guidelines have been developed. The first evidence-
based guidelines for AR, the ARIA guidelines, were distributed worldwide 
to primary care practitioners and specialists dealing with AR. They propose 
diagnostic recommendations and a stepwise treatment algorithm, based on a 
new classification for AR in terms of the duration of disease and its impact on 
quality of life.
First of all, it is relevant to understand how guidelines are created. The development 
of guidelines in general and for AR specifically, is critically reviewed and evaluated 
in a literature study (Chapter 2). In addition, we look into the specific choices that 
were made upon the generation of a guideline, e.g. the ARIA classification of AR, and 
estimate the usefulness of these decisions and their adaptation to daily practice, 
by applying (Chapter 3) and critically appraising (Chapter 4) the ARIA classification 
in a large patient population of AR patients recruited in general practice.
Secondly, after publication and distribution of guidelines, monitoring of their 
use and their impact on healthcare is essential and should be evaluated. Very 
little information, however, is available on the dissemination and implementation 
of the ARIA guidelines in clinical practice. Results of a questionnaire-based 
survey are used to analyze to what extent physicians, both general practitioners 
(Chapter 6) and specialists (Chapter 5), are familiar with these guidelines, if their 
directives influence everyday practice and whether physician characteristics 
influence guideline compliance. 
Finally, if differences in management of AR between healthcare providers exist, 
knowledge of and compliance with guidelines might not be the only explanation. 
Of interest, can personal factors, such as personal experience with AR, influence 
practitioners’ choices for their patients? A questionnaire distributed among a large 
number of general practitioners with and without AR compares the management 
of AR patients between these 2 groups of healthcare providers (Chapter 7).
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SPECIFIC AIMS OF THIS THESIS ARE:
1. To characterize the classes of AR described by ARIA in a large patient 
population (chapter 3) and to assess whether the ARIA classification at the 
basis of the ARIA treatment recommendations is useful in daily primary care 
practice (chapter 4) 
2. To assess the management practices of AR in general and specialist practice 
and to compare them with the evidence-based guideline recommendations 
(chapters 3, 5 and 6)
3. To evaluate the knowledge and use of the ARIA guidelines among general 
practitioners  and specialists and to gain information on physician 
characteristics that influence compliance with guideline recommendations 
(chapters 5 and 6)
4. To assess whether personal experience of healthcare providers with AR has 
an impact on the management of their AR patients (chapter 7)
Chapters 2, 3, 4, 5, 6 and 7 correspond to individual manuscripts. As each 
manuscript is self-containing some overlap between the chapters is possible.
CHAPTER I
41
CHAPTER II
CLINICAL GUIDELINES
FOR ALLERGIC RHINITIS
43
CHAPTER I I
Update of:
CRITICAL LOOK AT THE CLINICAL PRACTICE 
GUIDELINES FOR ALLERGIC RHINITIS.
Van Hoecke H, Van Cauwenberge P. 
Respir Med 2007;101(4):706-14.
INTRODUCTION
Clinical guidelines are systematically developed statements to assist practitioners 
and patients in making decisions about appropriate and effective healthcare in 
specific circumstances.1 Over the last 2 decades, clinical practice guidelines have 
gained much interest, both in clinical practice and in medical education, as a 
tool to synthesize clinical information and to improve the quality of healthcare. 
A large amount of national and international guidelines, covering diverse areas 
of medicine - including allergic rhinitis (AR) - have been published, and guideline 
users may even get overwhelmed and confused by this extensive offer.
To ensure the quality of clinical guidelines, increasing attention is paid to the 
methodology of guideline development2 and standards, such as the validated 
AGREE (Appraisal of Guidelines, Research and Evaluation) instrument, are used 
by an increasing number of guideline developers and appraisers to assess the 
methodological quality of a guideline and the documentation of the guideline 
development process.3, 4 (TABLE 1)
A rigorous and transparent methodology of guideline development is essential, 
but does not guarantee the validity and acceptance of clinical guidelines in the 
medical community. 
In this review we discuss the clinical practice guidelines for AR, with a special 
focus on the international ARIA (Allergic Rhinitis and its Impact on Asthma) 
guidelines. We critically appraise the methodology of guideline development, the 
composition of the guideline development panel and the efficacy and applicability 
of guidelines for AR. Furthermore, we describe the barriers that may rise when 
translating scientific knowledge into relevant and accessible information for the 
practitioner and we discuss the importance of a carefully planned and multifaceted 
dissemination and implementation strategy.
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EVOLUTION OF CLINICAL GUIDELINES 
FOR ALLERGIC RHINITIS
Before 2000, guidelines for AR were predominantly derived from unsystematically-
compiled opinions of experts, based on clinical trials and mechanistic approaches 
(opinion-based medicine).5-8 Among these opinion-based guidelines, the US 
guidelines for (allergic) rhinitis7, 8 represented a state-of-the-art revision of the 
clinical characteristics, the (differential) diagnosis and treatment options of rhinitis, 
but did not provide a practical flowchart, guiding practitioners in the management 
of their patients. The International Consensus on Rhinitis5 and the Guidelines of 
the European Academy of Allergy and Clinical Immunology (EAACI)6 contained very 
similar information to the US guidelines, but a prominent feature was that they 
included stepwise treatment algorithms for rhinitis, similar to the Global Inititiative 
for Asthma (GINA) guidelines for asthma.9 Whereas the International Consensus 
Statement on Rhinitis was especially developed for general practitioners (GPs), 
and only accounted for patients with mild or moderate disease, the newer EAACI 
guidelines were also aimed for specialists and also included recommendations for 
patients with severe disease. 
In 1999, the ARIA (Allergic Rhinitis and Its Impact on Asthma) Working Group 
was founded under the initiative of the WHO (World Health Organization). The 
ARIA guidelines, resulting from this collaboration and published in 2001,10 were 
the first evidence-based guidelines. They were intended for GPs and specialists 
dealing with AR around the world and were innovative in:
• Developing guidelines in collaboration with all stakeholders, including 
primary care physicians and patients
• Including experts from developed and developing countries
• Highlighting the impact of AR on asthma and emphasizing that rhinitis and 
asthma are different manifestations of one ‘united airway disease’
• Proposing a new classification for AR based on the duration of sympoms, 
instead of the type of allergen, and on their impact on quality of life, rather 
than on rating (nasal) symptom scores
• Providing an evidence-based documented revision of diagnostic methods 
for AR
• Providing an evidence-based documented revision of treatments for AR and 
evidence-based therapeutic algorithm with step-up and step-down options 
(FIGURE 1) .11
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TABLE 1.  The AGREE I I  Instrument,  a 23- i tem tool  compris ing 6 qual i ty 
domains to address the methodological  qual i ty  and transparency 
of  guidel ine development,  adapted from Brouwers et  al 4.
Domain 1: Scope and Purpose
1. The overall objective(s) of the guideline is (are) specifically described
2. The health question(s) covered by the guidelines is (are) specifically described
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically 
described
Domain 2: Stakeholder Involvement
1. The guideline development group includes individuals from all the relevant professional groups
2. The views and preferences of the target population (patients, public, etc. ) have been sought
3. The target users of the guideline are clearly defined
Domain 3: Rigour of Development
1. Systematic methods were used to search for evidence
2. The criteria for selecting evidence are clearly described
3. The strengths and limitations of the body of evidence are clearly described
4. The methods for formulating the recommendations are clearly described
5. The health benefits, side effects and risks have been considered in formulating the 
recommendations
6. There is an explicit link between the recommendations and the supporting evidence
7. The guidelines has been externally reviewed by experts prior to its publication
8. A procedure for updating the guideline is provided
Domain 4: Clarity of Presentation
1. The recommendations are specific and unambiguous
2. The different options for the management of the condition or health issue are clearly presented
3. Key recommendations are easily identifiable
Domain 5: Applicability
1. The guideline describes facilitators and barriers to its application
2. The guideline provides advice and/or tools on how recommendations can be put into practice
3. The potential resource implications of applying the recommendations have been considered
4. The guideline presents monitoring and/or auditing criteria
Domain 6: Editorial Independence
1. The views of the funding body have not influenced the content of the guideline
2. Competing interests of guideline development group members have been recorded and 
addressed
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After 2001, an evidence-based strategy, based on various evidence models, was 
used in the updated Practice Parameter for Rhinitis from the AAAAI (American 
Academy of Allergy, Asthma and Immunology) and the ACAAI (American College of 
Allergy, Asthma and Immunology),13 in the International Primary Care Respiratory 
Group (IPCRG) Guideline on the management of AR in primary care14  and of 
course in the updated ARIA guidelines,12, 15 but also in national or local guidelines 
such as the Guidelines for the Management of Allergic and Non-allergic Rhinitis 
from the British Society of Allergy and Clinical Immunology (BSACI) in the UK16 and 
the NHG Standard for allergic and non-allergic rhinitis, used in the Netherlands 
and Belgium.17 Although all these guidelines are evidence-based, some important 
differences between their recommendations remain. These differences can be 
explained by the use of different evidence grading systems, different selection and 
interpretation of the available medical literature, different available or approved 
treatments and different target population.18, 19 
The AR guidelines from the IPCRG14 and the NHG Standard17 took over the ARIA 
classification for AR, but the AAAAI/ACAAI13 and BSACI16 guidelines still classified 
AR into seasonal or perennial. Before the ARIA workshop, asthma and rhinitis 
comorbidity was disregarded, but after 2000 most guidelines for (allergic) rhinitis 
reported the link between rhinitis and asthma and made recommendations to 
assess the possibility of asthma in rhinitis patients. The ARIA Guidelines and its 
updates10, 12, 15 and the Spanish Asthma Management Guide,20 however, are the 
only guidelines that assess the management of patients with both asthma and 
rhinitis in the same document.
In 2009-2010, there was another important evolution in the development of 
AR guidelines with the ARIA 2010 update,15 that incorporated the GRADE (Grading 
of Recommendation, Assessment, Development and Evaluation) approach.21 
The ARIA 2010 update presents an analysis of the key clinical questions about 
allergy prevention, management of AR and management of AR and asthma in the 
same patient. The recommendations are presented as answers on 48 PICO-based 
questions (Patient problem or Population – Intervention – Control - Outcome), 
developed by clinical experts and methodologists. While the previous evidence-
based guidelines only based the strength of their recommendations on the quality 
of underlying evidence, the recommendations in the ARIA 2010 update, following 
the GRADE methodology, are also influenced by the balance between benefits and 
harms of following the recommended course of action, values and preferences of 
those for whom the guidelines are intended and considerations around resource 
utilization.22
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FIGURE 1.  Stepwise treatment algorithm for al lergic  rhinit is  in adolescents 
and adults ,  as recommended in the ARIA 2008 Guidel ine Update.  Adapted 
from Bousquet et  al 12.  CS:  cort icosteroid,  ALT:  anti leukotr iene.
Figure	   1:	   Stepwise	   treatment	   algorithm	   for	   allergic	   rhinitis	   in	   adolescents	   and	   adults,	   as	  
recommended	   in	   the	  ARIA	  2008	  Guideline	  Update.	  Adapted	   from	   	   (12).	  CS:	   corticosteroid,	  
ALT:	  antileukotriene	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In these cases - and if available - systematic reviews can contribute to 
resolving uncertainty.28 The Cochrane Library is a key source for systematic 
reviews of evidence on healthcare interventions. The Cochrane Collaboration is 
organized in more than 50 review groups, covering different areas of interest in 
medical research and provides methodological support in 16 methods groups.31 
In general, the comprehensive systematic reviews of the Cochrane Collaboration 
are more systematic and demonstrate less publication and reference bias than 
systematic reviews published in paper journals. A rigorous methodology is 
applied, characterized by an extensive review of published and pre-published 
data, obtained through database- and hand-searching, and the process of 
post-publication review is promoted.32 Nevertheless, even systematic Cochrane 
reviews are not completely free of errors and bias, and still must be interpreted 
with caution.21 Furthermore, systematic reviews are sometimes criticized for 
their failure to offer specific guidance, which is often due to few assessments of 
outcome measures in the primary studies that they analyze.33
GRADING RECOMMENDATIONS
For guideline users, it is important to know how much confidence they can place 
in guideline recommendations. Therefore, many guidelines use and disclose a 
method to grade the strength of their recommendations. Before the introduction 
of the GRADE methodology, the strength of guideline recommendations was 
exclusively based on the quality of the underlying evidence.
Several evidence grading systems have been developed. The ARIA 200110 and 
200812 guidelines and the 2008 US Practice Parameter for Rhinitis13 followed the 
grading system of the Agency for Health Care Policy and Research (AHCPR)34 
(TABLE 2) . Other grading systems include the SIGN (Scottish Intercollegiate 
Guidelines Network) system,35 the OCEBM (Oxford Centre for Evidence-Based 
Medicine) system36 and the evidence model of the Royal College of General 
Practitioners37 that was used in the AR Guideline from the IPCRG14. Although 
these different classification systems all share the same basic structure, they 
demonstrate differences in terminology and in gradation of evidence from specific 
publication types, which is of course confusing and limits easy communication.21, 25
EVIDENCE-BASED GUIDELINES: SEARCHING AND 
APPRAISING EVIDENCE, GRADING RECOMMENDATIONS
Evidence-based medicine (EBM) has become an increasingly important concept 
in medicine. The benefits of the methodology to provide a convenient logical 
framework from which the quality and relevance of clinical studies may be 
assessed in an unbiased manner are well described.23
For the healthcare practitioner, however, it is almost impossible to keep up-
to-date with the medical literature. It is even more difficult to critically appraise 
the value of research findings and to apply evidence from research in medical 
practice. To allow clinicians to efficiently use the information from research in 
making decisions about the care of the individual patient, the process of preparing 
and providing clinical practice guidelines, based on the best-available evidence 
from research regarding the efficacy of various procedures and interventions, has 
become essential.24 The recommendations of these ‘evidence-based guidelines’ 
are linked to a specific evidence background, which is identified through an 
extensive literature search, critically evaluated and rated by a specific grading 
system.25
SEARCHING AND APPRAISING EVIDENCE
Critical examination of evidence from clinical research is best done by performing 
a systematic evaluation of the literature. Ideally, evidence is based on results of 
randomized controlled trials (RCTs). Of course, not only the study design, but also 
the relevance and quality of the collected evidence must be assessed following pre-
established criteria. The CONSORT (Consolidated Standards of Reporting Trials),26 
and the QUORUM (Quality of Reporting of Meta-analyses) and MOOSE (Meta-
analysis Of Observational Studies in Epidemiology) statements27, 28 in particular, 
are intended to improve the reporting of RCTs and meta-analyses respectively. In 
addition, they enable readers, reviewers, researchers and editors to understand a 
trial’s conduct and to assess the validity of its results in a stepwise manner.29
It needs to be emphasized, however, that there are some obvious limitations 
when performing a systematic evaluation of the ‘best available evidence’. For many 
clinical questions, such as the role of allergen avoidance in the treatment of AR and 
asthma, there remains a lack of large-scale, well-developed and well-conducted 
clinical trials and consequently a lack of evidence. On the other hand, despite a 
thorough and hand-based search, it is not always possible to have access to or 
to review all relevant study results. Furthermore, results from different original 
studies often disagree.
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The grading of the recommended pharmacotherapy and immunotherapy in AR 
treatments as proposed in the ARIA 2008 guidelines12 has shown to be particularly 
strong (category A for most treatments), whereas evidence supporting the benefits 
of allergen avoidance is very low (category D) (TABLE 3) . It is important to remark, 
however, that the collected evidence12 is mostly based on trials that were carried 
out before the new classification of AR. Strength of evidence is therefore mainly 
reported for seasonal and perennial AR and cannot merely be extrapolated to 
intermittent and persistent AR.
But, there are more important shortcomings with this evidence grading 
methodology. 
First, there is no grading for ‘negative’ results. E.g. RCTs have demonstrated 
that the combination of an oral H1-antihistamine and a leukotriene receptor 
antagonist does not increase the efficacy of any single drug.38, 39 The AHCPR 
grading system,34 however, does not provide a category that allows to grade the 
strength (or weakness) of recommending this combined treatment.
Second, the clinical relevance of the strength of evidence supporting a specific 
recommendation can be questioned. E.g. RCTs have demonstrated that cromones 
have modest effects in the treatment or prophylaxis of  seasonal AR symptoms 
compared to placebo, which corresponds with a category A strength of evidence 
(TABLE 3) . In clinical practice, however, the use of cromones is limited, as they 
have demonstrated to be clearly less effective than other AR treatments such 
as H1-antihistamines and nasal corticosteroids. Nevertheless, the strength of 
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TABLE 2.  Evidence grading system of the Agency for Health Care 
Pol icy and Research (AHCPR) 34
Category of evidence
Ia Evidence from meta-analysis of randomized controlled trials
Ib Evidence from at least one randomized controlled trial
IIa Evidence from at least one controlled study without randomization
IIb Evidence from at least one type other type of quasi-experimental study
III Evidence from non-experimental descriptive studies, such as comparative studies, correlation 
studies and case-control studies
IV Evidence from expert committee reports or opinions or clinical experience of respected 
authorities or both
Strength of evidence of recommendations
A Directly based on category I evidence
B Directly based on category II evidence or extrapolated recommendation from category I 
evidence
C Directly based on category III evidence or extrapolated recommendation from category I or II 
evidence
D Directly based on category IV evidence or extrapolated recommendation from category I, II or 
III evidence
recommending an antihistamine, a nasal corticosteroid or a cromone in seasonal 
AR all receive the same “A” gradation.12
Third, the highest quality and strength of evidence from RCTs is often based 
on highly selected patients, that differ from the patient population seen in daily 
practice. Many clinicians feel that evidence-based recommendations are difficult 
to apply in a specific clinical setting and to integrate with individual clinical 
expertise.40
According to the definition of Sackett, however, EBM should not cancel the value of 
individual clinical expertise but should be regarded as “the conscientious, explicit 
and judicious use of current best evidence in making decisions about the care of 
the individual patient. It means integrating individual clinical expertise with the 
best available external clinical evidence from systematic research”.41 This implies 
that an evidence-based approach to make healthcare decisions acknowledges 
that only relying on the quality of literature is insufficient, but that values and 
preferences, clinical circumstances and clinical expertise inevitably influence 
decisions.42, 43
TABLE 3.  Strength of  evidence of  di f ferent AR treatments in ARIA 2008 
guidel ines 12 according to AHCPR gradation. 35 SAR:  seasonal  al lergic 
rhinit is ,  PAR:  perennial  al lergic  rhinit is ,  PER:  persistent al lergic  rhinit is . 
OAH1: oral  H1-antihistamine,  NAH1: nasal  H1-anthistamine,  NCS: 
nasal  cort icosteroid,  OCS:  oral  cort icosteroid,  ND: nasal  decongestant , 
OD: oral  decongestant ,  SCIT:  subcutaneous immunotherapy,  SLIT: 
subl ingual  immunotherapy,  nda:  no data avai lable,  (1):  evidence more 
recent than publ icat ion of  ARIA 2008 guidel ines
Intervention SAR Adult SAR Children SAR Adult SAR Children PER
OAH1 A A A A A
NAH1 A A A A nda
NCS A A A A A(1)
OCS A B B B nda
ND C C C C nda
OD A nda nda nda nda
Nasal cromone A A A B nda
Ocular cromone A A B B nda
ALT A A (>6y) nda nda nda
SCIT A A A A nda
SLIT A A A A nda
Anti-IgE A A (>12y) A A nda
Allergen avoidance D D D D nda
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The GRADE approach to developing clinical guidelines affirms that the quality of 
evidence is only one of the factors influencing the strength of a recommendation. 
The GRADE process starts with asking an explicit question, including specification 
of all important outcomes. After the evidence is collected and summarized, 
GRADE provides explicit criteria for rating the quality of evidence into 4 categories 
(high, moderate, low and very low) that include study design, risk of bias, 
imprecision, inconsistency, indirectness, and magnitude of effect. The strength of 
a recommendation is graded into 2 levels (strong or weak) according to the quality 
of the supporting evidence and the balance between desirable and undesirable 
consequences of the intervention and the alternative management options, 
resource utilization and user values and preferences.44 (FIGURE 2)
As recommended by the “guidelines for WHO guidelines”,45 the GRADE 
methodology was used in the ARIA 2010 guidelines15 (TABLE 4) . Separation of the 
strength of a recommendation and the quality of the supporting evidence allows:
• Strong recommendations supported by low quality evidence when other 
factors determining the strength of a recommendation suggest that this is 
the best course of action; e.g. ARIA 2010 makes a strong recommendation of 
total avoidance of environmental tobacco smoke in children and pregnant 
women to reduce the risk of developing allergy, wheezing or asthma despite 
only very low-quality evidence, as there is a clear balance between desirable 
and undesirable effects with this intervention.
• Weak recommendations in the presence of moderate or high quality of 
evidence for instance when there are potential important undesirable 
effects of an intervention; e.g. ARIA 2010 recommends not to use sublingual 
immunotherapy in children with AR caused by house dust mites as there is 
a relatively high chance of local adverse effects, despite moderate quality of 
evidence of reduction in nasal symptoms.15, 46 
The GRADE Working Group believes that their grading of recommendations better 
reflects the way clinicians think or behave before undertaking action (balancing the 
pros and cons) and is closer to patient and physician’s needs than former grading 
systems, that were only based on the quality of the underlying body of evidence. 
The GRADE classification has been adopted by over 50 major organizations 
worldwide.46, 47 But, also the GRADE system has limitatons. Inevitably, categorizing 
recommendations as strong or weak can be ‘arbitrary’ and criticism concerning its 
effectiveness, validity and internal consistency has risen.48
It remains to be emphasized that, irrespective of the type of grading system 
that is used, transparent reporting of the evaluations and judgements that 
support guideline recommendations is absolutely necessary in order to allow the 
implementation of the recommendations in an individual clinical setting.
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FIGURE 2.  Schematic v iew of  GRADE’s  process for developing 
recommendations.  RCT:  randomized control led tr ials ,  adapted 
from Guyatt  et  al 44.  S :  study,  OC:  outcome, *also labeled 
‘ condit ional ’  or  ‘discret ionary ’ .
Figure	   2.	   Schematic	   view	   of	   GRADE’s	   process	   for	   developing	   recommendations.	   RCT:	  
randomized	   controlled	   trials,	   adapted	   from	   Guyatt	   et	   al44.	   S:	   study,	   OC:	   outcome,	   ★also	  
labeled	  ‘conditional’	  or	  ‘discretionary’.	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TABLE 4.  Overview of  pharmacological  agents for the treatment of 
al lergic  rhinit is 11, 53,  54
Strength of  
recommendation 
and quality of 
evidence 
Clarity of balance 
desirable / 
undesirable 
effects
Quality of supporting 
evidence
Implications
1A Strong 
recommendation 
High-quality 
evidence
Desirable effects 
clearly outweigh 
undesirable 
effects, or vice 
versa 
Consistent evidence 
from well-performed 
RCTs or exceptionally 
strong evidence from 
unbiased observational  
studies
Recommendation can apply 
to most patients in most 
circumstances. Further 
research is unlikely to 
change our confidence in 
the estimate of effect
1B Strong  
recommendation 
Moderate-quality 
evidence
Evidence from RCTs 
with important 
limitations  (inconsistent 
results, methodological 
flaws, indirect or 
imprecise) or unusually  
strong evidence from 
unbiased observational 
studies
Recommendation can apply 
to most patients in most 
circumstances. Further 
research is likely to have an 
important  impact on our 
confidence in the estimate 
of effect and may change 
the estimate
1C Strong 
recommendation 
Low-quality 
evidence
Evidence for at least 
one critical outcome 
from RCTs with serious 
flaws, observational 
studies, or indirect 
evidence
Recommendation may 
change when higher 
quality evidence becomes 
available. Further research 
(if performed) is likely to 
have an important  impact 
on our confidence in the 
estimate of effect and 
is likely to change the 
estimate
1D Strong 
recommendation 
Very low-quality 
evidence (very 
rarely applicable)
Evidence for at least 
one of the  critical 
outcomes from  
unsystematic clinical 
observation or very 
indirect evidence
Recommendation may 
change when higher 
quality evidence becomes 
available. Any estimate of 
the effect for at least one 
critical outcome is very 
uncertain
Strength of  
recommendation 
and quality of 
evidence 
Clarity of balance 
desirable / 
undesirable 
effects
Quality of supporting 
evidence
Implications
2A Weak 
recommendation 
High-quality 
evidence
Desirable effects 
closely balanced 
with undesirable 
effects
Consistent evidence 
from well-performed 
RCTs or exceptionally 
strong evidence from 
unbiased observational 
studies
The best action may 
differ depending on 
circumstances or patients 
or societal views. Further 
research is very unlikely to 
change our confidence in 
the estimate of the effect
2B Weak 
recommendation 
Moderate-quality 
evidence
Evidence from RCTs 
wit-h important 
limitations (inconsistent 
results, methodological 
flaws, indirect or 
imprecise) or unusually 
strong evidence from 
unbiased observational 
studies
Alternative approach likely 
to be better for some 
patients under some 
circumstances. Further 
research is likely to have an 
important impact on our 
confidence of the estimate 
of effect and may change 
the estimate
2C Weak 
recommendation 
Low-quality 
evidence
Evidence for at least 
one critical outcome 
from RCTs with serious 
flaws, observational 
studies, or indirect 
evidence
Other alternatives may 
be equally reasonable. 
Further research is very 
likely to have important 
impact on our confidence 
in the estimate of effect 
and is likely to change the 
estimate
2D Weak 
recommendation 
Very low-quality 
evidence
Evidence for at least 
one of the critical 
outcomes from 
unsystematic clinical 
observation or very 
indirect evidence
Other alternatives may be 
equally reasonable Any 
estimate of the effect for at 
least one critical outcome is 
very uncertain
THE GUIDELINE DEVELOPMENT GROUP
The guideline development group is a committee of people, each exerting a 
specific role in the guideline development process. Usually, the group consists 
of a team leader that co-ordinates the group process (ensuring that it functions 
effectively) and the group task (ensuring that it achieves its aims), a group of team 
members, representing the stakeholders and people providing expert resource, 
methodological, technical and administrative support.34
According to Shekelle34 the panel should consist of at least 6, but no more 
than 12-15 members, as too few members limits adequate discussion and too 
many members hampers effective functioning of the group. Nevertheless, the 
recommendations on the number of panel members can be debated. Probably, 
large groups can also function adequately if the tasks are shared by subgroups, 
reporting the larger group at the end. 
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A BALANCED AND DIVERSE GUIDELINE PANEL
As mentioned above, different backgrounds of a guideline panel may lead to a 
better balancing of individual biases and to the production of more valid guidelines. 
The background of a guideline, however, not only refers to its stakeholder position, 
but is also influenced by type of affiliation and demographic factors such as age, 
gender and ethnicity.
If guidelines are intended for international use, it is necessary that experts and 
stakeholders from the different countries and continents are involved in their 
generation and formulation and in adapting them to meet local needs and local 
socio-economic and healthcare standards and resources. The ARIA guidelines 
were developed as a basis for the whole world and their global character is 
also reflected in the international and intercontinental composition of the ARIA 
panels.10, 12, 15
In most (allergic) rhinitis guideline groups,5-8, 10, 12, 13, 15 on the other hand, women 
and members affiliated to non-university institutions are very poorly represented. 
It is possible that only few women and non-academics were candidate to be 
part of the guideline development groups, but the selection of a more balanced 
composition of the panel for gender and  professional affiliation is definitely a 
point of discussion.
CONFLICT OF INTEREST
If guidelines are intended to be used as a basis for physicians and healthcare 
organizations, independence of pharmaceutical industry is strictly necessary. 
Instruments, such as AGREE, emphasize that guidelines need to include an explicit 
statement that views or interests of the funding body have not influenced the final 
recommendations and that all members of the guideline group have declared 
possible conflicts of interest.
Before 2001, conflict of interest among the members of the expert panels of AR 
guidelines was not disclosed. For the ARIA 2001 Working group, conflict of interest 
was reported to the WHO for all except one member, but this was not published 
in the ARIA report.10 For the following ARIA 2008 and 2010 guidelines12, 15 conflict of 
interest of the members of the guideline core group was reported, but not for the 
members of the review group.
EFFICACY AND APPLICABILITY OF GUIDELINES
The key role of guidelines is to assist healthcare providers in the management 
of their patients and to improve the patient care, compliance and satisfaction. 
Despite the vast number of guidelines and the increasing attention paid to the 
methodology of guideline development, there is limited evidence of the impact of 
guidelines on practice patterns, health outcomes and healthcare costs.49
To allow a successful guideline development with a very large working group, 
many guideline panels, including the ARIA 200812 and 2010 panel15, are organized 
into a guideline ‘core group’ undertaking the day to day running of the work and 
a larger group (or different subgroups) acting as consultants or reviewers and 
reporting to the core group.
STAKEHOLDER INVOLVEMENT
Probably more important than the number of guideline members, is the involve-
ment of stakeholders. Identifying stakeholders involves identifying all the groups 
whose activities are covered by the guideline or who have other legitimate reasons 
for having an input into the process.34 The representation of the stakeholders in 
the guideline development group is indeed of great value for the identification 
of the specific needs of those for whom the guidelines are intended and for the 
adaptation of data from research into useful and user-friendly recommendations. 
Furthermore, different backgrounds of the panel members may lead to a better 
balancing of individual biases, which in turn may lead to the production of more 
valid guidelines.
In a systematic review of 91 studies, Grimshaw and Russell concluded already 
20 years ago that guidelines have the greatest chance of changing clinical 
behavior when they are developed by clinicians for whom they are intended.49 
Many clinical conditions, including allergy and AR, are preferentially managed in 
a multidisciplinary setting, and consequently, it is recommended that the expert 
panel has a multidisciplinary composition. Guidelines for the management of AR 
are not only aimed for specialists, but are intended to assist GPs in particular.30 The 
important end-user group of GPs, however, was not represented in the guideline 
panel from the International Consensus Report5 and the EAACI guidelines.6 For 
the development of the ARIA guidelines,10, 12, 15 on the other hand, both specialists 
(ENT-specialists, Allergologists, Pulmonologists, Paediatricians) and GPs were 
involved from the start. Furthermore, an ARIA pocket guide was developed with 
the World Organization of Primary Care Physicians  (WONCA) and the IPCRG.50 
Although often underestimated, not only GPs and specialists, but also 
pharmacists can play a key role in the prevention, recognition and treatment of 
AR. The involvement of pharmacists in the collaborative management of AR is 
also recognized by ARIA, and is sustained by the publication of the ‘ARIA in the 
Pharmacy’ guidelines.51 This document is aimed as a practical stepwise guide 
for pharmacists and their staff in the recognition and management of patients 
suffering from AR.  Pharmacists were part of this guideline working group.
As the stakeholder with the most to lose or to gain, the input of patients in 
the process of guideline development should not be neglected. In contrast to the 
preceding international guidelines for AR, patient organizations were involved in 
the development of the ARIA guidelines and pocket guides.10, 12, 15, 51
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the recommendations at a local/national level, depending on the local values, 
available medications and interventions and costs.
As primary care practitioners diagnose and treat the majority of patients 
with AR, applicability of AR guidelines in primary care practice remains a major 
challenge. Whereas the ARIA guidelines, contrarely to the previous ‘International’, 
European and US Guidelines5-8, were the first to involve GPs in the development 
and formulation of their recommendations, they still lack explicit description 
of barriers and facilitators, and provision of tools and advices to implement 
their recommendations in the primary care setting. Many (primary) healthcare 
organizations, however, have developed their own guidelines or adapted an 
existing guideline. The NHG Standard for allergic and non-allergic rhinitis17 and 
the International Primary Care Respiratory Group (IPCRG) Guideline on the 
management of AR in primary care14 were both modified from the ARIA guidelines 
with specific considerations of the primary care health setting and resources. 
Another concern is the applicability of AR guidelines in developing countries. 
The EAACI guidelines6 assumed that the recommended treatments were available 
and financially affordable to the patient, and did not consider these situations 
where the suggested first-choice treatment was not an option. The International 
Consensus Report5 did mention that all recommendations of treatment 
strategies depend upon local availability of the therapeutic interventions, but 
did not formulate any concrete suggestions or recommendations. One of 
the principal goals of ARIA was to optimize the management of AR worldwide. 
The first version of the ARIA guidelines10 took into account the availability and 
affordability of medications, as well as the WHO essential list of medications.54 
In the WHO list that was available at the time of the 2001 ARIA guidelines, only 
first generation antihistamine chlorpheniramine was listed and consequently also 
recommended by the ARIA working group. In the 2010 ARIA revision15 16 experts 
from developing countries have drafted or reviewed the recommendations. 
Experts and reviewers have extensively discussed the relative risk/benefit ratio of 
first generation antihistamines,55 the WHO list has listed alternative drugs and the 
latest ARIA guidelines strongly recommend the use of new- over old-generation 
antihistamines.15
To guarantee the global applicability of guidelines, not only differing healthcare 
resources and facilities, but also local values and cultural differences need to 
be considered.  Furthermore, most of the (randomized controlled) studies at 
the basis of guideline recommendations have been carried out in developed, 
westernized countries. Different races, however, may metabolize drugs differently 
and risk versus benefit arguments regarding therapeutic decisions may also vary 
between populations. The risks associated with steroid therapy for instance, may 
possibly be greater when the patient is malnourished or pardoxically less when 
life expectancy is anyway low.56
Ideally, guidelines should be assessed for their efficacy and applicability in 
the target healthcare setting prior to its dissemination and implementation. This 
validation is rarely performed, but is nevertheless important as evidence-based 
recommendations in evidence-based guidelines are based on results from RCTs, 
which are often based on high selected patients, not representing the patient 
population seen in daily practice. The GRADE methodology that was used in the 
ARIA 2010 guidelines15 partly addresses these concerns by grading guidelines 
recommendations not only on the underlying body of evidence, but also on the 
presumed balance between benefits and downsides, user values and preferences 
and considerations around costs. But, there remains a clear need to perform 
real-life studies to provide concrete proof that evidence-based results from 
mechanistic RCTs and evidence-based or ‘strong’ guideline recommendations also 
translate into relevant and beneficial effects in daily clinical practice. Furthermore, 
studies need to be conducted in ‘special populations’, that are usually excluded in 
clinical trials, including young children, elderly patients, patients with comorbidity 
and patients in low resource countries.43
EFFICACY OF GUIDELINES
At present, 2 guidelines for AR have been assessed for their effects on health 
outcomes in patients with AR induced by pollens in multicentre, randomized, 
parallel group studies. A first study in general practice showed that treatment 
according to the International Consensus on Rhinitis3 was significantly better than 
treatment according to the GPs’ free choice, as reflected by reduced symptom 
scores and increased quality of life scores, patient compliance and satisfaction52.
A more recent pragmatic study in specialist practice demonstrated that 
treatment according to the ARIA guidelines12 resulted in significant improvements 
in quality of life scores, work productivity and daily symptom scores in comparison 
to the free-choice treatment group.53 Costs were not evaluated in both studies.
In these trials, however, GPs and specialists in the ‘guideline group’ were 
explicitely asked to follow the guideline recommendations, whereas, in real life, 
availability of guidelines does not ensure the use of guidelines. User-friendliness 
and applicability of guidelines and physician’s attitude towards and adherence 
to clinical guidelines should therefore also be evaluated next to measuring 
effectiveness of clinical practice guidelines based on patient outcomes. 
APPLICABILITY OF GUIDELINES
The applicability of guidelines refers to whether and how guidelines can be 
put into practice. It encompasses the provision of advice and/or tools to apply 
recommendations in the specific clinical setting and anticipation of resource 
implications of applying the recommendations. To make guidelines applicable in 
different local healthcare settings they may require adaptation, by reformatting 
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It is important to add that a first precondition to avoid a guideline to become 
to soon outdated is to minimize the time interval between the end date of 
the literature search and the publication date of the guideline. The first ARIA 
guidelines,10 however, were based on a literature search that ended in December 
1999, whereas the guideline report was only published 2 years later.
The chronology of the development and publication of the ARIA Guidelines and 
updates and the preceding International5 and European6 Consensus Report on 
(allergic) rhinitis is presented in FIGURE 3 .
But, as guidelines are living documents guideline development and updating 
should preferably be performed as a continuous process, rather than as a discrete 
event. This ongoing process could consist of regular automated literature searches 
and revision of relevant citations by members or subgroups of the guideline panel, 
followed by evaluation of the impact of new evidence on the validity of an existing 
guideline. Furthermore, if guidelines are available in an electronic form on the 
Web, recommendations that are considered as outdated or invalid could easily 
and systematically be deleted or changed by updating the underlying inputs. In 
addition, a mechanism could be added to electronically alert interested parties 
that changes have been made to the guideline.61
UPDATING GUIDELINES
To be useful and valuable in clinical practice, it is particularly important that 
guidelines are based on current scientific knowledge and that they are regularly 
revised and updated. 
There is, however, no consensus on the time interval and the methodology 
to perform a guideline update. Although guideline evaluators agree that periodic 
revision is important, 9 out of 18 guideline organizations reported that they lack 
formal procedures for keeping their guidelines up to date.57
Conducting a new, complete systematic literature review, starting from the end 
date of the original guideline search, is definitely the most thorough way to 
identify significant new evidence, but is very effort-, time- and money-consuming 
and has been identified as a major barrier to timely updates of guidelines.58 A 
more feasible method, is to first assess whether guideline updating is required, as 
undertaking a full update prematurely is a waste of resources.
Shekelle et al described six situations that require a guideline or guideline 
recommendation to be updated (or even withdrawn) (TABLE 5)  and proposed a 
pragmatic model to determine whether a guideline update should be performed.59
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TABLE 5.  Situations that require a guidel ine to be updated,  adapted 
from Shekel le  et  al59
1. Changes in the available interventions
2. Changes in the evidence on the benefits and harms of existing interventions
3. Changes in the outcomes that are considered important
4. Changes in the values placed on outcomes
5. Changes in evidence that current practice is optimal
6. Changes in resources available for healthcare
Shekelle’s model is based on the assumption ‘that evidence sufficient to invalidate 
an existing guideline’ would be known to clinical experts and/or discussed in 
reviews, commentaries, and editorials in major journals of general or specialty 
interest59 and has been validated as an efficient and acceptable method compared 
to a traditional systematic review method.60 Applying this model, analysis of 17 
clinical practice guidelines, published by the AHRQ (Agency for Healthcare Research 
and Quality), showed that about half of the guidelines become outdated in 5.8 
years, whereas 90% of the guidelines are still valid 3.6 years after delivery of the 
guideline. Based on these findings the authors of this study suggest that the best 
interval to assess whether guidelines are still up-to-date should be conservatively 
after a 3 years time period, when 90% of the guidelines are estimated to be still 
valid. For topics that are characterized by rapid scientific advances, however, a 
shorter interval may be indicated, for topics that are more stable a longer interval.61 
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TRANSLATING RESEARCH INTO PRACTICE, DISSEMINATION 
AND IMPLEMENTATION OF GUIDELINES 
A large gap between clinical research and clinical practice remains, and the 
development of clinical practice guidelines does not ensure their use in 
medical practice. Translating scientific knowledge into practical medicine is not 
straightforward and may be hampered by diverse structural, cultural, economic 
or behavioral barriers. Budgetary limitations, competing demands and restricted 
healthcare facilities in low-income countries have already been addressed. 
However, also in developed countries, allergy (and AR) has only recently gained a 
place on the agenda of Governments and Health Departments. In the individual 
patient care setting, physician adherence to guidelines may be restricted by lack of 
awareness, lack of familiarity, lack of self-efficacy, lack of outcome expectancy and 
by inertia of previous practice. Lack of time, lack of reimbursement for following 
guidelines or limited staff have also been put forward as barriers. Furthermore, 
physicians may experience difficulties in reconciling patient preferences with 
guideline recommendations, and sometimes guidelines themselves may be 
unclear or confusing.56, 72 Finally, barriers may also rise at the level of the patient, 
in terms of compliance with the recommended therapeutic strategies. 
To address the gap between research and practice, clinical guidelines should 
be simple, transparent, informative and adapted to the clinical setting, the cultural 
and socio-economical context. The main goal of guidelines is to assist physicians 
and to improve patient care. This implies that they should be developed and 
considered as a support for practitioners with space for flexibility, rather than as 
a set of constrained rules.2
There is no single effective way to introduce and ensure the use of guidelines 
into practice, but a carefully developed and multifaceted dissemination and 
implementation program should form an integrated part of the stepwise and 
continuous process of guideline production.
Dissemination usually starts with the publication of the full version guideline 
report in a professional journal. For practitioners - GPs in particular - taking care 
of patients with multiple diseases, however, it is impossible to read through 
these often very voluminous documents. The ARIA 2001 Workshop Report is 187 
pages long,10 the 2008 update counts 160 pages. Derivatives of guidelines such as 
summaries, pocket guides, web-based activities, documents and questionnaires 
are usually more useful and user-friendly and should follow the guideline 
recommendations exactly.
For the ARIA 2001 and 2008 guidelines, pocket guides were translated into 
more than 50 languages and distributed worldwide. The ARIA website73 provides 
a copy of the guidelines and pocket guides, and interactive rhinitis and asthma 
questionnaires.22
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FIGURE 3.  Chronology of  AR guidel ine development 62-71
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Over the last years the World Wide Web has gained interest as an alternate medium 
for guideline developers to disseminate guidelines. Web-based guidelines can 
incorporate a greater complexity than that afforded by paper-based format while 
maintaining a consistent structure and orientation for the user. The level of detail 
displayed can be varied and easy linking to supporting material is possible.74 Web-
based guidelines allow distance-learning and are more easily distributed, modified 
and updated. Furthermore, there is a growing interest in Web-based models to 
create guidelines based on decision models that can be disseminated over the 
Web. Local guideline users could then alter the input underlying the decision model 
and tailor the guidelines to a particular patient population.75 At present, however, 
research into Web-based guidelines is still in the early stages. The strengths and 
weaknesses of Web-based guidelines need to be further elucidated and the exact 
role of Web-based guidelines as a primary or secondary modality added to the 
traditional paper-based guidelines needs to be defined.
Furthermore, relatively passive methods of publication in professional journals 
or mailing to targeted healthcare professionals alone, are unlikely have an impact 
on professional acting.76, 77 The dissemination and implementation process should 
be arranged to take the intervention closer to the doctor/patient setting. In a 
systematic review of 91 studies, Grimshaw and Russell concluded that guidelines 
have the greatest chance of changing clinical behavior when they are disseminated 
via specific educational interventions, followed by continuing medical education, 
and implemented via patient-specific reminders during the consultation.78 A 
Cochrane Review analysed the effects of continuing education sessions and 
concluded that interactive workshops can result in moderately large changes 
in professional practice, whereas didactic sessions alone are unlikely to change 
professional practice.79 Other professional interventions that may lead to further 
reinforcement of guideline messages are reminders, audit and feedback.76 As for 
Web-based guidelines, Web-based learning in general possibly has a valuable 
educational contribution, but its full potential needs to be unlocked and its 
exact role needs to be established. Of course quality control of the disseminated 
information must be warranted and the principles of effective learning must be 
integrated. 
At present, there is insufficient evidence to allow an estimation of the 
efficiency and cost-effectiveness of the diverse professional dissemination and 
implementation strategies in different circumstances. Further research in this 
area is required to develop and validate a coherent framework that may sustain 
the process of introducing and establishing guidelines into clinical practice and 
may consequently result in significant improvements in educational outcomes 
and healthcare practices.80
Organizational interventions (e.g. expanded role of the pharmacist), financial 
interventions (e.g. professional incentives) and regulatory interventions (e.g. giving 
GPs access to specific diagnostic tests) have also been suggested to facilitate or 
stimulate the use of guidelines in clinical practice.81 However, caution should be 
paid to the implication of legal authorities or national health organizations in the 
process of guideline development, dissemination and implementation. Leaning 
on guidelines to guide or support governmental and healthcare policy decisions 
might generate discussions on the type of guidelines that should be used (e.g. 
national versus international). In addition,  it is associated with a potential risk of 
basing such important decisions on outdated guidelines,  and  of course it may 
imply a restriction of  medical freedom.
The final and most important step of putting guidelines into practice occurs at 
the level of the patient. Even if guidelines ensured the best clinical practice in the 
world, if patient’s behavior and knowledge is inappropriate, the outcomes may not 
change much. Patients should be considered as effective partners in healthcare. 
Educating the patient regarding the nature and management of their disease, 
teaching them how to verify received information, how to present symptoms and 
clinical history, and how to assess outcomes can maximize compliance, increase 
satisfaction and optimize health outcomes. Furthermore, patient’s feedback may 
act as a stimulus to health professional change.82
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CLASSIFICATION AND MANAGEMENT OF ALLERGIC RHINITIS 
PATIENTS IN GENERAL PRACTICE DURING POLLEN SEASON
Van Hoecke H, Vastesaeger N, Dewulf L,  Sys L, Van Cauwenberge P
Allergy 2006;61(6):705-11
ABSTRACT
BACKGROUND
AR (allergic rhinitis) represents a major challenge in primary care. The ARIA (Allergic 
Rhinitis and its Impact on Asthma) group proposed a new classification for AR and 
developed evidence-based guidelines for the management of this disease. We 
conducted this study to further characterize the classes of AR described by ARIA, 
and to evaluate whether the management of AR in general practice is happening 
according to the ARIA guidelines.
METHODS
During the pollen season of 2003, 95 Belgian GPs (general practitioners) enrolled 
804 patients, who presented with symptoms of AR. For each patient a questionnaire, 
comprising the clinical presentation and management was completed.
RESULTS
In 64% of the patients AR was classified as intermittent, in 36% as persistent. 
Persistent rhinitis caused more discomfort than intermittent rhinitis. Only 50% of 
the patients had ever undergone allergy testing. Among them, 51% were allergic to 
both seasonal and perennial allergens. 82% of the persistent rhinitics were allergic 
to at least one seasonal allergen and 72% of the intermittent rhinitics to at least 
one perennial allergen. When compared strictly with the ARIA recommendations, 
only 34.4% of the patients received a rhinitis treatment that was in accordance 
with the guidelines, 12.8% were undertreated and 52.7% were overtreated.
CONCLUSION
This study confirms that the previous classification of AR into seasonal and 
perennial is not satisfactory and that intermittent and persistent AR are not 
equivalent to seasonal and perennial AR respectively. Furthermore, persistent 
rhinitis has shown to be a distinct disease entity.
Further efforts are required to disseminate and implement evidence-based 
diagnostic and treatment guidelines for AR in primary care practice.
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INTRODUCTION
Over the last decades, the prevalence of allergic disorders has risen to epidemic 
proportions. Allergic rhinitis (AR) is the most common allergic disease, worldwide 
affecting up to 25% of the population. Due to its high and increasing prevalence, 
the significant impact on quality of life (QOL), the association with multiple 
comorbidities and the considerable costs in terms of use of healthcare resources, 
school or work absenteeism and loss of productivity, the disease represents a 
major global health concern. 
Nevertheless, the burden and consequences of AR are still often underestimated 
by healthcare providers, patients and their environment. Too often, the disease is 
underdiagnosed and remains mis- or un(der)treated, which leads to uncontrolled 
symptoms affecting work, home and social life.
To facilitate and standardize the management of AR and to improve the patient 
care -and consequently the patient satisfaction and compliance- several clinical 
guidelines have been developed. In 1994 and 2000, European guidelines for AR1,2 
were published, recommending a stepwise treatment approach. In 1999, the 
WHO initiative ARIA (Allergic Rhinitis and Its Impact on Asthma) Working Group 
was founded. The ARIA guidelines, resulting from this collaboration, are directed 
towards managing comorbid rhinitis and asthma as manifestations of one ‘united 
airway disease’, rather than as two separate diseases of the nose and lung. They 
also propose a stepwise treatment strategy for AR, but unlike the European 
guidelines, the ARIA guidelines are evidence-based.3
Whereas rhinitis was previously classified into seasonal and perennial (and by 
extension occupational), based on the type of exposure, the ARIA group reviewed 
and changed this classification into ‘intermittent’ or ‘persistent’ AR, on the basis of 
the duration of disease. The gradation of the severity of AR is based on the impact 
on QOL, rather than on (nasal) symptom scores.
For most patients suffering from AR, the GP (general practitioner) is the (first) 
point of contact and AR is identified as one of the top ten reasons for visits to 
primary care clinics.4 Consequently, the management of AR and the dissemination 
and implementation of guidelines for AR in general practice should receive much 
attention.
Despite the evidence that a guided strategy is superior to a non-guided one,5 the 
availability of rigorously developed guidelines does not ensure their use in clinical 
practice.6 We conducted this survey to evaluate whether the current knowledge 
regarding diagnostic methods and treatment regimens for AR is applied in daily 
primary care practice and to further characterize the different classes of AR, as 
described by ARIA.
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MATERIALS AND METHODS
DESIGN OF THE STUDY
In this cross-sectional pharmaco-epidemiological survey, Belgian GPs were asked 
to recruit consecutive patients who presented at their practice with symptoms 
of AR during the months February until July 2003, reflecting the tree- and grass 
pollen season. The GPs were instructed to include a maximum of 10 consecutive 
patients, to allow a fair distribution over the different practices. For every patient, a 
questionnaire was completed by the GP during the consultation. The questionnaire 
was designed in order to allow a classification of the patients according to ARIA 
and included following items: 
• Patient demographics: age and gender
• Duration of AR symptoms (number of days per week and number of 
consecutive weeks per year) 
• Impact of AR on the patient’s QOL, assessed by the 4 ARIA questions defining 
the severity of AR3 
• Clinical expression of AR and severity of symptoms, measured on a 4-point-
scale, evaluating whether AR manifests by these symptoms 1=never/rarely, 
2=occasionally, 3=frequently or 4=always. 
• Most bothersome symptom (rhinorrhea, nasal congestion, nasal itch, 
sneezing or conjunctivitis)
• Method of allergy diagnosis (with or without allergy testing: 
radioallergosorbent test (RAST) and/or skin test)
• Triggering allergens  (confirmed by positive allergy test)
• Treatment prescribed by GP: oral or nasal antihistamines, nasal 
decongestants, nasal or oral corticosteroids, ocular antihistamines or 
cromones  
• Referral to specialist
PATIENT CHARACTERISTICS, INCLUSION AND EXCLUSION CRITERIA
In order to have an optimal reflection of the AR patient population in daily practice, 
the exclusion criteria were reduced to a minimum: patients currently receiving 
treatment for AR and pregnant women. To avoid data based on hetero-anamnesis, 
the patients had to be at least 14 years old. A total of 804 patients, 50.9% males 
and 49.1% females, aged 36.4 ± 16.1 years old, were enrolled.
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RECRUITMENT OF GENERAL PRACTITIONERS
To allow maximal spread, 125 GPs were contacted and asked to participate in a 
total of 29 different geographical areas covering Belgium. 95 of the 125 contacted 
GPs agreed to participate, 77.9% males and 22.1% females. Among them, 
63.8% worked in a solo practice, 36.2% in a group practice. The distribution of 
the participating GPs was homogeneous throughout Belgium: 56.8% worked in 
Flanders, 35.8% in Wallonia and 7.4% in Brussels. 27.4% of the GPs practiced in 
an area with a population density of  < 250 inhabitants/km2, 24.2% in an area with 
251-500 inhabitants/km2, 25.3% in an area with 501-1000 inhabitants/km2 and 
23.1% in an area with more than 1000 inhabitants/km2.7 On average, 8.5 patients 
per investigator were included. 
STATISTICAL ANALYSIS
The descriptional part of the study uses conventional parameters: means ± 
standard deviations for quantitative variables; qualitative variables are represented 
in terms of percentages. Differences between subgroups are analyzed using Chi 
Squared Test for nominal or ordinal values, and Kruskal Wallis Test and Mann-
Whitney U Test for quantitative values. The significance level was set with an α risk 
= 0.05. All analyses were completed using SPSS Inc Chicago, version 11.
RESULTS
DURATION, SEVERITY AND ARIA CLASSIFICATION OF AR 
In 36.1% of the patients, symptoms of AR were present for more than 4 consecutive 
weeks and during more than 4 days a week. In 42.1% symptoms of AR were present 
for 4 or less consecutive weeks and in 21.8% symptoms of AR were present for 
more than 4 consecutive weeks, but only during 4 or less days a week. According 
to the ARIA classification, 36.1% of the patients were classified with persistent AR 
and 63.9% were classified with intermittent AR. 
Abnormal sleep was reported by 37.1% of the patients, impairment of daily 
activities, sports or leisure by 71.3%, impairment of work or school by 53.2% and 
troublesome symptoms by 77.6%. One or more of these 4 QOL items was (were) 
disturbed in 89.3% of the patients, who were consequently categorized with 
moderate/severe rhinitis. (TABLE 1)
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In the group of persistent rhinitics, all 4 QOL items were more frequently disturbed, 
when compared to the group of intermittent rhinitics. These differences reached 
significance for abnormal sleep and troublesome symptoms. Consequently, AR 
was significantly more often graded as moderate/severe in patients with persistent 
than in patients with intermittent disease. (TABLE 2)
TABLE 1.  Classi f icat ion of  the patients (n=804) into the 4 c lasses, 
as def ined by ARIA
Persistent Intermittent Total
Mild 17 (2.1%) 69 (8.6%) 86 (10.7%)
Moderate-Severe 273 (34.0%) 445 (55.3%) 718 (89.3%) 
Total 290 (36.1%) 514 (63.9%) 804 (100%)
TABLE 2.  Clinical  presentat ion of  patients with intermittent versus 
persistent al lergic  rhinit is .  NS:  no stat ist ical  s ignif icance
Persistent (n=514) Intermittent (n=290) P-value
Male/female 1.05 1.01 NS
Age in years (mean ± SD) 36.1 (± 15.9) 36.8 (± 16.5) NS 
Impaired sleep (%) 33.5 43.4 0.006
Impaired daily activit/leisure/sports (%) 69.8 73.8 NS
Impaired school/work (%) 51.4 56.6 NS
Troublesome symptoms (%) 73.5 84.8 <0.001
Moderate/severe AR (%) 86.6 94.1 0.001
Symptom scores (% with score 3 or 4)
Rhinorrhea 59.1 59.3 NS
Nasal congestion 58.4 66.2 0.03
Nasal itch 50.2 43.8 NS
Sneeze 61.9 62.4 NS
Conjunctivitis 37.4 43.8 0.09
Headache 11.7 15.5 NS
Somnolence 6.8 13.8 0.002
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CLINICAL PRESENTATION OF ALLERGIC RHINITIS
AR was accompanied by sneezing in 89.7% of the patients, by nasal congestion in 
86.6%, by rhinorrhea in 85.9%, by nasal itch in 81.0%, by conjunctivitis in 70.0%, by 
headache in 48.0% and by somnolence in 37.9%. (FIGURE 1)
Patients with moderate/severe rhinitis, demonstrated significantly higher symptom 
scores for rhinorrhea, nasal congestion, nasal itch, conjunctivitis, headache 
and somnolence compared to patients with mild rhinitis (TABLE 3).  Patients 
with persistent rhinitis had significantly higher scores for nasal congestion and 
somnolence and borderline significantly higher scores for conjunctivitis compared 
to patients with intermittent rhinitis (TABLE 2).
FIGURE 1.   Symptomatology of  al lergic  rhinit is  and severity  of  the 
manifestat ions (n=804)
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Of all patients, 38.3% were predominantly bothered by nasal congestion, 28.0% 
by rhinorrhea, 17.3% by conjunctivitis, 9.8% by sneezing and 6.6% by nasal itch. 
Patients predominantly suffering from nasal congestion reported significantly 
more abnormal sleep than all other patients (42.5% versus 33.7%, p=0.01), 
whereas patients especially bothered by conjunctivitis reported more impairment 
of daily activities, sport and leisure compared to all other patients (78.4% versus 
69.6%, p=0.05).
ALLERGY DIAGNOSIS AND RESPONSIBLE ALLERGENS
Of all patients, 47% had never undergone allergy testing to confirm the allergic 
basis of rhinitis. In 32% RAST and/or skin tests had been performed within the last 
2 years, and in 21% more than 2 years ago. The prevalence of allergy testing was 
significantly higher in the group of persistent rhinitics compared to intermittent 
rhinitics (69.3% versus 44.2%, p<0.001) and in the moderate/severe group 
compared to the mild AR group (54.6% versus 41.9%, p=0.03).
In 351 of the 428 ‘tested’ patients the cause of allergy was known: 65.2% of the 
patients were allergic to grass pollen, 63.8% to tree pollen, 63.0% to house dust 
mite (HDM) and 37.0% to animal dander. No significant differences were found 
between intermittent and persistent rhinitics in the prevalence of allergy due to 
grass pollen (respectively 65.4% and 65.1%), tree pollen (respectively 62.7% and 
53.6%), HDM (respectively 58.4% and 68.1%) or animal dander (respectively 34.6% 
and 39.8%).
Overall, 50.7% of the patients were allergic to both seasonal (grass and/or 
tree pollen) and perennial allergens (HDM and/or animal dander). In 82.5% of the 
persistent rhinitics, symptoms were provoked by at least one seasonal allergen 
(grass and/or tree pollen) and in 71.9% of those classified with intermittent rhinitis 
AR was triggered by at least one perennial allergen (HDM and/or animals). 
TABLE 3.  Clinical  presentat ion of  patients with mild versus 
moderate/severe al lergic  rhinit is .  NS:  no stat ist ical  s ignif icance
Mild (n=86) Mod/sev (n=718) P-value
Male/female 1.05 1.01 NS
Age in years (mean ± SD) 38.8 (± 18.5) 36.1 (± 15.8) NS 
Symptom scores (% with score 3 or 4)
Rhinorrhea 47.7 60.6 0.03
Nasal congestion 39.5 63.8 <0.001
Nasal itch 32.6 49.7 0.004
Sneeze 58.1 62.5 NS
Conjunctivitis 26.7 41.2 0.01
Headache 5.8 13.9 0.05
Somnolence 0.0 10.4 0.003
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PRESCRIBED TREATMENT AND SPECIALIST REFERRAL
None of the patients were on treatment for AR at the time of the visit (was part of 
the exclusion criteria). At the end of the visit, only 1 medication was prescribed in 
29.6% of the patients, 67.2% received a combination therapy and 3.2% received 
no prescription for medication. Overall, topical treatment was recommended in 
14.2%, oral therapy in 21.3%, while 61.3% received a combination of oral and 
topical medication. Oral antihistamines were the most frequently prescribed 
pharmacological agents (82.2%), followed by nasal corticosteroids (58.2%), nasal 
decongestants (18.6%), topical eye treatment (ocular antihistamine or cromone) 
(17.3%), nasal antihistamines (9.2%) and oral corticosteroids (5.3%).
9% of the patients were referred to a specialist. Specialist referral was 
significantly more often proposed in patients with persistent disease compared to 
patients with intermittent disease, but did not significantly differ between patients 
with mild or moderate/severe AR. Remarkably, 27.8% of the patients referred to a 
specialist did not receive any initial treatment from their GP.
Patients with mild AR more often received no medication than those with 
moderate/severe AR, but this difference only reached borderline significance. 
Corticosteroids were more often prescribed in persistent rhinitics than in 
intermittent rhinitics and in the moderate/severe group compared to the mild 
group. These differences reached significance for nasal corticosteroids, but not 
for oral corticosteroids. (TABLES 4 AND 5)
TABLE 4.  Therapeutic  management of  patients with intermittent 
versus persistent al lergic  rhinit is .  NS:  no stat ist ical  s ignif icance
Intermittent (n=514) Persistent (n=290) P-value
Oral antihistamines (%) 82.1 82.4 NS
Nasal antihistamines (%) 8.8 10 NS
Nasal corticosteroids (%) 53.1 67.2 <0.001
Oral corticosteroids (%) 4.9 6.2 NS
Nasal decongestants (%) 18.3 19.3 NS
Topical eye medication (%) 14.6 22.1 0.009
No medication prescribed (%) 3.3 3.1 NS
Specialist referral (%) 7.0 12.4 0.01
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We also compared the proposed medication for rhinitis symptoms in the different 
groups, defined by ARIA, with the recommendations of the ARIA guidelines 
(TABLE 6) . In total, only 34.4% of the patients received a rhinitis treatment that 
was  in accordance with the evidence-based ARIA treatment recommendations, 
12.8% were undertreated and 52.7% were overtreated.
TABLE 5.  Therapeutic  management of  patients with mild versus 
moderate/severe al lergic  rhinit is .  NS:  no stat ist ical  s ignif icance
Mild (n=86) Moderate/ Severe (n=290) P-value
Oral antihistamines (%) 62.8 84.5 <0.001
Nasal antihistamines (%) 8.1 9.3 NS
Nasal corticosteroids (%) 40.7 60.3 <0.001
Oral corticosteroids (%) 1.2 5.8 NS
Nasal decongestants (%) 22.1 18.2 NS
Topical eye medication (%) 12.8 17.8 NS
No medication prescribed (%) 7.0 2.8 0.08
Specialist referral (%) 7.0 9.2 NS
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TABLE 6.  Prescribed medicat ion for rhinit is  in the dif ferent patient 
groups,  c lassi f ied according to ARIA
Mild intermittent 
(n=69)
Mild persistent 
(n = 17)
Mod/sev intermitt 
(n = 445)
Mod/sev persis-
tent (n = 273)
NDC 3 (4.3%) / 5 (1.1%) 1 (0.4%)
AH1 21 (30.4%) 4 (23.5%) 134 (30.1%) 60 (22.0%)
AH1+NDC 15 (21.7%) / 29 (6.5%) 10 (3.7%)
NCS 11 (15.9%) 7 (41.2%) 30 (6.7%) 16 (5.9%)
NCS+NDC 1 (1.4%) / 4 (0.9%) 9 (3.3%)
NCS+AH1 10 (14.5%) 6 (35.3%) 178 (40%) 122 (44.7%)
NCS+AH1+NDC / / 27 (6.1%) 25 (9.2%)
OCS / / / /
OCS+AH1 1 (1.4%) / 7 (1.6%) 5 (1.8%)
OCS+NDC / / 2 (0.4%) /
OCS+AH1+NDC / / 4 (0.9%) 3 (1.1%)
OCS+NCS / / 1 (0.2%) /
OCS+NCS+AH1 / / 6 (1.3%) 2 (0.7%)
OCS+NCS+NDC / / / 1 (0.3%)
OCS+NCS+AH1+NDC / / 5 (1.1%) 7 (2.6%)
No rhinitis 
medication 7 (10.1%) / 13 (2.9%) 12 (4.4%)
Treated according 
to ARIA 39 (56.5%) 11 (64.7%) 202 (45.4%) 25 (9.2%)
‘Undertreated’ 7 (10.1%) 0 (0.0%) 13 (2.9%) 83 (30.4%)
‘Overtreated’ 23 (33.3%) 6 (35.3%) 230 (51.7%) 165 (60.4%)
NDC: nasal decongestant 
AH1: oral or nasal H1-antihistamine
NCS: nasal corticosteroid 
OCS: oral corticosteroid
Treated according to ARIA
Undertreated compared to ARIA recommendations
Overtreated compared to ARIA recommendations
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ALLERGIC RHINITIS TREATMENT IN VIEW OF THE MAIN 
SYMPTOMATOLOGY. 
Among the patients who predominantly suffered from nasal congestion 70.1% 
were prescribed a nasal corticosteroid, 20.8% a nasal decongestant and 4.2% 
an oral corticosteroid, whereas 19.8% received none of these potent anti-
congestive agents. Overall, patients who considered nasal congestion as the most 
bothersome symptom more often received a nasal corticosteroid (70.1% versus 
50.6%, p<0.001) compared to other patients, but no significant differences were 
found for nasal decongestants or oral corticosteroids.
Patients mostly bothered by eye symptoms received an ocular cromone or 
ocular antihistamine in 44.6% of the cases compared to 11.6% in the other patients 
(p<0.001); 48.5% did not receive topical eye medication, but were prescribed an 
oral antihistamine for the treatment of their allergic rhinoconjunctivitis.
DISCUSSION
For patients suffering from AR, the GP is often the first point of contact. As many 
rhinitis patients rely on their GP for the diagnosis and treatment of their symptoms, 
general healthcare practices represent an interesting and important target to 
evaluate the management of AR. The ARIA guidelines currently provide diagnostic 
and therapeutic recommendations for AR with the best available evidence. Our 
study was conducted 2 years after publication of the ARIA document,3 primarily to 
assess whether the criteria for diagnosis and the standards for effective treatment 
are applied in daily primary care practice (in Belgium).
Whereas ARIA insists on performing highly sensitive and specific in vivo or in 
vitro allergy tests to confirm or exclude an allergic etiology of rhinitis, we found that 
only half of the patients diagnosed with AR by their GP, had ever undergone allergy 
testing. In addition, less than 10% were referred to a specialist for further diagnostic 
or therapeutic management. These figures are similar to previous results,8, 9 and 
indicate that GPs do not commonly confirm or support their diagnosis of AR by 
skin or in vitro allergy tests and rarely ask advice from a specialist. In most cases, 
the diagnosis of AR is based on a typical clinical picture, consisting of sneezing, 
nasal congestion, rhinorrhea, nasal itch and often also conjunctivitis. In our study, 
these manifestations were part of the symptomatology in respectively 90%, 87%, 
86%, 81% and 70% of the patients. Although allergy tests were not routinely 
performed, we may assume that the number of falsely diagnosed allergic rhinitics 
is rathersmall, as the predictive value of clinical history alone in the diagnosis of 
AR has shown to vary between 82% and 85% for seasonal allergens and to be at 
least 77% for perennial allergens.10 
Similar to other pharmaco-epidemiological trials,8, 11 oral antihistamines were by 
far the most commonly prescribed first-line medications (82%). Despite of previous 
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reports that GPs seem to have some reluctance to use nasal corticosteroids 
for the treatment of AR,12 we found a rather high prescription rate, especially 
in patients with persistent (67%) or moderate/severe AR (60%) and in patients 
predominantly bothered by nasal congestion (70%). Currently, there is no proof for 
the additional beneficial effects of the combination of a nasal corticosteroid and 
an antihistamine compared to a nasal corticosteroid alone,13 but many experts 
feel that such superior value exists.2 This is also reflected in the pharmacological 
treatment, presented by the GPs in our study, with the combination of these 2 
agents (with or without addition of a nasal decongestant) prescribed in 15% of 
the mild intermittent, 35% of the mild persistent, 46% of the moderate/severe 
intermittent and 54% of the moderate/severe persistent rhinitis patients.
Nasal decongestants are very effective for the rapid relief of nasal congestion, 
but as they do not improve nasal itch, sneezing or rhinorrhea and hold a significant 
risk for rebound rhinitis in case of prolonged administration, their use(fulness) is 
limited. The GPs in our study, nevertheless, prescribed these agents in 20% of 
the patients and, remarkably, a similar prescription rate was found in patients 
who were and who were not predominantly bothered by nasal congestion! Oral 
corticosteroids, on the other hand, are never recommended as first-line treatment 
options for AR, but are preserved for the more treatment-resistant cases of AR. 
Belgian GPs, however, prescribed them as first-line treatment in 5% of the patients.
Only 34% of the patients received a rhinitis treatment that was  in accordance with 
the evidence-based ARIA treatment recommendations, 13% were undertreated 
and 53% were overtreated. Overtreatment mainly consisted of the prescription of 
nasal corticosteroids in the mild intermittent group and the combination of a nasal 
corticosteroid and an antihistamine in the mild persistent and moderate/severe 
intermittent and persistent groups. For moderate/severe persistent rhinitis, on 
the other hand, nasal corticosteroids are the first-choice treatment, but almost 
one third of this patient group was insufficiently treated.
From comparing the treatment strategies proposed by the GPs with the ARIA 
recommendations, we might conclude that the guidelines are only followed to 
some extent by the GPs. Of course, it should be recognized that the prescribed 
treatment is a result of an agreement between doctor and patient, and therefore 
some deviations from the gold standard are to be expected. In addition, the 
choice of treatment may also be affected by the presence of comorbid disease 
or the use of concomitant medication. In patients with comorbid asthma and 
rhinitis GP’s may prefer to prescribe a systemic treatment that is effective for both 
manifestations of the united airway disease and leads to increased compliance, 
instead of a combination of topical treatments. In patients, especially children, 
already treated with inhaled corticosteroids for asthma, on the other hand, they 
may want to limit the total corticosteroid dose by choosing other treatment 
options than nasal corticosteroids for AR.
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The results of this survey also allow us to formulate some reflections on the 
previous AR classification, based on the type of exposure, and on the newer ARIA 
classification, based on the duration of symptoms and their impact on QOL. The 
inclusion period of our study was limited to the tree and grass pollen season 
and this trial has an obvious recruitment bias. An overrepresentation of tree and 
grass pollen-allergic patients is expected, and this spring survey can not be used 
as an epidemiological study to assess the proportion of patients suffering from 
seasonal or perennial AR. Nevertheless, our results do confirm that the previous 
classification of AR is not adherent to real life as more than half of the patients had 
a ‘mixed’ form of AR, being allergic to both seasonal and perennial allergens. The 
ARIA classification has been validated by Demoly et al in a medical practice-based 
study in France14 and by Bauchau et al in a population-based cross-sectional study 
in 6 European countries15, 16. Both trials demonstrated that perennial allergens can 
cause intermittent symptoms and that seasonal allergens can cause persistent 
symptoms. We found 80% of the patients classified with persistent rhinitis to be 
allergic to tree- or grass pollen, and more than 70% of the intermittent rhinitics to 
be allergic to perennial allergens. These results, together and consistent with the 
findings of Demoly and Bauchau, demonstrate that persistent and intermittent 
AR are not equivalent to or interchangeable with perennial and seasonal AR 
respectively. Furthermore, persistent rhinitis has shown to be clearly different 
from and more debilitating than intermittent rhinitis. Bauchau et al reported a 
greater degree of self-awareness and previous diagnosis, more severe symptoms, 
a higher rate of doctor prescribed medication and a more regular use of 
medication in patients with persistent compared to intermittent rhinitis.16 We 
found that persistent rhinitics had a reduced QOL, marked by an increased rate 
of troublesome symptoms and impaired sleep, and that they reported more 
frequent symptoms of somnolence, conjunctivitis and nasal congestion compared 
to intermittent rhinitics. In addition, persistent rhinitis was associated with a 
higher degree of allergy testing and specialist referral. 
Furthermore, in our study, moderate/severe AR was associated with higher 
symptom scores for nasal congestion, rhinorrhea, nasal itch, conjunctivitis, 
headache and somnolence and a higher rate of doctor prescribed medication 
compared to mild AR. This demonstrates that the two severity categories for AR 
defined by ARIA based on the impact of AR on QOL, indeed represent a different 
burden of disease, also reflected by other outcome measures. Another important 
observation, however, is that - similar to the data of Demoly8, 11 - up to 90% of 
the patients were categorized with moderate/severe rhinitis. In addition, Bauchau 
reported that 45% of the AR patients in the general population are undiagnosed by 
a physician and that these previously undiagnosed patients have lower symptom 
severity.15 It may therefore be suggested that patients consulting their physician 
are those with moderate/severe rhinitis, whereas those with mild rhinitis often do 
not seek advice from professional healthcare providers.
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CONCLUSION
This study demonstrates that the ARIA guidelines are often not followed in 
general practice. To improve the management of a global health problem with 
increasing prevalence further efforts are required to disseminate and implement 
these evidence-based recommendations in primary care practice. In addition, our 
results support the validity of the ARIA classification and provide more information 
on the characteristics of AR patients in the different ARIA classification groups. 
A year-around assessment in the general population, however, is required to 
make an epidemiologically correct estimation of the proportion of AR patients in 
the four ARIA classes.
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IS THE ARIA CLASSIFICATION USEFUL IN DAILY 
PRIMARY CARE PRACTICE?
Van Hoecke H, Vastesaeger N, Dewulf L, De Bacquer D,  Van Cauwenberge P 
J Allergy Clin Immunol 2006;118(3):758-9
ABSTRACT 
BACKGROUND
The Allergic Rhinitis and its Impact on Asthma (ARIA) group proposed a new 
classification for allergic rhinitis (AR) based on the duration and severity of disease. 
AIM
As AR represents a major primary care problem and the ARIA guidelines were 
mainly developed to assist general practitioners, we wanted to assess whether 
the ARIA classification is applicable for the AR patient population in primary care 
practice. 
METHODS
During the pollen season of 2003, 95 Belgian general practitioners enrolled 804 
patients, who presented with symptoms of AR. For each patient a questionnaire, 
comprising the clinical presentation and management was completed.
RESULTS
As disease severity was graded as mild in only 10.7% and as moderate/severe 
in 89.3 %, we propose some suggestions to enlarge the criteria for ‘mild’ 
rhinitis and to subdivide ‘moderate/severe’ rhinitis into ‘moderate’ and ‘severe’. 
Classification of the 804 AR patients according to this empirical model results 
in 3 important groups, with the ‘moderate’ group containing most patients. The 
difference in disease severity between these 3 newly defined groups is reflected 
by the increasing symptom scores, the more profound diagnostic and therapeutic 
management from mild over moderate to severe AR.
CONCLUSION
We propose to change the ARIA classification for severity of AR from 2 to 3 
subgroups. Of course, this modification of the categorization of AR severity needs 
to be validated in large patient groups.
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INTRODUCTION
In 2001, the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative proposed a 
new classification for allergic rhinitis (AR) based on the duration of symptoms and 
their impact on the quality of life and formulated evidence-based guidelines for 
the treatment of this disease.1 AR is a major primary healthcare problem, and the 
ARIA guidelines were developed primarily to assist general practitioners (GPs) in 
their management of this condition. The classification scheme is the basis of the 
stepwise treatment recommendations and should be tailored to the AR patient 
population in daily general practice.
During the pollen season of 2003 we conducted a cross-sectional survey in 
general practice in Belgium. Ninety-five Belgian GPs enrolled 804 patients, who 
presented with symptoms of AR. For each patient a questionnaire, comprising 
the duration, severity, symptomatology and management of the disease, was 
completed. In a previous article we described the characteristics of the patients 
in the different ARIA classification groups, and we compared the management of 
AR in daily primary care practice with the ARIA recommendations.2 The results 
demonstrated that the classification of AR as persistent and intermittent, on the 
basis of the duration of disease, is not equivalent to the previous, unsatisfactory 
classification of AR as perennial or seasonal. These findings are similar to those 
from large epidemiological studies in the general population,3, 4 in primary care 
practice5 and in specialty practice6. On the other hand, the usefulness and validity 
of the classification of AR severity as mild or moderate-severe, based on the 
impact of AR on quality of life (QOL), are not verified with data. The results of 
our survey indicate that moderate-severe AR indeed represents a higher burden 
of disease than mild AR, as reflected by the higher scores for nasal and non-
nasal symptoms accompanying AR and the more complicated diagnostic and 
therapeutic management in moderate-severe compared to mild rhinitis.2 An 
important finding in our data is the disproportionate size of the classification, with 
the preponderance of subjects classified as moderate-severe rhinitis, 89.3%, and 
only 10.7% classified as mild.2 These data are similar to results of a year round 
assessment in general practice in France, in which 93% of the 3052 AR patients 
enrolled were classified with moderate/severe rhinitis.7 
We address the imbalance between mild and moderate/severe AR and propose 
a refinement of the current ARIA classification for AR severity. 
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RESULTS
Allergic Rhinitis and its Impact on Asthma defines the severity of AR on the 
basis of 4 quality of life items: (1) impairment of sleep; (2) impairment of daily 
activities, sports or leisure, (3) impairment of school or work; and (4) troublesome 
symptoms. If 1 or more of these items are present, rhinitis is classified as 
moderate/severe.1 In our study, abnormal sleep was reported by 37.1% of the 
patients, impairment of daily activities, sports or leisure by 71.3%, impairment 
of work or school by 53.2% and troublesome symptoms by 77.6%.2 Because 
86.9% of the patients with moderate/severe AR considered their symptoms as 
troublesome and only 9.8% of the patients reported troublesome symptoms in 
absence of impairment of daily activities/sports/leisure, school/work or sleep, the 
report of troublesome symptoms does not add appreciably to the assessment of 
disease severity. Furthermore, impairment of daily activities/sports/leisure and 
impairment of school/work both lead to a diminished quality of the active daily 
life, and we found an important overlap between these 2 items. Although more 
patients experienced discomfort from AR during their personal than during their 
professional life, 91.1% of those who reported problems at school or work were 
also bothered during daily activities, sports or leisure. 
On the basis of these findings, we suggest a modification in the current 
assessment of AR severity defined by ARIA. We propose to eliminate the question 
on troublesome symptoms as a key issue in the assessment of AR severity, and 
to recombine the question on impairment of daily activities, sports, leisure and 
the question on the impairment of school or work into 1 question evaluating the 
quality of the active daily life.
Taken together, this results in 2 questions to evaluate the severity of AR: 
1. Do your symptoms of AR cause sleep disturbance?
2. Do your symptoms of AR cause impairment of your daily personal (daily 
activities, leisure, sports) and/or professional life (school, work)? 
In this model, the severity of AR is classified into 3 groups, with patients responding 
‘no’ to both questions classified as ‘mild’, patients answering ‘yes’ to 1 of the 2 
questions as ‘moderate’ and patients answering ‘yes’ to both questions as ‘severe’. 
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Categorization of the 804 patients from our survey according to this empirical 
model resulted in 20.5% with ‘mild’ rhinitis, 45.9% with ‘moderate’ rhinitis and 
33.6% with ‘severe’ rhinitis. Table 1 compares symptom scores and Table 2 the 
diagnostic and therapeutic management in the new ‘mild’, ‘moderate’ and ‘severe’ 
AR groups.
CHAPTER IV
For all symptoms scores, except rhinorrhea, a linear increasing trend was found 
from mild to moderate to severe AR. Furthermore, the proportion of patients 
considering their symptoms as troublesome, the degree of allergy testing and 
the prescription rate of nasal and oral corticosteroids demonstrated a significant 
trend upwards with increasing AR severity category.
CONCLUSION
In conclusion, we propose to categorize the severity of AR into 3 instead of 2 groups, 
which in turn will allow a more gradual stepwise therapeutic approach. On the 
basis of the results of our study in general practice we suggest a modification in 
the current assessment of AR severity, using the 4 questions defined by ARIA. We 
here propose a very easy to use and to remember combination of two questions: 
one evaluating the patient’s quality of daily life and one evaluating the patient’s 
quality of sleep.
Classification of our patient population according to this empirical model 
results in 3 important groups, with the ‘moderate’ group containing most patients. 
The difference in disease severity between these 3 newly defined groups is 
reflected by the increasing symptom scores, the higher degree of allergy testing 
and increased prescription of corticosteroids from mild to moderate to severe AR.
Of course, this proposed modification in classification for AR severity needs to be 
validated in large patient groups. As the ARIA guidelines were mainly developed 
for GPs it is particularly important that the classification is applicable to the patient 
population in primary care practice. However, it would also be interesting to 
evaluate which types of AR patients remain undiagnosed in the general population 
and which types are most commonly in a specialist practice.
TABLE 1.  Symptom scores in the new ‘mild ’ ,  ‘moderate ’  and ‘severe ’ 
AR groups. 
Mild AR (165) Moderate AR (369) Severe AR (270) p
Rhinorrhea* 52.1 60.7 61.5 NS
Nasal congestion* 42.4 61.5 72.2 <0.0001
Nasal itch* 35.1 51.8 50.4 0.007
Sneeze* 55.8 61.0 67.4 0.01
Eye symptoms* 33.3 37.9 45.9 <0.0001
Headache* 4.2 12.5 19.2 <0.0001
Somnolence* 1.8 9.8 13.3 0.0001
Troublesome 
symptoms (%) 47.9 81.4 90.4 <0.0001
NS: not significant
Statistical analyses with Chi-square test for trends (Medcalc, version 8.1.0.0).
P<0.05 = statistically significant.
* Each symptom score is expressed as percentage of patients with score 3 or 4 (symptoms were 
scored on a 4-point-scale, evaluating whether AR manifests by these symptoms 1=never/rarely, 
2=occasionally, 3=frequently or 4=always.)
TABLE 2.  Symptom scores in the new ‘mild ’ ,  ‘moderate ’  and ‘severe ’ 
AR groups. 
Mild AR (165) Moderate AR (369) Severe AR (270) p
Allergy testing (ever) (%) 43.6 51.2 64.4 <0.0001
Treatment prescribed (%)
Oral antihistamines 70.3 84.8 85.9 0.0002
Nasal antihistamines 11.5 8.1 9.3 NS
Nasal corticosteroids 46.7 54.7 70.0 <0.0001
Oral corticosteroids 3.0 3.8 8.9 0.004
Nasal decongestants 17.6 15.4 23.7 NS
Topical eye medication 14.5 19.0 16.7 NS
Specialist referral (%) 7.9 6.2 13.3 0.02
NS: not siginificant
Statistical analyses with Chi-square test for trends (Medcalc version 8.1.0.0). 
P<0.05 = statistically significant.
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CHAPTER V
THE ARIA GUIDELINES IN SPECIALIST PRACTICE: 
A NATIONWIDE SURVEY
Van Hoecke H, Van Cauwenberge P, Thas O, Watelet JB
Rhinology 2010;48(1):28-34
ABSTRACT
PROBLEM
In 2001, the ARIA guidelines were published to assist healthcare practitioners 
in managing allergic rhinitis (AR) according to the best evidence. Very limited 
information, however, is available on the impact of these guidelines on clinical 
practice.
METHODS
All Belgian Otorhinolaryngologists were invited to complete a questionnaire, 
covering demographic and professional characteristics, knowledge, use and 
perception of the ARIA guidelines and 4 clinical case scenarios of AR. 
RESULTS
Of the 258 (44%) Belgian Otorhinolaryngologists who participated, almost 90% 
had ever heard about ARIA and 64% had followed a lecture specifically dedicated 
to the ARIA guidelines. Furthermore, 62% stated to always or mostly follow the 
ARIA treatment algorithms in the daily management of AR patients. In the clinical 
case section, adherence to the ARIA guidelines raised with increased self-reported 
knowledge and use of the ARIA guidelines and among participants that considered 
the guidelines more user-friendly. Of the respondents, 51% were considered as 
good compliers. Younger age was a significant predictor for good compliance.
CONCLUSION
More efforts are required to improve the translation of scientific knowledge into 
clinical practice and to further identify which factors may influence guideline 
compliance.
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INTRODUCTION
Allergic rhinitis (AR) affects one into four people worldwide, causes significant 
impairment of the personal, social and professional life and has substantial 
economic consequences.1, 2 Despite the wealth of information available on the 
pathophysiology, diagnosis and treatment of AR, this disease remains too often 
unrecognized, underestimated and inadequately treated.3, 4
Over the last decades, clinical practice guidelines have gained a lot of interest 
as a support to synthesize clinical information, to assist health care providers in 
the management of their patients and to improve the quality of healthcare.
Several national and international guidelines, specifically dedicated to AR have 
been designed,5-8 but it wasn’t until 2001 that the first evidence-based guidelines 
for AR, the ARIA guidelines (Allergic Rhinitis and its Impact on Asthma) guidelines, 
were published.9 The ARIA guidelines were developed in collaboration with the 
World Health Organization (WHO) and provide general practitioners (GPs) and 
specialists dealing with AR patients with stepwise treatment algorithms, based on 
a new classification of AR in terms of the duration and severity of disease.
It has previously been demonstrated that following guidelines has favorable 
effects on healthcare and patient outcomes. Implementation of the GINA guidelines 
in childhood asthma showed to reduce daytime and nighttime symptoms, activity 
limitations and drug use and to improve quality of life in patients and their 
families.10 At the time of this publication, the only guidelines for AR that have been 
assessed for their effects on health outcomes are those from the International 
Rhinitis Management Group.5 Application of these guidelines demonstrated to be 
significantly better than treatment according to the GPs’ free choice, as reflected 
by reduced symptom scores and increased quality of life, patient compliance and 
satisfaction.11 In these validation studies, however, healthcare providers were 
explicitly asked to follow the guideline recommendations, whereas, in real life, 
availability of guidelines does not ensure their use, and the impact of guidelines 
on daily practice patterns remains uncertain.
The translation of scientific knowledge into clinical practice and physician 
adherence to guidelines is often complicated by structural, cultural, socio-
economic and behavioral barriers.12-14 Physicians’ knowledge of, attitude towards 
and compliance with clinical guidelines should therefore also be evaluated next to 
measuring effectiveness of clinical practice guidelines, based on patient outcomes. 
As specialists of the upper respiratory tract, Otorhinolaryngologists play a 
key role in the management of AR and its several associated conditions in the 
upper airways, including rhinosinusitis, nasal polyps, adenoid hypertrophy, tubal 
dysfunction, otitis media with effusion and laryngitis.15 Furthermore, they are 
often considered as a point of referral when rhinitis management in primary care 
practice remains unsatisfactory.
CHAPTER V
We conducted a survey 1) to assess treatment practices of AR in specialist 
practice, 2) to assess the knowledge and use of the ARIA guidelines among Belgian 
Otorhinolaryngologists, and 3) to gain information on physician characteristics 
that may influence compliance with the guideline recommendations.
MATERIALS AND METHODS
QUESTIONNAIRE DEVELOPMENT AND DATA COLLECTION
We designed a questionnaire in multiple response format that covered following 
items:
• Demographic and professional details;
• Dissemination of the ARIA guidelines; 
• User-friendliness of the ARIA guidelines ;
• Self-reported knowledge of the ARIA classification and ARIA treatment 
recommendations, assessed with a four-point Likert scale  (1: not at all 
familiar, 2: a little familiar, 3: somewhat familiar, 4: very familiar); 
• Test question on the ARIA classification to detect potential bias in self-
reported knowledge (‘According to ARIA allergic rhinitis is classified into: 
1: seasonal or perennial, 2: acute, chronic or recurrent 3: intermittent or 
persistent, 4: periodic or non-periodic);
• Self-reported use of the ARIA classification and ARIA treatment 
recommendations, assessed with a four-point Likert scale (1: never, 2: 
sometimes, 3: mostly, 4: always);
• Presentation of 4 clinical scenarios, representing different types of AR, 
where the respondents were asked to select the treatment or combination 
of treatments they would recommend (environmental control measures, 
oral H1-antihistamine, oral decongestant, oral corticosteroid, nasal 
H1-antihistamine, nasal decongestant, nasal corticosteroid, ocular H1-
antihistamine, ocular cromone, (referral) for immunotherapy or other, with 
free text space to specify).
Initially, the questionnaire was developed in English and translated into French 
and Flemish, followed by back-translation into English, with modifications if 
necessary. The questionnaire was distributed in French and Flemish, the 2 major 
national languages. Additional minor amendments of the initial survey were made 
after the questionnaire was pilot tested among 15 Otorhinolaryngologists. In May 
2005, the final questionnaire was sent to all fully-trained and practicing Belgian 
Otorhinolaryngologists (n=598). A reminder was sent to the non-respondents 
4 weeks after the initial mailing. The physicians had the possibility to respond 
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by completing and sending back the anonymized postal questionnaire in an 
accompanying return-stamped envelope or by completing the questionnaire on a 
website for which they received a login.
The Ethics Committee of Ghent University Hospital approved the conditions 
and application of the survey.
CLINICAL CASE SECTION
For the 4 clinical scenarios the treatment proposed by the respondents was 
strictly compared with the treatment recommendations of the ARIA guidelines, 
available at that time9 (APPENDIX 1) . A score of 0 (treatment not consistent with 
ARIA recommendations, resulting from over- or undertreatment) or 1 (treatment 
consistent with ARIA recommendations) was attributed per case, resulting in a 
total score ranging from 0 to 4 per respondent. Upon further analysis, compliance 
with the ARIA guidelines in the clinical scenarios was dichotomized into ‘poor 
compliance’ or ‘good compliance’. Good compliance was set at a total score above 
the mean outcome.
STATISTICAL ANALYSIS 
The descriptive part of the study uses conventional parameters: means ± standard 
deviations for quantitative variables; qualitative variables are represented in 
terms of percentages. Statistical differences for means of quantitative values 
were analyzed using the independent samples t-test. To assess a linear trend in 
proportions of nominal or ordinal values across subgroups Chi square test for 
trends was used.
The influence of demographic and professional variables on compliance with 
the ARIA guidelines in clinical case scenarios was assessed using multivariate 
logistic regression. The following demographic and professional characteristics 
were considered to potentially influence guideline compliance and were included 
in the regression analysis: gender, age, years of practice, specialty, proportion of 
AR patients in practice and type of practice. As age and years in practice were 
strongly correlated (Spearman correlation coefficient 0.98, p<0.001), only age was 
entered into the regression model. 
Significance level was set at α = 0.05. Analyses were completed using SPSS Inc 
(Chicago, ILL, USA; version 16.0, Nov 2007).
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RESULTS
BASELINE CHARACTERISTICS OF THE RESPONDENTS
Of the 598 Otorhinolaryngologists that were contacted, 4 were ineligible because 
they were no longer practicing Otorhinolaryngology and 6 questionnaires were 
returned because of incorrect mail addresses. After 2 mailings, 258 questionnaires 
were returned, yielding an overall response rate of 43.9%. Demographic and 
professional details of the respondents are summarized in TABLE 1 .
TABLE 1.  Demographic and professional  detai ls  of  the respondents 
N % Mean (SD) Range
Gender (male) (256 respondents) 166 64.8
Age (years) (257 respondents) 47.9  (11.2) 31-77
Number of years in practice (years) 
(257 respondents)
17.8  (11) 1-48
Estimated proportion of AR patients among 
all patients treated (254 respondents) 
<10% 57 22.4
10-20% 137 53.9
20-30% 49 19.3
>30% 11 4.3
Practice type (258 respondents)   
University hospital 58 22.5
Non-university, teaching hospital 46 17.8
Non-university, non-teaching hospital 123 47.7
Not hospital affiliated 31 12.0
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42.6% (110/258) of the respondents considered the ARIA guidelines as very user-
friendly, 26.7% (69/258) as moderately user-friendly and 15.9% (41/258) as not 
user-friendly, with an additional 14.7% (38/258) claiming they were not familiar 
enough with guidelines to formulate an opinion.
CHAPTER V
SELF-REPORTED KNOWLEDGE AND USE OF THE ARIA 
CLASSIFICATION AND ARIA TREATMENT RECOMMENDATIONS
26.4% (68/257) of the respondents reported to be very, 38.9% (100/257) 
somewhat, 18.7% (48/257) a little and 16.0% (41/257) not at all familiar with the 
ARIA classification. Similarly, 31.4% (81/258) responded to be very, 41.5% (107/258) 
somewhat, 12.4% (32/258) a little and 14.7% (38/258) not at all familiar with the 
ARIA treatment recommendations. To detect potential bias in self-reported 
knowledge, a test question on the ARIA classification was included. The correct 
response rate to this question significantly increased (p<0.001) with increased 
self-reported knowledge of the ARIA classification, and among participants 
claiming to be very familiar with the ARIA classification only 7.4% gave an incorrect 
answer (TABLE 2) .
DISSEMINATION OF THE ARIA GUIDELINES
87.2% (224/257) of the respondents stated that they had ever heard about the 
ARIA guidelines and 64.2% (165/257) had ever followed a lecture specifically on this 
topic. For the group that had ever heard about ARIA, scientific presentations were 
the most frequently cited source to become aware of the guidelines, whereas the 
medical literature, representatives from the pharmaceutical industry, colleagues 
and the internet were less often mentioned (FIG 1) . 
FIGURE 1.   Sources of  init ial  contact  with the ARIA guidel ines.  Among the 
respondents that had ever heard about the ARIA guidel ines,  sources of 
ini t ial  contact  were scient i f ic  presentat ions (146/224) ,  peer-reviewed 
journals (14/224) ,  leaf lets/brochures (15/224) ,  col leagues (11/224) , 
pharmaceutical  industry representat ives (16/224) and other sources 
including the internet and company sponsored events (22/224) .
65.20%
Scientific presentation
Peer-reviewed journal
Leaflet, Brochure, …
Colleague
Pharmaceutical industry 
representatives
Other e.g. internet, 
company sponsored, …
6.3%
6.7%
4.9%
7.1%
9.8%
10.5% (27/257) of the respondents reported to use the ARIA classification always, 
20.2% (52/257) sometimes, 17.9% (46/257) mostly, but the majority of 51.4% 
(132/257), answered that they never used this classification. On the other hand, 
only 23.6% (61/258) of the respondents claimed they never followed the ARIA 
treatment recommendations, whereas 48.8% (126/258) reported to follow them 
mostly, 13.6% (35/258) always and 14.0% (36/258) sometimes.
Self-reported use of the ARIA classification and ARIA treatment recommendations 
significantly (p<0.001) increased with increased level of self-reported knowledge 
of the classification (TABLE 2)  and the recommendations (results not displayed, 
p<0.001) respectively.
TREATMENT PRACTICES OF AR, COMPLIANCE WITH THE ARIA 
GUIDELINES IN CLINICAL CASE SCENARIOS
APPENDIX 2  represents the treatment modalities selected in the 4 clinical scenarios. 
A treatment consistent with the ARIA recommendations was proposed by 18.2% 
of the participants for scenario 1, 49.2% for scenario 2, 50.0% for scenario 3 and 
47.2% for scenario 4. Upon calculation of the individual total scores obtained in 
TABLE 2.  Self -reported knowledge and use of  the ARIA c lassi f icat ion
Self-reported knowledge of ARIA 
classification in % (n)
Self-reported use of ARIA 
classification 
(% using classification 
mostly or always)
ARIA classification test 
(% with correct response)
Not at all familiar 16.0 (n=41) 0.0 26.8 
A little familiar 18.7 (n=48) 2.1 39.6
Somewhat familiar 38.9 (n=100) 27.0 70.0
Very familiar 26.5 (n=68) 75.0 92.6
Significance of linear trend (p) <0.001 <0.001
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the 4 clinical scenarios, 21.0% (53/252) of the participants obtained a score of 0, 
27.8% (70/252) a score of 1, 29.0% (73/252) a score of 2, 18.3% (46/252) a score of 
3 and 4.0% (10/252) a score of 4. 
Significantly higher scores were obtained by respondents self-reporting to be 
very or somewhat familiar with the ARIA treatment recommendations compared to 
those that were a little or not at all familiar with the recommendations (mean score 
of 1.67 ± 1.12 versus 1.27 ± 1.10, t = -2.46, p = 0.015) and by Otorhinolaryngologists 
that considered the ARIA guidelines as very user-friendly compared to those that 
considered them as moderately or not user-friendly (1.82 ± 1.09 versus 1.40 ± 
1.14, t = -2.71, p = 0.007). Specialists self-reporting to always or mostly follow the 
ARIA recommendations scored significantly higher than those reporting to follow 
them sometimes or never (mean score of 1.69 ± 1.10 versus 1.35 ± 1.14, t = -2.39, 
p= 0.018). Nevertheless, only 9% (3/33) of the respondents claiming to always follow 
the ARIA recommendations proposed a treatment that was fully consistent with 
the ARIA guidelines in all 4 clinical case scenarios and still 45% (15/33) obtained a 
score of only 0 or 1 (indicating that they proposed a treatment was not consistent 
with the ARIA recommendations in respectively 4 or 3 of the 4 presented clinical 
scenarios). (FIG 2)
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DETERMINANTS OF GUIDELINE COMPLIANCE
Good compliance with the ARIA guidelines was defined as obtaining a score of 
≥ 2 in the clinical scenario section, resulting in 48.8% (123/252) poor compliers and 
51.2% (129/252) good compliers. Multivariate logistic regression analysis showed 
no influence at the 5% significance level of gender, practice type, (sub)specialty or 
proportion of AR patients on compliance with the ARIA recommendations. Age, 
on the other hand, was identified as a significant predictor of compliance. For an 
increase of age with one year the odds of guideline compliance decreased with a 
factor 0.92 (95% confidence interval = 0.89 to 0.95). This conclusion is corrected 
for all other factors in the model (TABLE 3). 
FIGURE 2.   Symptomatology of  al lergic  rhinit is  and severity  of  the 
manifestat ions (n=804)
TABLE 3.  Adjusted odds rat io and confidence interval  for compliance 
with ARIA guidel ines in c l inical  case scenarios (* = p<0.001)
Odds ratio 95% confidence interval
Age 0.92 0.89 to 0.95*
Gender
Male 1.48 0.78 to 2.83
Female 1
 (Sub)specialisation
General ENT specialist 0.61 0.25 to 1.46
Rhinologist/allergologist 0.96 0.4 to 2.3
Other subspecialist 1
Proportion of AR patients 
<10% 0.85 0.19 to 3.80
10-20% 0.74 0.18 to 3.02
20-30% 0.74 0.17 to 3.18
>30% 1
Practice type
University hospital 0.63 0.19 to 2.06
Non university teaching hospital 0.44 0.14 to 1.39
Non university non teaching hospital 0.73 0.28 to 1.90
No hospital practice 1
114 115
CHAPTER V
DISCUSSION
Four years after publication of the ARIA guidelines for AR, the dissemination and 
implementation of these guidelines among Otorhinolaryngologists were assessed 
for the first time. This study has some obvious limitations. First, results are based 
on the responses of Otorhinolaryngologists, who were willing to participate. 
Nothing can be said about the non-respondents, who made up 56 % of the original 
sample, why they did not return the questionnaire and whether they differ from 
those who did return it. Second, the study population was limited to Belgian 
Otorhinolaryngologists, whose behavior may vary from that of their colleagues 
in other parts of the world. Third, data are based on self-reports and responses 
to hypothetical case descriptions, which may be different from actual practice 
patterns. Well-constructed clinical case scenarios, however, have demonstrated 
to reflect the actual clinical behavior of a group of physicians.16-18 Fourth, in the 
case scenario section, for every treatment that was not entirely consistent with 
the ARIA recommendations a score of 0 was attributed and no distinction was 
made between treatments that deviated ‘strongly’ or ‘slightly’ from the ARIA 
recommendations.
Despite these limitations, our results clearly show that there remains an 
apparent lack of influence of guidelines on health professionals’ behavior. In this 
context, three broad areas of concern have to be considered: i) the methodology 
of guideline development, ii) the process of guideline dissemination and, finally, iii) 
the implementation of the guideline recommendations in daily medical practice.19 
For the ARIA guidelines, considerable attention has been paid to the development 
and dissemination processes. The ARIA guidelines are evidence-based, developed 
by a multidisciplinary, international panel and introduced a new classification for 
AR, whose benefits have already previously been validated.20, 21 The guidelines have 
been widely distributed to healthcare providers dealing with AR patients, through 
publication of a full workshop report,9 an executive summary,22 ample citations 
in other articles, pocket guides in more than 20 languages and an impressive 
amount of lectures in all corners of the world. The extensive promulgation efforts 
are reflected in our survey, with 87% of the respondents having ever heard about 
ARIA, 64% having ever followed a scientific lecture on the ARIA guidelines, and 73% 
reporting to be very or somewhat familiar with the ARIA recommendations. 
Whereas the dissemination process is focused on educational interventions 
that aim at influencing clinicians’ awareness and understanding of the guidelines, 
implementation is much more complex, and involves strategies to translate 
knowledge into changes in medical practice, with impact on patient care. Very few 
data are available on the implementation of the ARIA guidelines, which should 
be evaluated as a continuum from dissemination, to awareness, to attitude, and 
finally, to adherence.12 In the present survey, ENT-specialist’s  adherence to the 
ARIA guidelines was assessed in 4 clinical case scenarios. Overall, only 51% of 
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the respondents were considered as good compliers, but specialists, that were 
more familiar with the ARIA guidelines and that considered the ARIA guidelines 
as user-friendly, more often proposed a treatment consistent with the ARIA 
recommendations. However, we acknowledge that other factors than lack of 
awareness, lack of familiarity and lack of user-friendliness of guidelines can act as 
barriers to guideline implementation. In the future, the impact of agreement or 
disagreement with the specific guideline recommendations, outcome expectancy, 
self-efficacy, motivation, practice habits, time, resources, infrastructure, 
reimbursement strategies, organizational or regulatory framework and patient 
preferences on guideline compliance  should also be evaluated.12
As expected, a higher self-reported use of the ARIA guidelines was also reflected 
in increased adherence to the ARIA treatment recommendations in the clinical 
case section. But still, among the Otorhinolaryngologists, self-reporting to always 
practice in accordance with the ARIA guidelines, only 9% proposed a treatment 
that was fully consistent with the ARIA recommendations. These findings could 
demonstrate that self-reported adherence to guidelines is subject to social 
desirability bias and interviewer bias, and in general represents an overestimation 
of actual guideline adherence.23 On the other hand, it could also indicate that 
application of the ARIA guidelines in a clinical setting is not straightforward or that 
the ARIA recommendations are sometimes misinterpreted.
Whereas gender, subspecialty in rhinology/allergology, working at a University 
or teaching hospital and a higher proportion of AR patients in practice did not seem 
to influence compliance with the ARIA guidelines, we found that younger age was a 
significant predictor for good compliance. Similar findings of declining adherence 
to clinical practice standards and evidence-based guidelines with increasing age 
and experience have also been reported in other areas of medicine.24, 25 A possible 
explanation is that the introduction of guidelines into clinical training and practice 
and the evolution of opinion-based to evidence-based medicine dates from the 
last 15 years. It is well known that physicians not easily change their longstanding 
prescribing patterns, and inertia of previous practice has been identified as a 
barrier to the incorporation of guidelines into practice.12 On the other hand, we 
recognize that staying up-to-date can be difficult and even confusing when different 
guidelines, providing conflicting recommendations, are promoted within a short 
time interval. Less than 2 years before the publication of the ARIA guidelines, the 
‘Consensus statement on the treatment of allergic rhinitis’ was developed by the 
European Academy of Allergology and Clinical Immunology (EAACI)6. Although 
not evidence-based, these guidelines also provide stepwise treatment algorithms 
for the management of AR. An important difference is that the EAACI guidelines 
recommend to combine an antihistamine and a nasal corticosteroid as a first-
line treatment in severe cases of AR, whereas the ARIA guidelines follow a more 
stepwise approach and only recommend this combination if treatment with an 
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antihistamine or a nasal corticosteroid alone fails.6, 9 In the clinical case scenarios 
we found that the combination of an antihistamine and a nasal corticosteroid 
as a first-line treatment was recommended by many specialists, and that the 
prescription of this combination accounted for one of the most frequent reasons 
of inconsistency with the ARIA guidelines.
CONCLUSION
Despite the wide promulgation of the ARIA guidelines, many specialists dealing 
with AR patients remain only poorly influenced by these evidence-based 
recommendations. Translation of scientific knowledge into clinical practice is not 
straightforward and adherence to guidelines is undermined by several barriers at 
the level of physicians’ knowledge, attitudes and practice behavior.
We found that older, more experienced Otorhinolaryngologists were more 
unlikely to adhere to the guidelines than their younger colleagues and that younger 
age (or less clinical experience) was a significant and independent predictor for 
good compliance with the ARIA treatment recommendations. However, further 
research is needed to determine the factors influencing poor compliance before 
selecting effective interventions to change physicians’ practice behavior.
Nevertheless, we recognize that a treatment remains a result of an agreement 
between doctor and patient and is always influenced by the individual context. 
The main goal of guidelines is to assist physicians and to improve patient care, 
which implies that they should be developed and considered as a support for 
practitioners with space for flexibility, rather than as a set of constrained rules.
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APPENDIX 1:  Treatment recommendations of  the ARIA guidel ines 9 
for the dif ferent case scenarios.  Decongestant*:  short  course of 
oral  or nasal  decongestant.
Case scenario AR classification 
(according to ARIA)
Treatment recommended 
according to ARIA guidelines9
1 Currently untreated patient, allergic 
to house dust mite, who is suffering 
from rhinorrhea, sneezing and 
nasal congestion since 2 months. 
Symptoms interfere with the patient’s 
quality of sleep.
Moderate-severe 
persistent AR
• Allergen avoidance
• And nasal corticosteroid ± 
decongestant*
2 Currently untreated patient who has 
experienced sneezing, rhinorrhea, 
nasal congestion and red and tearing 
eyes for the last month, especially 
when he’s working in the garden. 
Besides these symptoms, the patient 
has no complaints.
Mild intermittent AR 
with conjunctivitis
• (Allergen avoidance)
• (And) oral H1-antihistamine ± 
decongestant* 
Or nasal H1-antihistamine 
+ topical eye treatment ± 
decongestant*
3 Currently untreated patient, allergic 
to birch, who is especially suffering 
from nasal congestion for the last 2 
weeks. The patient is having exams 
and says that he’s bothered during 
studying.
Moderate-severe 
intermittent AR
• (Allergen avoidance)
• (And) oral H1-antihistamine ± 
decongestant* 
Or nasal H1-antihistamine ± 
decongestant* 
Or decongestant 
Or nasal corticosteroid ± 
decongestant*
4 Patient with manifest symptoms of 
allergic rhinitis due to house dust 
mite and currently treated with an 
oral antihistamine. This treatment 
provides insufficient symptom relief.
Step up treatment 
oral antihistamine
• Allergen avoidance
• And nasal corticosteroid ± 
decongestant* 
Or oral H1-antihistamine 
+ nasal corticosteroid ± 
decongestant*
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APPENDIX 2:  Treatment modali t ies selected in 4 case scenarios of  al lergic 
rhinit is .  Treatments consistent with the ARIA guidel ines 9 are in bold.
Clinical scenario 1 
Selected treatment or combination of treatments % (n)
OAH1/NAH1 + NCS + AA  45.6 (115)
NCS + AA  18.2 (46)
IT*  9.9 (25)
OCS**  4.8 (12)
OAH1/NAH1 + NCS  5.6 (14)
OAH1/NAH1 + NCS + DC + AA  5.2 (13)
OAH1/NAH1 + AA  4.0 (10)
OAH1/NAH1  2.0 (5)
OAH1/NAH1 + NCS + DC  1.6 (4)
NCS  1.2 (3)
AA  1.2 (3)
Other  0.8 (2)
Consistent with ARIA recommendations 18.2 (46)
Clinical scenario 2 
Selected treatment or combination of treatments % (n)
OAH1 +/- TEM +/- AA  42.5 (107)
OAH1 + NCS  +/- TEM +/- AA  30.6 (77)
NCS + TEM +/- AA  7.9 (20)
IT*  6.0 (15)
NAH1+ TEM +/- AA  4.4 (11)
OAH1 +/- TEM + DC +/- AA  2.4 (6)
NCS +/- AA  2.4 (6)
OCS**  1.6 (4)
Other  2.4 (6)
Consistent with ARIA recommendations 49.2 (124)
Clinical scenario 3 
Selected treatment or combination of treatments % (n)
OCS**  17.1 (43)
NCS +/-AA  16.3 (41)
OAH1/NAH1 + NCS  +/- DC  14.7 (37)
NCS + DC +/- AA  13.1 (33)
OAH1/NAH1 + DC +/- AA  10.7 (27)
OAH1/NAH1 + NCS + DC +/- AA  10.7 (27)
OAH1/NAH1 + DC +/- AA  5.2 (13)
IT*  5.2 (13)
DC +/- AA  4.8 (12)
IMCS  2.4 (6)
Consistent with ARIA recommendations 50.0 (126)
Clinical scenario 4 
Selected treatment or combination of treatments % (n)
IT*  45.2 (114)
NCS + AA  21.4 (54)
OAH1/NAH1 + NCS  + AA  15.1 (38)
NCS  6.0 (15) 
OCS**  5.2 (13)
OAH1 + NCS  3.2 (8)
OAH1 + NCS + DC + AA  1.6 (4)
AA  1.6 (4)
Other  0.8 (2)
Consistent with ARIA recommendations 47.2 (119)
OAH1: oral H1-antihistamine 
NAH1: nasal H1-antihistamine 
NCS: nasal corticosteroid 
OCS: oral corticosteroid (short course) 
OCS**: usually proposed in combination with or followed by diverse anti-allergic medications 
DC: oral or nasal decongestant (short course) 
TEM: topical eye medication (ocular H1-antihistamine or cromone) 
IMCS: intramuscular corticosteroid 
IT: immunotherapy 
IT*: usually proposed in initial combination with diverse anti-allergic medications 
AA: allergen avoidance
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ABSTRACT
BACKGROUND
Allergic rhinitis (AR) is a prevalent problem in general practice. The first evidence-
based guidelines for AR, the ARIA guidelines, were published and repeatedly 
updated since 2001 in order to improve the care of AR patients. Very limited 
information, however, is available on the impact of these guidelines on everyday 
clinical practice. The aim of this study was to evaluate the dissemination and 
implementation of the ARIA guidelines in general practice. 
METHODS
 350 Flemish general practitioners (GPs) were recruited to complete a questionnaire, 
covering demographic and professional characteristics, awareness, perception 
and implementation of the ARIA guidelines. To assess compliance with the ARIA 
treatment recommendations, 4 fictitious case scenarios of AR were presented, in 
which the respondents were asked to select the treatment of choice. 
RESULTS
Of the 350 included GPs, only 31% were aware of the ARIA guidelines and 10% 
stated to implement them. For the diagnosis of AR, 71% of the GPs ask specific IgE 
tests or perform skin prick tests, whereas only 29% perform an anterior rhinoscopy. 
ARIA users are more likely to screen for concomitant asthma. In the clinical case 
section there was a large variability in proposed therapeutic strategies. Adherence 
to the evidence-based ARIA treatment guidelines was low, but recent graduation 
was a significant predictor of compliance with these recommendations.
CONCLUSIONS
The ARIA guidelines remain relatively unknown among Flemish GPs and even those 
who are aware of them still tend to treat AR independently from the guideline 
recommendations. 
126 127
CHAPTER VI
INTRODUCTION
Allergic rhinitis (AR) is the most common chronic disease of the developed world, 
and is becoming increasingly important in developing countries.1 AR is estimated 
to affect up to one into 4 people, has a serious impact on the personal and social 
well-being, the professional and academic performance, is associated with several 
coexisting conditions (e.g. asthma, sinusitis, conjunctivitis and otitis media), and 
represents an important source of direct and indirect costs for the individuals 
and the society. Nevertheless the disease often remains unrecognized, un(der)
diagnosed, trivialized and inadequately treated.2
In 2001 the first evidence-based guidelines for AR were published: the ARIA 
(Allergic Rhinitis and its Impact on Asthma) guidelines.3 They were developed by 
an international, multidisciplinary panel and provide diagnostic and therapeutic 
recommendations for the management of AR patients in primary and specialist 
healthcare settings throughout the world. The ARIA guidelines also changed the 
previous and unsatisfactory classification of AR based on the type of sensitization 
to cyclic pollens or year-around allergens (into seasonal or perennial) in a new 
classification based on the duration of the symptoms and their impact on the 
quality of life (QOL). Furthermore, the ARIA working group emphasized that AR is 
not an isolated disorder, but is often associated with asthma, as part of a ‘united 
airway disease’. In the meanwhile the ARIA guidelines have been updated4, 5 and 
the benefits on patient outcomes (symptom scores, QOL and work productivity) of 
following the ARIA recommendations compared to using a nonstandard treatment 
regimen have been validated in a pragmatic randomized study.6
Less than 50% of AR patients seek medical help for their condition,7 but the 
majority of patients who do seek medical help, consult their general practitioner 
(GP), highlighting the key role of GPs in the diagnosis, treatment and follow-up 
of AR.1 Nevertheless previous studies have demonstrated considerable scope for 
improvement in GP awareness, diagnostic skills and management of AR.8
Primary care physicians have always played an important role in the 
development of the ARIA guidelines3-5 and the ARIA 2008 pocket guide was 
developed with the World Organization of Primary Care Physicians (WONCA).9 
Furthermore, the ARIA guidelines are not intended to be a global standard of care, 
but serve as a basis to develop relevant local guidelines adapted to the healthcare 
setting. The “NHG Standard for allergic and non-allergic rhinitis”10 is such a local 
evidence-based guideline. The NHG clinical practice guidelines, written in Dutch, 
are developed by the Dutch College of General Practitioners and were initially 
intended for GPs in the Netherlands, but also became popular among the 
Dutch speaking (Flemish) GPs in the northern part of Belgium (Flanders). The 
recommendations of the NHG guideline for (allergic) rhinitis are in many ways 
very similar to the ARIA guidelines, proposing the same ARIA classification and the 
same first-line treatments according to the duration and severity of disease, but 
the NHG Standard is specifically adapted to the primary care setting.
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Despite the availability of evidence-based guidelines for the management of AR 
and their proven effectiveness,6 very little is known about the adoption of these 
guidelines in daily general practice. 
We performed a questionnaire-based study among Flemish GPs 1) to assess 
the level of dissemination and penetration of clinical guidelines for AR in general 
practice, 2) to evaluate the diagnostic and therapeutic management of AR by 
GPs, 3) to compare these practices with the evidence-based ARIA guideline 
recommendations, and 4) to gain information on GPs’ socio-professional 
characteristics that may influence guideline compliance.
MATERIAL AND METHODS
QUESTIONNAIRE DEVELOPMENT
We designed a questionnaire in multiple choice response format that covered 
following items:
• Demographic and professional details 
• Classification of AR
• Diagnostic procedures for AR 
• Self-reported use of clinical guidelines for AR in daily practice
• Awareness of, familiarity with and attitude towards the ARIA guidelines 
• Therapeutic management of AR through presentation of 4 fictitious clinical 
scenarios.
The questionnaire was formulated in Dutch. Part of the questionnaire was 
similar to a previously performed survey among Belgian ear-, nose-, throat (ENT) 
specialists,11 with some modifications to make it more suitable for the primary 
care setting. Prior to its distribution, the questionnaire was pilot tested among 15 
GPs, resulting in some minor changes.
SAMPLE AND DATA COLLECTION
All Flemish local quality peer review groups (LQPRGs) of general practitioners 
that planned a group meeting between January and March 2009, were contacted 
through their chairs and were invited to participate in this study. In total 33 
LQPRGs throughout Flanders participated. At the time of the LQPRG meeting, the 
paper-based questionnaires were individually and anonymously completed by 
all GPs attending the meeting, resulting in 350 participants. There were no non-
responders. After completion, the questionnaires were collected by the chairman 
of the group and send back to the investigators in a prestamped envelop by 
the end of the study period (March 2009). All distributed questionnaires were 
recollected. There was no incentive for participation. 
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The Ethics Committee of Ghent University Hospital approved the contents, 
conditions and application of the survey.
CLINICAL CASE SECTION
For the 4 fictitious case scenarios the treatment proposed by the respondents was 
strictly compared with the treatment recommendations of the ARIA guidelines, 
available at the time of the study4 (APPENDIX 1) . A score of 0 (treatment not 
consistent with ARIA recommendations) or 1 (treatment consistent with ARIA 
recommendations) was attributed per case, resulting in a total score ranging from 
0 to 4 per respondent. Upon further analysis, compliance with the ARIA guidelines 
in the clinical scenarios was dichotomized into ‘poor compliance’ or ‘good 
compliance’. Good compliance was set at a total score above the mean outcome.
STATISTICAL ANALYSIS
The descriptive part of the study uses conventional parameters: percentages for 
nominal and ordinal variables. Chi square test was used to analyze differences 
in nominal or ordinal values between 2 subgroups and to compare demographic 
characteristics of our sample group with the target group of all Flemish GPs. 
To assess a linear trend in proportions of nominal or ordinal values across more 
than 2 subgroups Chi square test for trends was used. 
The influence of demographic and professional variables on compliance 
with the ARIA recommendations was assessed using multiple logistic regression 
analysis. The following demographic and professional characteristics were 
considered to potentially influence guideline compliance and were included in 
the regression analysis: gender, years of practice, type of practice, special interest 
in ENT pathology/allergology, peer-reviewed journal subscriptions, obtained 
continuing medical education (CME) credits and self-reported implementation 
of guidelines for AR. Significance level was set at α = 0.05 throughout the whole 
study. Analyses were completed using SPSS Inc (Chicago, ILL, USA; version 19).
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RESULTS
BASELINE CHARACTERISTICS OF THE RESPONDENTS
Demographic and professional details of the sample population of 350 GPs are 
summarized in TABLES 1A  and 1B  and compared with the available demographics 
of the target population, all Flemish GPs, in TABLE 1A . For age and gender no 
significant differences were found between the sample and the target population, 
but there was a significant overrepresentation of GPs working in a group practice 
within our sample population.
TABLE 1A.  Demographics of  the sample populat ion of  350 part ic ipating 
GPs compared with the target  populat ion of  al l  F lemish GPs.  The latter was 
obtained through the annual report  (2009) of  Domus Medica,  a F lemish 
associat ion representing the interests  of  GPs.  *stat ist ical ly  s ignif icant
Participating GPs  (n=350) All Flemish GPs (n = 7367) P value
% n % n
Gender 0.77
Male 68.6 240 67.6 4981
Female 31.4 110 32.2 2374
Unknown 0.0 0 0.2 12
Years of practice 0.41
≤5 years 8.0 28 3.1 228
6-10 years 8.9 31 12.4 915
11-20 years 20.6 72 21.9 1615
21-30 years 32.6 114 33.6 2473
>30 years 30.0 105 28.8 2122
Unknown 0.2 14
Type of practice <0.001*
Solo practice 46.6 163 72.3 5323
Group practice 53.4 187 27.7 2044
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SELF-REPORTED AWARENESS OF ARIA 
GUIDELINES FOR ALLERGIC RHINITIS
Of all participants 31.1% knew about the ARIA guidelines. Among this group, 
21.1% considered the ARIA guidelines as very user-friendly, 33.9% as moderately 
user-friendly, 1.8% as not user-friendly and 43.1% were insufficiently familiar with 
these guidelines to evaluate their user-friendliness.
Respondents that were aware of the ARIA guidelines, first heard about these 
guidelines through scientific lectures or postgraduate medical education (36.4%), 
representatives of pharmaceutical companies (32.7%), peer reviewed medical 
journals (16.4%), non-peer reviewed medical journals, leaflets or brochures (8.2%), 
colleagues (4.5%) or during medical training (1.8%).
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Self-reported awareness of the ARIA guidelines was significantly higher among 
male compared to female GPs (35.8% versus 20.9%, p=0.006), among GPs with a 
specific interest in ENT pathology/allergology compared to the rest of GPs (43.5% 
versus 27.2%, p=0.007) and showed a significant increasing trend with increasing 
number of subscriptions to peer-reviewed journals (24.3% among GPs without 
peer reviewed journal subscription, 33.5% among GPs holding 1 or 2 subscriptions 
and 55.0% among those with 3 or more peer reviewed journal subscriptions, 
p=0.002) and with increasing number of obtained CME credits (19.4% among GPs 
that obtained <20 CME units the last year, 29.2% among those that obtained 20-40 
CME units and 47.3% for those that obtained > 40 CME units, p =0.002).
SELF-REPORTED IMPLEMENTATION OF (ARIA) 
GUIDELINES FOR ALLERGIC RHINITIS
In total, 34.3% of the participants reported to follow clinical guidelines in the daily 
care of patients with AR. 7.4% of this group stated to strictly follow the guideline 
recommendations in the management of all AR patients 76.9% considered the 
guideline as a basis for the management of AR patients, which they adapt according 
to the specific context, and 15.7% stated to only implement the guidelines in 
special or difficult cases.
28.3% of the GPs, stating to implement AR guidelines, used paper or computer 
summaries, pocket guides or flowcharts of the guidelines during daily practice. 
Self-reported implementation of guidelines for AR was significantly higher among 
GPs with a special interest in ENT pathology/allergology compared to the rest 
of GPs (49.4% versus 29.4%, p=0.001) and showed a significant increasing trend 
with increasing number of peer reviewed journal subscriptions (26.5% among 
GPs without peer reviewed journal subscription, 37.1% among GPs holding 1 or 
2 subscriptions and 60.0% among those with 3 or more peer reviewed journal 
subscriptions, p=0.001).
The majority of GPs (70.0%) reporting to implement guidelines for AR, followed 
the “NHG Standard for allergic and non-allergic rhinitis”,10 whereas only 29.2% 
(i.e. 32.1% of the GPs that were aware of the ARIA guidelines or 10.0% of all 
respondents), followed the ARIA guidelines in daily clinical practice. There were 
significantly more female GPs and significantly more GPs working in a group 
practice among the NHG standard users compared to the ARIA users (respectively 
40.4% versus 17.1%, p=0.018 and 69.9% versus 40.0%, p<0.001)
TABLE 1B.  Addit ional  demographic and professional  characterist ics 
of the sample populat ion (n = 350)  (no data avai lable for al l 
Flemish GPs) .  CME credits  = credits  obtained for continuing 
medical  education,   1 credit  accounts for 1 hour of  CME
Sample population (n=350)
Number of patients/week % n
<50 5.1 18
50-100 39.1 137
100-200 48.3 169
>200 7.4 26
Special interest in ENT/
Allergology
Yes 24.3 85
No 75.7 265
Peer reviewed journal 
subscriptions
No 38.9 136
1 or 2 55.4 194
≥3 5.7 20
CME credits last year
<20 8.9 31
20-40 75.4 264
>40 15.7 55
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CLASSIFICATION AND DIAGNOSIS 
OF ALLERGIC RHINITIS
Within our sample population, 30.6% of the GPs did not use a classification for AR 
in daily practice. 38.9% classified AR as seasonal or perennial. 11.4% classified AR 
consistent with the ARIA (and NHG) guidelines into intermittent or persistent and 
19.1% stated to use another, spurious classification for AR. Of interest, 40% of the 
GPs that reported to follow the ARIA guidelines and 40.5% of those declaring to 
follow the NHG guidelines, still used the previous classification of AR into seasonal 
or perennial. 
GPs’ common practice(s) to diagnose AR are presented in TABLE 2 . Almost all 
GPs perform a thorough clinical history, 71.1% ask additional serum allergen-
specific IgE tests or perform skin prick tests, whereas only 28.6% perform an 
anterior rhinoscopy. Almost 50% of the respondents ask for a total serum IgE 
measurement. Anterior rhinoscopy, specific IgE measurement and skin prick tests 
were more frequently performed among the self-declared guideline user group, 
but these differences were not significant. Further analysis showed no significant 
differences in the diagnostic procedures for AR between ARIA users and the rest 
of the GPs, or between ARIA and NHG standard users (data not presented). 
74.3% of all respondents reported to screen routinely for concomitant asthma 
in patients with AR. The screening rate for asthma was significantly higher among 
GPs that reported to implement AR guidelines than among those who did not 
(84.2% versus 69.1%, p=0.003), and was not significantly higher in the subgroup of 
GPs that reported to implement the ARIA guidelines compared to those using the 
NHG standards (94.3% versus 81.0%, p=0.091). 
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TREATMENT OF ALLERGIC RHINITIS AND COMPLIANCE 
WITH THE ARIA RECOMMENDATIONS
The treatment modalities selected by the respondents in the 4 clinical case scenarios 
are presented in Appendix 2 and compared with the ARIA recommendations.4 
A treatment consistent with the ARIA recommendations was proposed by 84.8% 
(297/350) of the participants for scenario 1, 34.0% (119/350) for scenario 2, 42.8% 
(150/350) for scenario 3 and 75.7% (265/350) for scenario 4. 
For the 4 case scenarios in total 2.9% (10/350) of the participants obtained a 
total score of 0, while 12.9% (45/350) had a score of 1, 36.0% (126/350) a score of 
2, 38.3% (134/350) a score of 3, and 10.0% (35/350) a score of 4. The mean score 
was 2.4. Respondents that obtained a score above the mean (i.e. 3 or 4) were 
considered as ‘good compliers’, resulting in 51.7% (181/350) poor compliers and 
48.3% (169/350) good compliers.
Multiple logistic regression analysis revealed recent graduation (<5y of clinical 
experience) to be the only independent significant predictor of good compliance 
TABLE 2.  Common procedures,  reported by GPs,  to diagnose 
al lergic  rhinit is .  Comparison is  made between GPs that report  to 
implement guidel ines for AR and those who don’t .
All respondents 
n=350
Guideline users 
n=120
Non-guideline users 
n=230
P value
Clinical history 342 (97.7%) 117 (97.5%) 225 (97.8%) 1.00
Anterior rhinoscopy 100 (28.6%) 40 (33.3%) 60 (26.1%) 0.17
Allergy testing
Skin prick test 14 (4.0%) 7 (5.8%) 7 (3.0%) 0.25
Skin patch test 3 (0.9%) 2 (1.7%) 1 (0.4%) 0.55
Total IgE 174 (49.7%) 66 (55.0%) 108 (47.0%) 0.18
Specific IgE 235 (67.1%) 83 (69.2%) 152 (66.1%) 0.63
Eosinophilia 100 (28.6%) 36 (30.0%) 64 (27.8%) 0.71
Imaging paranasal sinuses 27 (7.7%) 12 (10.0%) 15 (6.5%) 0.29
Therapeutic trial 4 (1.1%) 0 (0.0%) 4 (1.7%) 0.30
Specialist referral 5 (1.4%) 2 (1.7%) 3 (1.3%) 1.00
Screening for asthma 260 (74.3%) 101 (84.2%) 159 (69.1%) 0.003
Clinical history 247 (70.6%) 92 (76.7%) 155 (67.4%) 0.09
Lung auscultation 166 (47.4%) 68 (56.7%) 98 (42.6%) 0.02
Peak flow measurement 114 (32.6%) 47 (39.2%) 67 (29.1%) 0.07
Thorax radiography 4 (1.1%) 3 (2.5%) 1 (0.4%) 0.23
Self-performed spirometry 28 (8.0%) 14 (11.7%) 14 (6.1%) 0.11
Referral to pulmonologist 45 (12.9%) 17 (14.2%) 28 (12.2%) 0.72
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DISCUSSION
Although AR is a prevalent problem in general practice and the ARIA guidelines 
have been developed to standardize and improve the quality of care of AR patients, 
the results of this survey demonstrate that the penetration of these guidelines 
among Flemish GPs remains very poor. The first barrier to physician adherence to 
guidelines is lack of awareness.12 This barrier is obvious in our sample population, 
with more than two thirds of the participating GPs having never heard about the 
ARIA guidelines. Among GPs with a particular interest in ENT/allergology, a higher 
number of peer-reviewed journal subscriptions and increased CME credits, self-
reported awareness of the ARIA guidelines was higher. When we compare our 
results with a similar study in France, where 48% of the GPs declared to be familiar 
with the ARIA guidelines13 and a survey completed by Belgian ENT specialists, with 
up to 87% having ever heard about the ARIA guidelines11, dissemination of the 
ARIA guidelines among Flemish GPs seems to have failed…
Awareness of a guideline, on the other hand, does not necessarily lead to 
its implementation. Guideline utilization is a stepwise process resulting from 
awareness, to agreement, to adoption, and finally adherence, with a variety 
of internal and external barriers that may raise at the different levels.12 In our 
survey, only 32% of the GPs aware of the ARIA guidelines, reported to also use 
this guideline in the daily management of AR patients. The majority (70%) of GPs 
using a guideline for AR, preferred the NHG Standard from the Dutch College of 
General Practitioners.10 It is well-known that physicians have more confidence in 
guidelines that are developed by their own specialty organization14 and family 
physicians in particular prefer receiving guideline information from their own 
peer group15. The ARIA initiative never intended to be the universal standard of 
care and also recommends the ‘best practice recommendations’ to be tailored 
to local circumstances and population characteristics, including the healthcare 
system regulations. In this context adherence to a local evidence-based guideline 
can only be promoted. The NHG standard is evidence-based and in many ways 
very similar to the ARIA guidelines: it recommends the ARIA classification for AR 
based on the duration of symptoms and their impact on QOL, emphasizes on the 
comorbid relationship between rhinitis and asthma and recommends the same 
first-line treatment regimens. In terms of recommended diagnostic approach, 
however, there are some important differences. Whereas ARIA recommends to 
perform a nasal examination and additional allergy tests by means of skin prick 
tests or serum allergen-specific IgE measurements in all suspected AR patients, 
the NHG Standard states that a nasal examination in general practice by means 
of an anterior rhinoscopy has limited additional value and is only mandatory 
when suspicion of other diagnoses exists. Furthermore, the NHG Standard finds 
additional allergy tests unnecessary in case of straightforward and isolated grass 
or tree pollen induced AR symptoms, given the high predictive value of clinical 
history in these cases.16
with the ARIA guidelines (P=0.049, TABLE 3). Compared to the group with more 
than 30 years of experience, compliance was increased with a factor 2.6. Gender, 
practice type, interest in ENT/allergology, journal subscription, CME credits and self-
reported implementation of guidelines for AR showed no independent influence 
at the 5% significance level on compliance with the ARIA recommendations.
TABLE 3.  Adjusted odds rat ios and confidence intervals  for 
compliance with ARIA guidel ines,  based on the results  of  c l inical 
case scenarios.  Data were calculated using mult iple logist ic 
regression,  *stat ist ical ly  s ignif icant.
Odds Ratio 95% confidence interval P value
Gender
Male 0.620 0.363-1.059 0.080
Female 1 ref
Experience
0-5y 2.618 1.004-6.830 0.049*
6-10y 1.481 0.612-3.586 0.384
11-20y 1.695 0.866-3.318 0.124
21-30y 1.372 0.790-2.381 0.261
>30y 1 ref
Type of practice
Solo 1.206 0.748-1.943 0.442
Group 1 ref
Special interest in 
ENT/allergology
No 0.958 0.570-1.609 0.871
Yes 1 ref
Journal subscription
No 1.163 0.424-3.190 0.769
Yes, 1-2 1.446 0.544-3.843 0.460
Yes, >2 1 ref
CME
<20 0.813 0.317-2.086 0.666
20-40 0.677 0.364-1.258 0.217
>40 1 ref
Self-reported 
implementation 
of AR guidelines
No 1.129 0.699-1.823 0.619
Yes 1 ref
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In our sample population, 74% of all participants stated to routinely screen for 
asthma in AR patients and this raised to 84% among self-declared AR guideline 
users and 94% in the subgroup of self-declared ARIA users. These data indicate 
that overall awareness of the comorbid association between AR and asthma was 
high, with additional and positive attentiveness for the upper-lower airway link 
among guideline-users and ARIA users in particular.
More than 70% of the GPs indicated to routinely perform adequate allergy 
testing, but no significant differences were found between self-declared guideline 
or non-guideline users, ARIA or NHG users. Anterior rhinoscopy, on the other 
hand, was only done by 29% of the GPs, with no significant differences between 
self-declared guideline or non-guideline users, and, remarkably, neither between 
ARIA or NHG Standard users. On the other hand, total serum IgE measurement in 
suspected AR patients was still advised by almost 50% of the respondents (with no 
significant differences between self-declared guideline en non-guideline users), 
whereas the (ARIA and NHG) guidelines do not recommend this investigation, due 
to its lack of specificity.
Conflicting responses between self-reported and actual guideline adherence 
were also found when assessing the classification of AR, with 40% of the self-
declared ARIA and NHG Standard users indicating to use the classification of AR 
based on the type of allergen, that is no longer recommended by the current 
guidelines, but, however, still appears in the literature. Also, in the fictitious 
case scenario section self-declared guideline users did not demonstrate higher 
compliance with the evidence-based (ARIA) guideline treatment recommendations. 
These data indicate that self-reported adherence must be interpreted with caution 
as it does not necessarily reflect actual practice and might be susceptible to social 
desirability bias and interviewer bias.17 On the other hand, it could also indicate 
that application of guidelines in a clinical setting is not straightforward.11
In the clinical case scenarios we found a tremendous variability in the proposed 
treatment regimens, with only 10% of the GPs recommending a treatment entirely 
consistent with the evidence-based guidelines in all 4 case scenarios.  Based on our 
scoring system, only 48% of the respondents were considered as ‘good’ compliers 
with the evidence-based treatment recommendations for AR. This indicates that 
next to a lack of dissemination and implementation of the ARIA guidelines in 
Flemish general practice, scientific evidence concerning AR management has not 
yet found its way into the daily routine of GPs. As discussed above, self-reported 
adherence to the ARIA or NHG guidelines did not lead to  increased compliance 
with evidence-based treatment principles for AR, but neither did physician’s 
interest in ENT/allergology, increased journal subscriptions, obtained CME credits, 
working in a group practice or gender. The only independent significant predictor 
of increased implementation of evidence was recent graduation, with ≤ 5 years 
of clinical experience. Although the less experienced GPs did not report a higher 
awareness of the ARIA guidelines, their treatment practices seem to be more 
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concordant with the underlying evidence of these guidelines compared to their 
more experienced colleagues. The same was found in our previous survey in ENT 
specialists, where younger age was a significant predictor of better compliance 
with the ARIA recommendations.11 Similar findings of declining adherence to 
clinical practice standards and evidence-based recommendations with increasing 
age and experience have also been reported in other areas of medicine.18-20 A 
possible explanation is that the evolution from opinion-based to evidence-based 
medicine dates from the last 15 years. It is well known that physicians not easily 
change their long- standing prescribing patterns and this has been identified as 
a barrier to the incorporation of scientific evidence and guidelines into practice.12 
Younger, less experienced physicians on the other hand, more often tend to rely 
on the current scientific knowledge to support their clinical practice.
Clinical practice guidelines like ARIA and the NHG Standard were developed 
to improve and facilitate the implementation of scientific evidence into clinical 
practice, but the impact of these guidelines on everyday clinical practice remains 
limited. There is no single effective way to introduce and ensure the use of 
guidelines into practice, but research into guideline implementation in primary 
care practice has suggested that strategies might be more effective when tailored 
to pre-identified barriers. Further research is needed to determine the factors 
that influence poor compliance and the barriers that raise at the different 
levels of guideline dissemination and implementation before selecting effective 
interventions to change physicians’ practice behavior.21
LIMITATIONS OF THE STUDY
There are some obvious limitations to this study.
First, results are based on responses of a sample population of 350 Flemish 
GPs. The knowledge and behavior of Flemish GPs might differ from that of 
colleagues elsewhere, and obviously our results cannot merely be extrapolated 
to the international GP population. Although our sample was quite representative 
for the total Flemish GP population, there was an overrepresentation of GPs 
working in a group practice. Type of practice, however, did not demonstrate an 
important influence on our results. Furthermore the setting of recruitment at 
a LQPRG meeting, whose mission is to promote interprofessional dialogue, to 
organize continued medical education and to improve the quality of care, might 
have led to bias in the results. On the other hand, in Flanders it is compulsory 
for GPs to be part of a LQPRG and to regularly participate at the group meetings. 
Additionally, all GPs present at the meetings completed the survey, which excludes 
a non-respondent bias.
Second, the data are based on self-reports and fictitious case scenarios. The 
limits of self-reported guideline adherence and the risk of social desirability bias 
are already discussed above. We, however, tried to limit social desirability bias 
by conducting and handling the surveys under complete anonymous conditions. 
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By using hypothetical clinical situations we gained information on the physician’s 
intention to treat, resulting from their integrated knowledge of scientific evidence 
or guideline recommendations. However, this might differ from actual treatment 
practices in the daily clinical setting, which is much more influenced by the 
individual context and patient preferences.22 Nevertheless, well-constructed 
clinical case scenarios have demonstrated to reflect the actual clinical behavior 
of a group of physicians23, 24 and have the advantage of being much less time and 
cost consuming and lead to a more straightforward interpretation compared to 
assessing physician’s treatment practices based on medical patient files.22 
Third, in assessment of the diagnostic strategy for AR and screening for asthma, 
we asked to indicate the diagnostic modalities of choice from a proposed list 
and we directly questioned whether or not the participant screened for asthma. 
This may have forced reply and possibly led to interviewer bias and an increased 
reporting of routine allergy testing and screening for asthma.
Fourth, in the case scenario section, for every treatment that was not entirely 
consistent with the ARIA recommendations4 a score of 0 was attributed. No 
distinction was made between treatments that deviated ‘strongly’ or ‘slightly’ from 
the guideline recommendations. This stern scoring system probably contributed 
to the overall low compliance rates.
CONCLUSION
In summary, the ARIA guidelines remain relatively unknown among Flemish GPs. 
Although GPs are familiar with general concepts about AR, such as the upper-
lower airway link, their daily treatment practices often differ from the evidence-
based recommendations. More efforts are required to translate scientific evidence 
into practice and to increase the implementation of evidence-based guidelines 
adapted to the end-user group and healthcare setting.
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APPENDIX 1:  Treatment recommended by the ARIA guidel ines 4 for 
the 4 f ict i t ious case scenarios (decongestant*:  a short  course (<10 
days)  of  oral  or nasal  decongestant;  ALT:  anti leukotr iene) .
1 Patient, currently untreated, is allergic to house dust mite and suffering from rhinorrhea, 
sneezing and nasal congestion since 2 months. Symptoms impair the quality of sleep.
ARIA classification group Moderate-severe persistent allergic rhinitis
Treatment recommended 
by ARIA guidelines
Nasal corticosteroid ± H1-antihistamine or ALT ± 
decongestant* ± allergen avoidance
2 Patient, currently untreated, with symptoms of sneezing, runny nose, red and tearing eyes 
since 1 month, especially when he’s working in the garden. Besides these symptoms, the 
patient has no complaints.
ARIA classification group Mild intermittent allergic rhinoconjunctivitis
Treatment recommended 
by ARIA guidelines
Oral H1-antihistamine ± decongestant* ± allergen avoidance
or
Nasal H1-antihistamine or ALT + ocular cromone or  
H1-antihistamine ± decongestant* ± allergen avoidance
3 Patient, currently untreated, allergic to birch, is especially suffering from nasal congestion 
for the last 2 weeks. The patient is having exams and says that he’s bothered during 
studying.
ARIA classification group Moderate-severe intermittent allergic rhinitis
Treatment recommended 
by ARIA guidelines
Oral or nasal H1-antihistamine or ALT ± decongestant* ± 
allergen avoidance
or
Decongestant* ± allergen avoidance
or
Nasal corticosteroid ± decongestant* ± allergen avoidance
4 Patient with severe symptoms of allergic rhinitis due to house dust mite for many years. 
Current treatment with oral antihistamine provides insufficient symptom relief.
ARIA classification group Moderate-severe persistent allergic rhinitis, step-up 
treatment oral antihistamine
Treatment recommended 
by ARIA guidelines
Nasal corticosteroid ± decongestant* ± allergen avoidance
or
Nasal corticosteroid + oral or nasal H1-antihistamine or ALT 
± decongestant* ± allergen avoidance
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APPENDIX 2:  Treatment modali t ies selected in 4 case scenarios of  al lergic 
rhinit is .  Treatments consistent with the ARIA guidel ines 4 are in bold.
Clinical scenario 1 
Selected treatment or combination of treatments % (n)
AA + OAH1/NAH1 + NCS 38.3 % (134)
OAH1/NAH1 + NCS 16.3% (57)
AA + OAH1/NAH1 + ODC/NDC + NCS 9.7% (34)
AA + NCS 9.1% (32)
OAH1/NAH1 + ODC/NDC + NCS 5.7% (20)
NCS 4.6% (16)
AA + OAH1/NAH1 3.1% (11)
AA + OAH1/NAH1 + ODC/NDC 3.1% (11)
OGCS 1.7% (6)
OAH1/NAH1 + ODC/NDC 1.4% (5)
OAH1/NAH1 1.4% (5)
AA + ODC/NDC + NCS 0.8% (3)
IT 0.6% (2)
AA + NCS + ALT 0.3% (1)
OAH1 + NCS + ALT +/- AA 0.6% (2)
Other 3.1% (11)
Consistent with ARIA recommendations 84.8% (297)
Clinical scenario 2 
Selected treatment or combination of treatments % (n)
OAH1 + NCS +/- TEM +/- AA 32.8% (115)
OAH1 +/- TEM +/- AA 30.3% (106)
NCS +/- AA 9.4% (33)
No treatment 6.3% (22)
OAH1 + ODC/NDC + NCS +/- AA 5.7% (20)
AA 3.1% (11)
OAH1 + ODC/NDC +/- TEM +/- AA 3.1% (11)
NCS + TEM +/- AA 2.3% (8)
OCS 0.8% (3)
NAH + TEM 0.6% (2)
ODC/NDC +/- AA 0.6% (2)
TEM 0.6% (2)
OAH1 + NCS + ALT + /- TEM +/- AA 0.6% (2)
Other 3.7% (13)
Consistent with ARIA recommendations 34.0% (119)
Clinical scenario 3 
Selected treatment or combination of treatments % (n)
OAH1/NAH1 + NCS +/- AA 26,6% (93)
OAH1/NAH1 + ODC/NDC + NCS +/- AA 20.8% (73)
NCS +/- AA 17.7% (62)
OAH1/NAH1  + ODC/NDC +/- AA 11.4% (40)
OAH1/NAH1 +/- AA 7.4% (26)
OCS 6.6% (23)
ODC/NDC + NCS +/- AA 4.6% (16)
ODC/NDC 1.7% (6)
No treatment 1.1% (4)
Other 2.0% (7)
Consistent with ARIA recommendations 42.8% (150)
Clinical scenario 4 
Selected treatment or combination of treatments % (n)
AA + NCS +/- OAH1/NAH1 42.6% (149)
NCS +/- OAH1/NAH1 24.6% (86)
AA + ODC/NDC + NCS +/- OAH/NAH 4.8% (17)
IT 4.8% (17)
OGCS 4.6% (16)
AA +/- OAH1/NAH1 3.4% (12)
ODC/NDC +/- OAH1/NAH1 2.3% (8)
ODC/NDC + NCS +/- OAH1/NAH1 2.0% (7)
NCS + ALT +/- AA 1.1% (4)
ODC/NDC + NCS 0.6% (2)
AA + ODC/NDC +/- OAH1/NAH1 0.6% (2)
NAH1 0.3% (1)
No treatment 0.3% (1)
NCS + OAH1 + ODC + ALT +/- AA 0.6% (2)
Other 7.4% (26)
Consistent with ARIA recommendations 75.7% (265)
AA: allergen avoidance 
OAH1: oral H1-antihistamine 
NAH1: nasal H1-antihistamine, 
ALT: antileukotriene, 
NCS: nasal corticosteroid 
OCS: oral corticosteroid (short course) 
ODC: oral decongestant (short course) 
NDC: nasal decongestant 
TEM: topical eye medication (ocular H1-antihistamine or cromone) 
IT: immunotherapy
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AMONG GENERAL PRACTITIONERS AND ITS 
IMPACT ON PATIENT MANAGEMENT
Van Cauwenberge P*, Van Hoecke H*, Kardos P, Price D, Waserman S
Prim Care Resp J 2009;18(1):27-33
ABSTRACT
AIMS
To investigate the burden of allergic rhinitis (AR) among general practitioners 
(GPs), the impact of AR on GPs’ professional lives, and the effect of GPs’ personal 
experience of AR on the management of AR patients.
METHODS
An on-line questionnaire was completed by 1201 GPs (50% AR sufferers) from 
eight countries.
RESULTS
21% of GPs reported very well controlled symptoms and 66% quite good control. 
Six hours work per week, on average, were missed by GPs whose AR symptoms 
resulted in absence. AR symptoms affected concentration, stress level, mood, time 
spent with patients and physical contact with patients. GPs with AR reported a 
significantly higher proportion of AR patients in their practice. In the management 
of their AR patients, they gave a significantly higher ranking to patient requests 
for specific treatment and emotional well-being of the patient, and a significantly 
lower ranking to preventing comorbidity development and providing a treatment 
most likely to result in high patient compliance.
DISCUSSION
This is the first study demonstrating the impact of AR on GPs and showing 
association with lost productivity, absenteeism and reduction in professional 
performance. Personal experience of AR might influence GPs’ management of 
AR, but first qualitative research, followed by additional quantitive research is 
required.
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INTRODUCTION 
Allergic rhinitis (AR) is a common, symptomatic disorder induced by allergen 
exposure and is due to an IgE-mediated inflammation of the membranes lining 
the nose.1 In 2001, the Allergic Rhinitis and its Impact on Asthma (ARIA) Workshop 
Group, in collaboration with the World Health Organization (WHO), introduced a 
new classification which subdivided AR as either intermittent or persistent, and 
mild or moderate-severe, depending on the duration, severity and impact of 
symptoms on quality of life (TABLE 1) .1
Although many sufferers self-treat and seek medical help only when their 
symptoms become intolerable,2 AR remains among the top ten reasons for visits 
to primary care clinics3 and updated management guidelines have been published 
by the International Primary Care Respiratory Group (IPCRG)4. Several studies 
have examined the detrimental effects of AR on the working lives of sufferers 
among the general population,5-9 but to date there has been no published 
research investigating the effects of AR symptoms on the professional lives of 
general practitioners (GPs) themselves.
TABLE 1.  ARIA c lassi f icat ion of  al lergic  rhinit is 1.
Intermittent Symptoms are present:
• Less than 4 days a week
• Or for less than 4 weeks
Persistent Symptoms are present:
• More than 4 days a week
• And for more than 4 weeks
Mild None of the following items are present 
• Sleep disturbance
• Impairment of daily activities, leisure and/or sport
• Impairment of school or work
• Troublesome symptoms
Moderate-severe One or more of the following items are present:
• Sleep disturbance
• Impairment of daily activities, leisure and/or sport
• Impairment of school or work
• Troublesome symptoms
Therefore, the aim of this study was to investigate whether suffering from AR 
has a negative impact on the professional lives and performance of GPs and to 
examine if personal experience of AR influences their management of patients 
with the disease.
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METHODS
DESIGN OF THE STUDY
The questionnaire, which was quantitative and devised for on-line completion, 
was derived from existing and validated questionnaires,10 with the addition 
of a number of novel questions covering: demographic details, GPs’ personal 
experience of AR, self-treatment, impact of AR on their working lives as well as 
their management of patients with AR. In order to test the viability and technical 
functionality of the electronic questionnaire, 10 pilot online interviews were 
conducted among GPs who qualified according to the eligibility criteria for the 
main study as described below. Amendment of the initial questionnaire resulted 
in a final version (APPENDIX) , which consisted of 21 closed questions. GPs were 
advised that the questionnaire would take approximately 15 minutes to complete, 
that it would be available for completion for a period of four weeks, and that 
those who participated would receive a small cash payment for completing the 
questionnaire. The questionnaire was translated from English into five other 
languages (French, German, Italian, Portuguese and Spanish), but there was no 
allowance made for regional variations in English or French.
RECRUITMENT AND ELIGIBILITY OF GPS
In order to ensure sufficiently high numbers of participants from eight countries, 
GPs were recruited from a panel of healthcare professionals, of all specialties, 
who were prepared to take part in such studies, but were not pre-selected for 
health-related or other reasons. The panel was managed by an independent group 
specializing in healthcare recruitment. All GPs on the panel received a personal 
invitation and were eligible for inclusion if at the time of participation they were 
aged 25-65 years, were qualified and currently practising, had been in practice 
for 2-30 years, and had not participated in research on allergies of any kind in the 
previous three months.
In order to be able to compare GPs with and without AR, 50% of the total sample 
from each country had to be AR sufferers and 50% AR non-sufferers. AR status was 
probably most often self-diagnosed by the GPs. Self-diagnosis by GPs of AR for the 
purposes of this study reflects normal clinical practice for such conditions.The GPs 
were also asked to classify their AR into intermittent or persistent according to the 
ARIA classification, that was outlined in the questionnaire.
The total sample was designed to include 1200 GPs, recruited from eight 
countries (Australia, Brazil, Canada, France, Germany, Italy, Spain and the UK).
150 151
CHAPTER VII
STATISTICAL ANALYSIS
Data were entered into QPSMR software (Wallingford, UK) and tabulated for 
analysis. Statistical differences were assessed for means using t-testing of two 
independent sample means. This method was selected as use of a t-test is 
standard practice in market research when analyzing rating scales. Although the 
data are not strictly of interval form and often not normally distributed, the t-test 
was considered robust enough to allow for this. For proportions z-testing of two 
independent sample proportions was used. Statistical significance was recognized 
at the 5% level in all cases. For Question 11 of the questionnaire (impact of AR 
symptoms on ability to perform daily tasks), the following statistical method 
was used: GPs rated only the symptoms they personally experienced for their 
impact on ability to perform daily tasks. As the number of symptoms varied for 
each individual, each symptom was allocated a new rank value on a comparable 
scale ranging from 1 to 3. The impact of each symptom was determined from its 
prevalence in the top, middle or bottom third of individual rankings, with symptoms 
appearing more frequently in the top third than bottom third considered as being 
more impactful on the GP population suffering from AR as a whole.
RESULTS
DEMOGRAPHICS OF THE STUDY POPULATION
Of the 2817 GPs assessed for eligibility, 894 were unable or unwilling to complete 
the study. A further 343 GPs did not meet the eligibility criteria. The last 379 GPs 
were excluded because the pre-specified populations with or without AR had been 
achieved by the time of their recruitment.
The total study population consisted of 1201 GPs from the eight countries - 
Australia, Brazil, Canada, France, Germany, Italy, Spain and the UK - with 150 GPs 
from each, with the exception of Brazil where the online program closed when 
one extra GP above the required 150 had completed the questionnaire. The mean 
age of the GPs was 47 years; with 7% aged 25 to 34 years, 29% aged 35 to 44 years, 
46% aged 45 to 54 years and 18% aged 55 to 65 years. Seventy three per cent 
were male and 27% were female. Of the 600 GPs (self-) diagnosed with AR, 70% 
reported to have intermittent AR, 25% persistent AR and 5% reported having both 
intermittent AR and persistent AR.
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PERCEIVED SYMPTOM CONTROL 
AMONGST GPS WITH AR
Nasal symptoms of sneezing, and runny, blocked or itchy nose, were the most 
commonly reported symptoms by GPs (TABLE 2) . Both nasal and ocular symptoms 
were reported by 55% (n=326) of the GPs, 41% (n = 248) had nasal symptoms only, 
and 1% (n = 5) ocular symptoms only.
Oral antihistamines were the most frequently used treatment (66%), followed 
by nasal corticosteroids (44%), environmental control measures (29%) and nasal 
decongestants (26%) (TABLE 3) . GPs using oral antihistamines were significantly 
more likely to report that their AR symptoms were quite or very well controlled 
than quite or very poorly controlled (p = 0.037). GPs using environmental control 
measures or nasal decongestants were significantly less likely to report that their 
symptoms were quite or very well controlled than quite or very poorly controlled 
(p = 0.013 for environment control measures; p < 0.0001 for nasal decongestants). 
Overall, 21% of GPs considered their symptoms to be very well controlled and 
66% reported quite good control. No significant difference in the perception of the 
level of symptom control was demonstrated between GPs with nasal symptoms 
only and GPs with both nasal and ocular symptoms and the results obtained for 
symptom control were very similar between countries (data not displayed).
TABLE 2.  Symptoms reported by GPs with AR (when not taking medicat ion) .
Symptoms suffered Percentage of GP AR sufferers (n=600)
Sneezing 72%
Runny nose 66%
Blocked nose 59%
Itchy nose 58%
Itchy/red eyes 45%
Watery eyes 39%
Post nasal drip 33%
Itchy palate 29%
Cough 26%
Headache 23%
Snoring 22%
Sinus pressure 21%
Waking at night 19%
Sore throat 17%
Wheezing 15%
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EFFECTS OF AR SYMPTOMS ON GPS’ PROFESSIONAL LIVES 
27% of GPs said their AR symptoms resulted in absence from work, late arrival 
or early departure. This group reported an average of six hours work missed per 
week during a typical week encountering AR symptoms.
GPs reporting very good symptom control were significantly more likely to 
report no time lost from work compared with those reporting very poor control 
(85% versus 50%; p = 0.010). The results indicated that, compared to those who 
were not self-employed, self-employed GPs were significantly less likely to miss 
work (p = 0.022) and also missed significantly fewer hours of work a week during a 
week of symptoms (0.8 hours versus 1.8 hours; p = 0.001) due to AR, although this 
was independent of the level of symptom control. Compared with nasal symptoms 
alone, the presence of both ocular and nasal symptoms was also significantly 
associated with time missed from work (23% versus 31%; p = 0.031).
TABLE 3.  Treatment use and symptom control  reported by GPs with AR.
Symptom control reported by GPs
Treatment type All GPs 
(n=600)
Very poorly 
controlled 
(n=8)
Quite poorly 
controlled 
(n=69)
Quite well 
controlled 
(n=371)
Very well 
controlled 
(n=116)
Oral antihistamines 66% 63% 59% 72% 69%
Nasal corticosteroids 44% 75% 43% 46% 49%
Environmental control 29% 63% 41% 32% 20%
Nasal decongenstants 26% 63% 45% 27% 16%
Oral decongestants 19% 63% 25% 21% 12%
Nasal antihistamines 14% 25% 14% 16% 9%
Asthma treatments 13% 25% 19% 13% 13%
Ocular antihistamine 12% 13% 13% 14% 9%
Oral corticosteroids 8% 13% 6% 9% 8%
Ocular cromone 6% 13% 9% 6% 4%
Immunotherapy (referral) 5% 25% 4% 4% 6%
None of the above 6% N/A N/A N/A N/A
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Ability to perform daily tasks was affected most by runny or blocked nose and 
itchy red eyes. GPs reported that their AR symptoms moderately or considerably 
affected their concentration (31%), stress level (31%), general mood when dealing 
with patients (28%), level of physical contact with patients (22%), time spent with 
each patient (18%) and the number of patients that they saw (16%) (TABLE 4) .
INFLUENCE OF PERSONAL EXPERIENCE OF AR 
ON GPS’ MANAGEMENT OF AR PATIENTS
The mean reported prevalence of AR patients in the GPs’ practice populations was 
16.5% (with a mean estimated distribution of 66% patients with intermittent AR 
and 34% with persistent AR), though there was a wide variation in the reported 
prevalence. GPs with AR reported a slightly, but significantly, higher mean 
proportion of AR patients in their practice than those not suffering from AR (17.7% 
and 15.3% respectively; p = 0.015). Results were broadly similar between countries, 
although GPs from Brazil did report a higher proportion of patients suffering from 
persistent AR (40%) compared to the other countries (30%-35%).
Awareness of the ARIA guidelines was not significantly affected by the GPs AR 
status or classification type, with 41% being unaware of the guidelines and 29% 
stating that they preferred to treat patients’ individual needs irrespective of the 
guidelines. GPs from Australia (46.9%), Canada (44.7%) and the UK (49.3%) were 
significantly more likely to be unaware of the ARIA guidelines when compared to 
the other countries. Only 3% of all of the GPs stated to follow the guidelines for 
all AR patients, with a further 27% reporting to base their management on the 
guidelines, but adapting them according to the individual patient.
TABLE 4.  Effect  of  AR symptoms on the abi l i ty  of  GPs to perform 
dai ly  tasks.
Percentage of GPs reporting effect of AR on ability 
to perform daily tasks (n=600)
Task No effect Limited effect Moderate effect Considerable effect
Concentration 32% 37% 23% 8%
Number of patients seen 59% 26% 12% 4%
Time with patient 50% 33% 14% 4%
Level of physical contact 
with patient
42% 36% 16% 6%
Stress 39% 31% 22% 9%
Mood 33% 39% 21% 7%
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The results of the questionnaire indicated that the relative importance given by 
GPs to patient-relevant factors of AR treatment was very similar between GPs with 
and without AR, for example improvement in their AR patients’ overall quality of 
life was the most important patient-relevant factor to all physicians (TABLE 5) . 
Some significant differences were, however, highlighted. Compared to GPs 
without AR, those with the disease gave a significantly higher ranking to patients’ 
requests for a specific treatment (p = 0.011) and emotional well-being (p = 0.008), 
and a significantly lower ranking to preventing the onset or development of 
comorbidities (p < 0.0001) and providing a treatment most likely to result in high 
patient compliance (p = 0.005). 
When considering treatment attributes, the two groups were also similar 
with safety and effectiveness being the most important for all GPs. However, 
some specific differences were again identified, for example GPs with AR ranked 
treatment costs to their practice or state health service slightly, but significantly, 
higher than GPs without AR (p = 0.012) (TABLE 6) , although the cost of treatment 
did not rank highly when compared to some other treatment attributes for both 
GPs suffering with AR and those without the disease.
TABLE 5.  Importance to GPs (with and without AR)  of  patient-
relevant factors of  AR treatment ( the lower score indicates the 
higher level  of  importance) .
Importance to GPs of patient-relevant factors
Patient-relevant factors of treatment Total 
(n=1201)
AR sufferer 
(n=600)
Non AR sufferer 
(n=601)
Improving patient quality of life 2.1 2.2 2.0
Providing a treatment most likely to 
result in high patient compliance
3.5 3.6 3.3
Preventing the onset of or development 
of comorbidities of AR
3.5 3.8 3.3
Patient emotional well being 5.0 4.8 5.1
Providing affordable treatment for 
patients
5.2 5.2 5.1
Demands on patients from their 
professional lives
5.3 5.2 5.4
Demands on patients from their 
personal lives
5.5 5.5 5.6
Patient requests for specific treatment 5.9 5.8 6.1
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When using monotherapy to treat mild AR, all GPs were most likely to recommend 
or prescribe oral antihistamines (64%) as their first-choice treatment. GPs without 
AR, however, were significantly more likely to recommend environmental control 
measures (53% versus 38% of GPs with AR; p < 0.0001), a nasal antihistamine 
(29% versus 19%; p = 0.0001), and a nasal decongestant (28% versus 22%; p = 
0.010). There was no difference between GPs with and without AR in their first-
choice monotherapy for moderate-severe AR, which was equally likely an oral 
antihistamine (54%) or a nasal corticosteroid (52%). Compared to GPs with AR, 
GPs without the disease were significantly more likely to recommend a nasal 
corticosteroid (55% versus 48%; p = 0.009), a nasal decongestant (23% versus 17%; 
p = 0.003) and environmental control measures (33% versus 27%; p = 0.001).
There was no difference between GPs with and without AR in their choice of 
combination therapy for either mild or moderate-severe AR. Significantly fewer 
GPs would prescribe or recommend combination therapy for mild AR than 
for moderate-severe AR (93% versus 99%; p < 0.0001). GPs using combination 
therapy for mild AR suggested over 300 different combinations but, the most 
frequent choice (by 15% of GPs; n=177) was an oral antihistamine plus a nasal 
corticosteroid. GPs chose over 450 different combinations for moderate-severe 
AR, but again the most frequent combination (recommended or prescribed by 9% 
of GPs; n=112) was an oral antihistamine plus a nasal corticosteroid.
TABLE 6.  Importance to GPs (with and without AR)  of  AR treatment 
attr ibutes ( the lower score indicates the higher level  of  importance)
Importance to GPs of treatment attributes
Treatment attributes Total 
(n=1201)
AR sufferer 
(n=600)
Non AR sufferer 
(n=601)
Reduction of symptom severity 2.6   2.7 2.6
Safety /side effects 3.5 3.6 3.5
Speed of onset of action 4.0 4.1 4.0
Experience of GP with the treatment 4.7 4.6 4.7
Ease of administration 4.8 4.8 4.9
Duration of action 5.0 4.9 5.0
Guideline recommendation 6.0 6.0 6.0
Treatment cost to practice or state 
health service
7.0 6.8 7.1
Formulary recommendation 7.3 7.4 7.3
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DISCUSSION
EFFECTS OF AR ON GPS’ WORKING LIVES
This is the first study to examine the impact of AR on the lives of GPs. It shows 
that AR is associated with lost productivity, work absenteeism and presenteeism 
(present at work, but not fully functioning), similar to AR sufferers in the general 
population.5-9
Over one quarter of GPs with AR reported losing an average of six hours of work 
a week during a typical week of AR symptoms. Yet, those who did not miss work 
also reported detrimental effects on their professional effectiveness during their 
contact with patients. The study indicated an association between AR symptoms, 
symptom control and lost productivity, and that effective control of AR symptoms 
significantly reduced the likelihood of absence from work. There was a significant 
association between self-employment status and continuing presence at work 
by GPs, although this was not influenced by AR symptom severity. This reflects 
research in the general European population, demonstrating relatively low rates 
of absenteeism among self-employed sole traders and small employers despite 
their higher rates of stress and fatigue compared to employed individuals.11 Self-
employment status was, however, less influential than AR symptom control, and 
so the burden of AR symptoms appears to be a more important contributor to 
absenteeism among GPs in our study.
INFLUENCE OF GPS’ PERSONAL EXPERIENCE OF 
AR ON THEIR MANAGEMENT OF AR PATIENTS
This is the first study to show that personal experience of AR influences GPs’ 
management of patients with the disease. All GPs aim to provide the most 
effective treatment for their patients, but those with AR assigned a higher ranking 
to patients’ requests for a specific treatment and their emotional well-being. It 
was therefore surprising that, when choosing a specific treatment, GPs with AR 
appeared to be more influenced than their colleagues without AR by costs to the 
practice or state health service. Although significant, the difference between the 
two groups remained small, and cost was still a relatively minor consideration 
compared to the main influences of effectiveness and safety.
The results also suggest that personal experience of AR may improve a GP’s ability 
to recognize the disease amongst their patients, since the AR patient population 
was slightly, but significantly, higher for GPs with AR compared to those without 
AR. It remains unclear whether this was due to GPs’ greater awareness of the 
disease and superior diagnostic abilities, or because AR patients were more 
likely to consult them. GPs with AR were significantly less likely than GPs without 
the disease to recommend a nasal antihistamine, a nasal decongestant or 
environmental control measures, possibly because of less favorable personal 
experience with these interventions and classes of drug. Further explanations 
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could be the cost implications of these therapies or that environment control 
measures can be complicated, time-consuming, costly and not always practical to 
incorporate into everyday life.
In contrast, personal experience of AR did not influence GPs’ most frequent first 
choice of monotherapy or combination therapy in either mild or moderate-severe 
AR. There is similarly no indication that GPs with AR are more likely to incorporate 
current evidence-based guidelines into their clinical practice when treating either 
themselves or their AR patients. Indeed, it is remarkable GPs with AR were less 
likely than GPs without AR to recommend a nasal corticosteroid, the most effective 
treatment for moderate-severe AR.
Some GPs may have been following the ARIA guidelines without being aware of the 
fact, since the guidelines’ provisions have been included in national AR guidelines 
in some of the countries included in the study. Previous studies have, however, 
also demonstrated suboptimal management of AR patients in primary care12,13 
and GPs’ lack of awareness of, or adherence to the ARIA guidelines is confirmed in 
our study by their low ranking of guideline recommendations, first-line choice of 
treatment and the hundreds of reported therapy combinations. 
LIMITATIONS OF THE STUDY
The results of this survey are based on self-reports and personal estimations of 
the participating GPs, which obviously can differ from actual figures and practice 
habits.
The study population was drawn from a panel of healthcare professionals, with 
no special interest in AR, but willing to be involved in research. This method, 
rather than approaching the general population of healthcare professionals, was 
employed in order to obtain the large study population required by the study and 
to provide the wide geographical spread of countries, but may have induced bias 
as this population might not entirely be representative for the general population 
of GPs.
The balance between persistent AR and intermittent AR in our study is equivalent to 
that in the general population,1, 15 but the preponderance of male GPs (73% versus 
27% female) does not reflect the epidemiology of AR, and is greater than the mean 
of 62% amongst GPs in the countries included in the study (data unavailable in 
Brazil).16 In the general population, women are absent from work more often than 
men in similar employment17 but, since gender was not included in the eligibility 
criteria for our study, it is not possible to conclude that gender imbalance led us to 
underestimate AR-related absenteeism among the GPs in our study.
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Some subsets of the total large study population, for example AR sufferers whose 
symptoms were poorly controlled, were very small resulting in a low sample base 
for that group of GPs.
This study only provides a first snapshot of the influence of AR on the professional 
lives of healthcare providers and the impact on the management of patients 
suffering from the same disease. In order to enable more detailed investigation 
qualitative research is also needed to resolve important questions highlighted by 
our study, including the reasons for GPs’ choice of treatment, the influence of 
personal experience of AR symptoms on the management of their patients with 
AR, and their attitudes to the use of evidence-based guidelines when managing 
their own and their patients’ AR.
ACKNOWLEDGEMENTS
The authors acknowledge the contribution of Sue Lyon and Stella Deane. The 
data were analyzed by personnel employed by Healthcare Research Worldwide, 
an international market research company with a special interest in healthcare 
issues. The study was funded by GlaxoSmithKline R&D Limited.
CHAPTER VII
REFERENCES
1. Bousquet J, Van Cauwenberge P, Khaltaev N, ARIA Workshop Group, World Health 
Organisation. AR and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 
5):S147-334.
2. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a 
cross-sectional survey. Allergy 2007;62(9):1057-63.
3.  Gregory C, Cifaldi M, Tanner LA. Targeted intervention programs. Creating a customized 
practice model to improve treatment of allergic rhinitis in a managed care population. 
Am J Managed Care 1999;5(4):485-96.
4. Price D, Bond C, Bouchard J, Costa R, Keenan J, Levy M, et al. International Primary Care 
Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis. Primary Care 
Respiratory Journal. 2006;15(1):58-70.
5. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The impact of allergies and 
allergy treatment on worker productivity. J Occup Environ Med 2001;43(1):64-71.
6.  Kessler RC, Almeida DM, Berglund P, Stang P. Pollen and mold exposure impairs the 
work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 
2001;87(4):289-95.
7.  Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D, et al. Economic impact 
of workplace productivity losses due to allergic rhinitis compared with select medical 
conditions in the United States from an employer perspective. Curr Med Res Opin 
2006;22(6):1203-10.
8. Shedden A. Impact of nasal congestion on the quality of life and work productivity in 
allergic rhinitis: findings from a large online survey. Treat Respir Med 2005;4(6):439-46.
9.  Szeinbach SL, Seoane-Vasquez EC, Beyer A, Williams PB. The impact of rhinitis on work 
productivity. Prim Care Respir J 2007;16(2):98-105.
10. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity 
and activity impairment instrument. Pharmacoeconomics 1993;4(5):353-65.
11. Benavides FG, Benach J, Diez-Roux, Roman C. How do types of employment relate to 
health indicators? Findings from the Second European Survey on Working Conditions. J 
Epidemiol Community Health 2000;54(7):494-501.
12. Ryan D, Grant-Casey J, Scadding G, Pereira S, Pinnock H, Sheikh A. Management of allergic 
rhinitis in UK primary care: baseline audit. Prim Care Respir J 2005;14(4):204-9.
13. Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact 
and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci 
2000;25(6):551-7.
161160
CHAPTER VII
14. Bachau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur 
Respir J 2004;24(5):758-64.
15. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and 
persistent types of allergic rhinitis. Allergy 2005;60(3):350-3. 
16. European Pharmaceutical Market Research Association - Doctor Universe Statistics In 
Major Markets. http://www.ephmra.org/PDF/Dr%20Universereportpdf19December03.
pdf
17. Mastekaasa A, Olsen KM. Gender, absenteeism and job characteristics. Work Occupation 
1998;25(2):195-228.
APPENDIX: GENERAL PRACTITIONERS’ STUDY ONLINE QUESTIONNAIRE  Al l 
GPs answered quest ions 1-8 and 16-21,  whi le quest ions 10-15 
were answered only by GPs with AR.
SECTION 1: RESPONDENT PROFILE (ALL RESPONDENTS)
1. Which, if any, of the following areas have you participated in any market research on within 
the past 3 months?
⃞ Asthma
⃞ Acid-peptic disorders and treatments
⃞ Diabetes
⃞ Allergies
⃞ Emollients and antipruritics
⃞ Oncology
2. Are you male / female?
3. What is your age?
4. How many years have you been practicing as a general practitioner?
5. What is your current working status? Please check as many boxes as are applicable.
⃞ Full-time  ⃞ Part-time  ⃞ Retired  ⃞ Self-employed  ⃞ Other
6 How many hours do you normally work in a week?
7 How many other general practitioners are there in the practice in which you work?
8 Approximately, how many patients do you have on your personal list?
SECTION 2: GP AR SUFFERERS (ALL RESPONDENTS)
9. We would now like to ask you about your own experience of any of the following symptoms. 
Which, if any, of the following do you suffer from?
⃞ Intermittent allergic rhinitis (IAR)
⃞ Persistent allergic rhinitis (PER)
⃞ Both IAR and PER
⃞ None of the above
10 Thinking about allergic rhinitis (AR), which, if any, of the following do you suffer from when 
not taking AR medication?
⃞ Cough
⃞ Sore throat
⃞ Headache
⃞ Sneezing
⃞ Wheezing
⃞ Watery eyes
⃞ Itchy palate
⃞ Runny nose
⃞ Blocked nose
⃞ Itchy nose
⃞ Post nasal drip
⃞ Sinus pressure
⃞ Itchy / red eyes
⃞ Snoring as a result of any 
of the above
⃞ Waking up in the night as 
a result of any of the above
11 For each of the symptoms you’ve mentioned, please rank this in order of the degree of 
impact they have on your ability to perform your daily tasks, where 1 means this symptom 
has the most impact.
⃞ Cough
⃞ Sore throat
⃞ Headache
⃞ Sneezing
⃞ Wheezing
⃞ Watery eyes
⃞ Itchy palate
⃞ Runny nose
⃞ Blocked nose
⃞ Itchy nose
⃞ Post nasal drip
⃞ Sinus pressure
⃞ Itchy / red eyes
⃞ Snoring
⃞ Waking up in the night
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17 To what extent do you follow the ARIA-guidelines in the treatment of allergic rhinitis?
⃞ I follow them for all AR patients 
⃞ I base the management my AR patients on these guidelines and I adapt according to the 
individual situation
⃞ I prefer not to treat patients’ individual needs irrespective of the ARIA-guidelines
⃞ I am not aware of the ARIA-guideline
18 Please rank the following factors in order of importance to you, where 1 is the most 
important to you and 8 is the least important to you
⃞ Improving patients’ overall quality of life
⃞ Preventing the onset or development of comorbidities of allergic rhinitis (AR) e.g. asthma
⃞ Providing a treatment that is most l likely to result in high patient compliance
⃞ Patient requests for specific treatment
⃞ Providing affordable treatments for patients
⃞ Demand on patients’ personal lives e.g. family commitments
⃞ Demands on patients’ professional lives
⃞ Patients’ emotional well-being
19 A. Which of the following treatments, if any, would you prescribe or recommend as a 
monotherapy for a patient with mild AR? 
Please indicate any treatments you would prescribe or recommend as stand alone treatment 
for mild AR.
⃞ Environmental control measures e.g. 
lifestyle changes
⃞ Oral antihistamine
⃞ Oral decongestant
⃞ Oral corticosteroid
⃞ Nasal antihistamine 
⃞ Nasal decongestant
⃞ Nasal corticosteroid
⃞ Ocular antihistamine
⃞ Ocular cromone
⃞ (Referral for) immunotherapy
⃞ Intramuscular corticosteroid treatment
⃞ Ocular decongestant
⃞ Ocular corticosteroid
⃞ I would not recommend any stand-alone 
treatment for a patient with mild AR
⃞ I would not recommend any treatment for a 
patient with mild AR
B. Which of the following treatments, if any, would you prescribe or recommend as a 
combination therapy for a patient with mild AR?
Please indicate which 2 or more treatments that you would typically prescribe or recommend 
in combination for a patient with mild AR.
⃞ Environmental control measures e.g. 
lifestyle changes
⃞ Oral antihistamine
⃞ Oral decongestant
⃞ Oral corticosteroid
⃞ Nasal antihistamine 
⃞ Nasal decongestant
⃞ Nasal corticosteroid
⃞ Ocular antihistamine
⃞ Ocular cromone
⃞ (Referral for) immunotherapy
⃞ Intramuscular corticosteroid treatment
⃞ Ocular decongestant
⃞ Ocular corticosteroid
⃞ I would not recommend any combination 
treatment for a patient with mild AR
12 Which, if any, of the following do you use to treat these symptoms that you experience?
⃞ Oral antihistamine
⃞ Oral decongestant
⃞ Oral corticosteroid
⃞ Ocular antihistamine
⃞ Ocular cromone
⃞ Nasal antihistamine
⃞ Nasal decongestant 
⃞ Nasal corticosteroid
⃞ Referral for diagnostics / possible immunotherapy
⃞ Treatment for asthma
⃞ Environmental control measures e.g. lifestyle changes
13 How well do you feel your symptoms are controlled with this medication?
⃞ Not at all well controlled
⃞ Not very well controlled
⃞ Quite well controlled
⃞ Very well controlled 
SECTION 3: IMPACT ON WORK FOR GP AR SUFFERERS (AR SUFFERERS ONLY)
14 For this next question, please think about a week when you typically encounter the 
symptoms you have described experiencing yourself.
During this week, how many hours did you miss from work because of these problems 
typically associated with these symptoms? Please include hours you missed on sick days, 
times you went in late, left early etc. because of these symptoms.
Hours missed in a week because of these typical symptoms 
15 To what extent do these symptoms affect you in the following ways?
My symptoms 
affect me 
considerably
My symptoms 
affect me 
moderately
My symptoms  
affect me to a 
limited extent
My symptoms  
do not affect 
me at all
a My concentration at work
b The number of patients I see
c The time I spend with each 
patient
d My level of physical patient 
contact (e.g. touching, 
handling)
e My stress level at work
f My general mood when 
dealing with patients
SECTION 4: IMPACT ON PATIENT MANAGEMENT (ALL RESPONDENTS)
16 A. Of all your patients, approximately what percentage has any form of allergic rhinitis?
B. And of all your patients with allergic rhinitis, what percentage has intermittent allergic 
rhinitis and what percentage of patients have persistent allergic rhinitis?
Percentage of patients with intermittent allergic rhinitis (IAR)
Percentage of patients with persistent allergic rhinitis (PER)
CHAPTER VII CHAPTER VII
164
20 A. Which of the following treatments, if any, would you prescribe or recommend as a 
monotherapy for a patient with moderate-severe AR?
Please indicate any treatments you would prescribe or recommend as stand alone treatment 
for moderate to severe AR.
⃞ Environmental control measures e.g. 
lifestyle changes
⃞ Oral antihistamine
⃞ Oral decongestant
⃞ Oral corticosteroid
⃞ Nasal antihistamine 
⃞ Nasal decongestant
⃞ Nasal corticosteroid
⃞ Ocular antihistamine
⃞ Ocular cromone
⃞ (Referral for) immunotherapy
⃞ Intramuscular corticosteroid treatment
⃞ Ocular decongestant
⃞ Ocular corticosteroid
⃞ I would not recommend any stand-alone 
treatment for a patient with moderate-severe AR
⃞ I would not recommend any treatment for a 
patient with moderate-severe AR
B. Which of the following treatments, if any, would you prescribe or recommend as a 
combination therapy for a patient moderate to severe AR?
Please indicate which 2 or more treatments that you would typically prescribe or recommend 
in combination for a patient with moderate-severe AR.
⃞ Environmental control measures e.g. 
lifestyle changes
⃞ Oral antihistamine
⃞ Oral decongestant
⃞ Oral corticosteroid
⃞ Nasal antihistamine 
⃞ Nasal decongestant
⃞ Nasal corticosteroid
⃞ Ocular antihistamine
⃞ Ocular cromone
⃞ (Referral for) immunotherapy
⃞ Intramuscular corticosteroid treatment
⃞ Ocular decongestant
⃞ Ocular corticosteroid
⃞ I would not recommend any combination 
treatment for a patient with moderate-severe AR
21 Please rank the following treatment attributes in order of importance to you when 
considering treatment options for patients suffering from allergic rhinitis. 1 means this 
treatment attribute is most important to you and 9 means this treatment attribute is least 
important to you.
⃞ Reduction of symptom severity
⃞ Duration of action
⃞ Speed of onset of action
⃞ Safety / side effects
⃞ Ease of administration
⃞ Treatment cost to your practice or state health service
⃞ Your experience with the treatment
⃞ Guideline recommendation
⃞ Formulary recommendation
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Allergic rhinitis (AR) is the most common chronic respiratory disease. If poorly 
controlled, the disease is known to result in significant disease morbidity and 
reduced quality of life (QOL). It can lead to the development or exacerbation of 
comorbidities and has important economic consequences.
In 2001, the first ARIA guidelines1 for AR were published to assist physicians in 
ameliorating the management of their patients by providing them with a guide for 
optimal clinical practices, based on a systematic review of the available evidence 
about the diagnostic and treatment options for AR. The main goal of this thesis 
was to assess the impact of the ARIA guidelines on clinical practice.
We started this work by a critical review of the ARIA guidelines (CHAPTER 2) . In 
this review, also the latest ARIA 2010 guideline, that was  developed using the GRADE 
methodology,2 was included. The advantages of the GRADE approach are that it 
focuses on outcomes that are important to patients, explicitly considers patient 
values and preferences, uses a systematic approach to collecting the evidence, 
clearly separates the quality of evidence and the strength of recommendations, and 
transparantly reports the decision process.3 This GRADING of recommendations 
seems to better reflect the way clinicians make decisions and to come closer to 
the individual patient’s needs. On the other hand, it leaves much more place for 
individual interpretation and judgement and does not provide a framework that 
eliminates disagreements in interpreting evidence and in deciding on the best 
among alternative courses of action, making them also very difficult to implement 
when evaluating or auditing clinical practice.4 The ARIA 2010 guideline, furthermore, 
only addressed a limited number of clinical questions and recommendations on 
additional questions e.g. covering the outcome of combination treatments and 
step-up or step-down regimens should be prioritized. The ARIA 2010 guideline, 
however, was not included in the further scope of this work, as it was not yet 
available when we performed our surveys.
At present, no guideline for AR has been subjected to an independent quality 
appraisal according to the validated AGREE instrument,5 and there is a urgent need 
to perform such a systematic analysis. Based on our updated review,6 however, 
we can assume that the ARIA 20011 and 2008  guidelines,7 that were used in our 
surveys, meet the quality domains defined by AGREE as ‘purpose and scope’, 
‘stakeholder involvement’ and ‘editorial independence’. 
When we consider their ‘rigour of development’, we can conclude that 
systematic methods were used to describe evidence and that the criteria for 
selecting evidence, the strengths and limitations of the body of evidence are clearly 
described. The practical treatment recommendations of the ARIA guidelines, on 
the other hand, are formulated as a stepwise treatment algorithm, based on a 
new classification for AR, developed by the ARIA working group.  As the collected 
evidence underlying the therapeutic choices is mainly based on trials that were 
carried out before the new classification for AR, there is no explicit link between 
the treatment algorithm and the supporting evidence. Furthermore, although the 
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and work performance11 questionnaires, and increased asthma prevalence11, 12 
in the moderate-severe compared to the mild AR patient group. 
On the other hand, we noted a clear disproportion in the distribution of patients 
graded as mild or moderate-severe among our patient population, with almost 
90% classified as moderate-severe. Other epidemiological trials performed in 
general and specialist practice10, 11, 13 reported a similar high proportion of patients 
classified with moderate-severe AR, raising the question whether this large group 
of patients with moderate-severe AR does not demonstrate wide heterogeneity 
in disease severity and whether it would not be beneficial to further stratify this 
severity gradation into two separate moderate and severe AR groups.
In CHAPTER 4  we made a proposition to adapt the ARIA classification of AR 
severity by differentiating 3 severity categories: mild, moderate, severe. In our 
model, the definition of AR severity was in many ways very similar to the original 
ARIA definition, but we omitted one of the 4 QOL items from the original ARIA 
classification, namely the absence or presence of troublesome symptoms, as this 
was found to be the least discriminative, and combined the 2 QOL items assessing 
the impact on the daily life into 1 item, resulting in following definitions:
• ‘Mild’ AR: symptoms of AR cause no sleep disturbance and no impairment of 
daily personal (daily activities, leisure, sports) and/or professional (school, 
work) life
• ‘Moderate’ AR: symptoms of AR cause sleep disturbance or impairment of 
daily personal (daily activities, leisure, sports) and/ or professional (school, 
work) life
• ‘Severe’ AR: symptoms of AR cause sleep disturbance and impairment of 
daily personal (daily activities, leisure, sports) and/or professional (school, 
work) life
When applying this ‘modified’ ARIA classification in our patient group of 804 
patients, 20.5% of our patients were classified with mild AR, 45.9% with moderate 
AR and 33.6% with severe AR. A significant linear increasing trend in severity scores 
of all assessed symptoms, except rhinorrhea, was found from mild to moderate 
to severe AR and the degree of allergy testing and prescription of nasal and oral 
corticosteroids significantly increased with increased AR severity category.
Demoly et al applied our modified ARIA severity classification to a large AR 
patient group (n=5140) recruited in French general and specialist practice and 
classified them as ‘mild’, ‘moderate’ or ‘severe’ according to our definitions 
resulting in 48.6% patients classified as moderate and 44.4% as severe.15 
For the prevalence of nasal and eye symptoms the mild and moderate group were 
found to be very similar (with overlap of the 95% confidence interval), compared 
to the severe group that demonstrated significantly more nasal obstruction, 
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shortcomings of the previous AR classification, based on the time of exposure 
to the offending allergen(s), were extensively described in the ARIA Workshop 
Report,1 the new ARIA classification, based on the duration of symptoms and 
their impact on QOL was developed empirically and based on expert consensus 
and had not been evaluated and validated in a patient population prior to the 
publication of the ARIA guidelines. 
The AGREE collaboration also emphasizes that the implementability of a 
guideline should already be anticipated on at the time of the development of the 
guideline by ensuring a clear presentation of the guideline recommendations 
and considering the applicability of the guideline. The latter, however, was not 
clearly addressed in the ARIA reports and, still very little is known about the 
implementation of the ARIA guidelines and factors that may influence this process. 
Assessment of the ARIA classification in a large patient population and 
evaluation of the implementation of the ARIA guidelines by general practitioners 
and specialists were the 2 main topics of this thesis, resulting in some interesting 
conclusions and hypotheses, but also raising additional questions and opening 
future research perspectives. The discussion on ‘the ARIA classification for allergic 
rhinitis’ and ‘the implementation of the ARIA guidelines for allergic rhinitis’ will 
separately be addressed in this chapter.
THE ARIA CLASSIFICATION FOR ALLERGIC RHINITIS
In CHAPTER 3  we classified a large AR patient population, recruited in general 
practice and untreated at the time of presentation, according to the ARIA 
classification. Similar to previous studies performed in the general population8 
and in medical practice9, we found that the classification of AR into persistent 
and intermittent AR is not synonymous and interchangeable with the former 
classification into seasonal and perennial AR, and that intermittent and persistent 
AR represent distinct disease categories in terms of clinical symptoms, impact on 
QOL and recommended therapeutic management. 
We, however, were the first to report that not only the classification of AR based 
on duration of symptoms, but also the gradation of severity, based on impact on 
4 health-related QOL items (1. sleep disturbance, 2. impairment of daily activities, 
leisure and/or sport, 3. impairment of school or work, 4. troublesome symptoms; 
see definitions) into mild and moderate-severe in an untreated patient population 
(see definitions of ARIA classification) has significant discriminating capacity, 
supporting its validity to stratify AR patients. This was confirmed in other large 
clinical trials conducted in general and specialist practice, but mostly including both 
treated and untreated patients. These studies also analyzed the ARIA grading for 
disease severity and reported significantly higher prevalence10, 11 and severity12, 13 
of nasal and non-nasal AR symptoms and visual analogue scale (VAS) scores for 
disease severity,12-14 significantly reduced outcome on validated QOL,12, 14 sleep11 
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moderate and severe) the modified ARIA severity classification proved to have 
discriminative value with significantly worse T4SS among the different severity 
grades and QOL scores (assessed with the validated AR-specific ESPRINT-15 
questionnaire) in the severe compared to the moderate and the moderate 
compared to the mild AR group.
CONCLUSIONS AND UNANSWERED QUESTIONS
We can conclude that the moderate-severe AR patient group, as defined by ARIA, 
represents a very large proportion of the patients presenting in medical practice 
and undoubtedly encompasses heterogeneity in disease severity. 
Proposals by our group and by the group of Valero have been made to 
differentiate moderate from severe AR. Our proposed ‘modified AR severity 
gradation’ was applied on our own patient group, recruited in general practice, and 
by Demoly et al15 on a large patient group and has shown to have discriminative 
value between the ‘modified’ mild, moderate and severe group in terms of severity 
and prevalence of several nasal and paranasal symptoms and (suggested) medical 
treatment practices. On the other hand, we acknowledge that further assessment 
of this classification and its discriminative impact on validated symptom and QOL 
scores is required. 
In contrast to our proposal, the modified AR severity classification by Valero16 
did not alter the definition of mild AR and preserved the 4 ARIA-QOL items, which 
might be an advantage, as the original ARIA classification was widely distributed 
and less change might have beneficial effects in acceptance of a modification. 
Furthermore, Valero validated the stratification of moderate and severe AR in both 
an adult and pediatric AR patient population and demonstrated the discriminative 
impact on validated disease severity scores (T4SS, VAS and ESPRINT-15).17, 18
Irrespective of which modified ARIA severity classification has the most benefit, 
there remain some unresolved questions that definitely require to be addressed 
in future research before deciding that the original ARIA classification should be 
adapted.
• First, an assessment of the original and modified ARIA severity classifications 
should be performed in the general AR population to evaluate the distribution 
and characteristics of the different severity grades. It is known that many 
AR patients do not seek medical help or even remain undiagnosed. There 
are indications that this group of patients probably has lower symptom 
severity19 and might represent an important group of ‘mild’ AR patients, that 
are ‘underrepresented’ in medical practice but, at present, clear data are 
lacking.
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loss of olfaction and eye symptoms (watering, itching and redness). The severe 
group also demonstrated significantly more lung symptoms (cough, wheezing), 
pharyngeal irritation, fatigue and headache than the moderate group, which in 
turn reported significantly more wheezing, pharyngeal irritation and fatigue than 
the mild group. None of the nasal or non-nasal symptoms were more prevalent in 
the mild than in the moderate group or in the moderate group compared to the 
severe group. Furthermore, a significant increase in use of oral corticosteroids was 
noted in the moderate compared to the mild group and in the severe compared to 
the moderate group. Although the authors concluded that the observed statistical 
differences were mainly because of the very large sample size and that no clear 
clinically relevant trends were observed to support the need for a distinction 
between mild, moderate and severe AR patients, the main goal of our proposed 
‘modified ARIA severity classification’ was to further differentiate the large group of 
patients with moderate-severe AR. From this perspective we dare to conclude that 
the observed increased prevalence of almost all assessed non-nasal symptoms 
and the higher use of oral corticosteroids in the severe compared to the moderate 
group support the idea that the moderate-severe group, as defined by the original 
ARIA classification, demonstrates significant internal heterogeneity in disease 
severity. Furthermore, it needs to be noted, that the large patient group from 
Demoly15 was assessed for the presence of symptoms and not for the severity of 
symptoms, as in our patient group, making both studies difficult to compare.  
Shortly after publication of our proposition of a modified ARIA severity 
classification, Valero et al16 also reported substantial heterogeneity in terms of 
nasal symptom scores and QOL impairment in a group of 141 untreated moderate-
severe AR patients, recruited in specialist practice, and formulated a proposal 
to differentiate moderate from severe AR, that, however, was different from 
our proposal. Based on a linear regression model, they measured a significant 
effect from the number of affected ARIA-QOL domains on nasal symptom and 
QOL scores, with the clearest distinction between patients that were affected 
with 4 versus 3, 2 or 1 items.  The latter criterion was used to define respectively 
severe and moderate AR. No change was proposed to the definition of mild AR. 
The group of Valero performed validation studies of their modified ARIA severity 
classification in a large group of untreated pediatric AR patients (n=1269), recruited 
in specialist practice, 17  and a large group of untreated (1058) and treated (1066) 
adult AR patients, recruited in general and specialist practice.18 In the pediatric 
patient group the modified ARIA severity classification was found to be useful to 
discriminate severe (30.5% of patients) from moderate (59.5% of patients) from 
mild AR (10% of patients) with significantly worse T4SS (Total 4 Symptom Scores) 
and VAS scores for disease severity in the severe compared to the moderate and 
moderate compared to mild group. Also in both the untreated (with 17.8%, 63.1% 
and 19.1% classified as respectively mild, moderate and severe) and treated adult 
AR patient group (with 8.9%, 62.2% and 28.9% classified as respectively mild, 
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control have shown to be beneficial in clinical decision making, has increased 
awareness of the important partnership between patient and caregiver 
when setting and aiming treatment goals, and probably also increased the 
guideline penetration in the medical community when the level of asthma 
control was incorporated in the GINA 2006 guidelines to guide treatment.30
IMPLEMENTATION OF THE ARIA 
GUIDELINES IN CLINICAL PRACTICE
The ARIA guidelines were intended to improve the quality of AR patient care by 
optimizing the practice patterns of healthcare providers dealing with AR patients. 
A first step to improving the quality of care, is to know whether current practice 
patterns differ from those that are thought to be optimal.
In CHAPTER 3  we described the results of a cross-sectional survey in Belgium, 
that evaluated the diagnostic and therapeutic management of 804 AR patients by 
95 GPs. We chose to perform this study in general practice, as most people who do 
seek medical help for AR, consult their GP, making AR a very prevalent condition 
in general practice and supporting the necessity to investigate the management 
practices of AR in this healthcare setting.
Whereas the ARIA guidelines recommend that the diagnosis of AR should be 
supported by highly sensitive and  specific in vivo or in vitro allergy tests, only 
50% of the patients diagnosed by their GP with AR, underwent allergy testing. 
These figures are similar to the results of a pharmacoepidemiological survey of 
intermittent AR patients presenting in everyday medical practice in France, where 
the diagnosis of AR was confirmed  with allergy tests in only 50% of the patients.31
Only 33.4% of the patients received a rhinitis treatment that was in accordance 
with the evidence-based ARIA treatment recommendations, available at the 
time of the survey,1 12.8% were undertreated and 52.7% were overtreated. 
Many GPs immediately prescribed the combination of an antihistamine and a nasal 
corticosteroid, which was the most popular treatment regimen and was initiated in 
45.5% of the patients, instead of following a stepwise treatment regimen. Despite 
the costs of this combined treatment and the lack of evidence supporting the 
superior value of immediately adding an antihistamine to a nasal corticosteroid, 
the high prescription rate of this combined treatment was also reported in other 
European studies32, 33 and was also found in our studies assessing the proposed 
treatment for AR by GPs and ENT-specialists in clinical case scenarios (CHAPTER 5 
AND 6) . Nevertheless the co-prescription of a nasal steroid and an antihistamine 
remains an important topic of debate.32 Also guideline recommendations seem 
conflicting, with the opinion-based EAACI guidelines,34 preceding the first ARIA 
guidelines, recommending to combine an antihistamine and a nasal steroid as a 
first-line treatment in severe cases of AR, the ARIA 2001 guidelines recommending 
a stepwise approach and only recommending this combination if treatment with 
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• Second, current studies evaluating the ARIA classification were mainly 
performed in Western countries and there still is a paucity of data analyzing 
the ARIA classification in the rest of the world.20, 21 As the ARIA guidelines 
were intended as a basis for the entire world, these studies are absolutely 
required.
• Third, the phenotype of moderate-severe (or severe) AR should be further 
characterized. By now, we know that this group of patients has more 
invalidating symptoms and per definition impaired quality of life, affecting 
social functioning, sleep, and school/work performance. However, there 
is a need of more objective evaluation tools for disease severity. In this 
context, also the identification and characterization of biological markers 
for endotypes that might be used in the diagnosis, but also in the severity 
classification, follow up and treatment monitoring, have been defined as 
future research needs, not only for AR, but for all allergic diseases.22
• Fourth, we have to keep in mind that the main purpose of classifying AR 
patients is to inititiate an appropriate treatment. At present, it is absolutely 
not clear whether the heterogeneous group of moderate-severe AR patients 
would also benefit from a stratified therapeutic approach and consequently 
whether a modification of the ARIA classification would result in a different 
therapeutic algorithm.
• Fifth, as originally defined by the ARIA Working Group, the ARIA classification 
is intended for untreated patients. Although most studies evaluating or 
‘validating’ the ARIA classification also included patients that were already 
treated, it is not sure what the impact of treatment is on the validity of 
the ARIA classification and on the conclusions that resulted from these 
studies. By analogy to trends in the management of asthma and other 
respiratory or allergic diseases, it seems appropriate or even essential to 
also introduce the concept “control of AR” as a complementary instrument 
next to the ARIA classification for purposes of follow-up, to evaluate 
the status of disease and plan future treatment, especially for patients 
already under treatment. There is no single definition of “disease control”. 
Demoly et al proposed a very complete definition of disease control in 
AR, combining measurements of the severity and/or frequency of daily 
or nocturnal symptoms, impairments in social, physical, professional and 
educational activities, respiratory function monitoring and exacerbations.23 
Different instruments for assessing disease control in AR have already been 
developed and underwent validation studies, but at present no comparative 
studies of these different control instruments have been performed23-29 
and the AR control concept is not yet integrated in clinical AR guidelines. 
The introduction of the asthma control concept and simple tools to assess 
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and severity of disease, but are specifically addressed and adapated to the primary 
care health setting. It is well-known that physicians, and GPs in particular, prefer 
receiving guideline information from their own peer group.37 If these guidelines 
are well-developed and evidence-based, the implementation of guidelines that are 
tailored to local circumstances, patient population characteristics and healthcare 
system regulations can only be encouraged.
Nevertheless, the self-reported use or implementation of any guideline for AR 
among our GP population remains very poor (34.3%). Of course, we need to consider 
that GPs in particular manage many different illnesses and that many might not 
consider AR among their priorities. Indeed, the self-reported implementation of 
guidelines for AR was significantly higher among GPs with a special interest in 
ENT pathology/allergology compared to the rest of GPs (49.4% versus 29.4%). But, 
on the other hand, AR is known to be among the top 10 reasons for a doctor’s visit 
in general practice,38 and this important patient group is entitled to receive the 
best standards of care.
Furthermore, it is well-known that self-reported adherence to guidelines must be 
interpreted with caution, might be susceptible to social desirability and interviewer 
bias and does not necessarily reflect actual practice.39  In our surveys we found 
that that physicians who self-reported to implement the ARIA (or NHG) guidelines 
only to a limited extent adhered  to the guideline recommendations when we 
further questioned their diagnostic management (only performed in GP survey) 
and treatment strategies for AR. 
Whereas the ARIA guidelines recommend to perform a nasal examination as 
a standard part of the diagnosis of AR, only one third of the ‘ARIA users’ indicated 
to routinely perform this examination. Allergen testing and screening for asthma, 
on the other hand, were indicated as a routine part of the diagnostic work-out of 
AR patients by the majority of GPs (respectively 71% and 74%), but only screening 
for asthma was significantly more performed by the self-reported guideline users 
(84.2%) (and ARIA users in particular (94.3%)) compared to the rest of the GPs 
(69.1%). We acknowledge that these results must be interpreted with caution 
because of the low number of self-reported guideline (and ARIA in particular) users 
and the explicit questioning about diagnostic procedures, which may have forced 
reply and probably contributed to the overall high reporting of asthma screening 
and allergen testing, compared to what is found in most epidemiological studies 
evaluating the diagnostic management of AR patients in general practice.35, 38, 40
Also, when assessing the treatment strategies proposed by GPs and ENT-
specialists in 4 fictitious clinical scenarios, we found that self-reported use of the 
ARIA (or NHG) guidelines was not a good predictor of adherence to the stepwise 
ARIA treatment recommendations. In the specialist survey self-declared ARIA 
users still demonstrated some higher scores indicative for better compliance with 
the ARIA guidelines compared to the self-declared non-users, but in both the GP 
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an antihistamine or a nasal steroid alone fails1 and the ARIA 2008 guidelines 
allowing to immediately combine a nasal steroid and an antihistamine in patients 
with moderate-severe persistent AR when symptoms are severe7 (without 
further specification of ‘severe’ and not clearly supported by evidence!). The ARIA 
2010 revision does not formulate recommendations concerning this combined 
treatment.2
From chapter 3 we can conclude that the management practices for AR in Belgian 
general practice often differ from the ARIA recommendations, but we did not gain 
information on the practioners’ awareness of and intention to comply with these 
guidelines. 
This led to the surveys, described in CHAPTER 5 AND 6 , that were specifically 
developed to evaluate the dissemination and implementation of the ARIA 
guidelines in Belgian general and specialist practice.
In these surveys, the spreading of the ARIA guidelines to the GPs was found 
to be very poor with only 31.1% of them being aware of the ARIA guidelines 
compared to 87.2% of the Belgian ENT-specialists. Data from a French cross-
sectional study also reported a higher familiarity with the ARIA guideline among 
French ENT-specialists (65.0%) compared to GPs (48.4%),35 but also indicate that, in 
France, the ARIA guidelines seem to have better reached the GP population than 
in Belgium (Flanders). Possibly, in France, more initiatives were undertaken for a 
wide  dissemination of the ARIA guidelines, under the impulse of the French ARIA 
Chairmanship (Prof. Jean Bousquet). For Belgium, on the other hand, the particularly 
high awareness among Belgian ENT-specialists can probably be explained by 
the fact that the co-chair of the ARIA initiative (Prof. Paul Van Cauwenberge) is 
a renowned Belgian ENT-specialist, leading to specific dissemination initiatives 
and interest in the ARIA guidelines within this specialist group. Furthermore, 
the French and the Belgian surveys cannot strictly be compared, as we assessed 
‘awareness of’ the ARIA guidelines, whereas Demoly35 questioned ‘familiarity with 
the ARIA guidelines’, which are not exactly synonyms.
Spreading and awareness of and familiarity with the ARIA guidelines, on the 
other hand, does not necessarily lead to adherence with these guideline 
recommendations in clinical practice. 62% of the ENT specialists, and only 10% 
of the GPs in our surveys stated to follow the ARIA recommendations in their 
daily practice. An additional 24% of the GPs, however reported to follow the 
’NHG Standard for Allergic and Non-allergic Rhinitis”,36 developed  by the Dutch 
College of General Practitioners, in the daily management of their AR patients. The 
recommendations of the NHG guideline for (allergic) rhinitis36 are also supported 
by evidence and in many ways very similar to the ARIA guidelines, proposing the 
same classification and the same first-line treatments according to the duration 
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CONCLUSIONS AND UNANSWERED QUESTIONS
From the surveys described in chapters 3, 5 and 6, and discussed in the above 
section, we can conclude that the management of AR in Belgian general and 
specialist practice often differs from the evidence-based recommendations, and 
that there remains a lack of influence of clinical guidelines on health professionals’ 
behavior.
On the other hand, we acknowledge that our results provide only a snapshot of 
how GPs and specialists deliver care to AR patients, are subject to some limitations 
and raise additional research questions.
Evaluating healthcare practices through questionnaires obviously has some 
limitations
• First, only a limited number of items can be addressed.
• Second, results are based on the answers of respondents and can be subject 
to non-response bias. We, however, tried to limit this bias by obtaining a 
relatively high response rate (ENT survey) or a sample population that is 
representative for the entire target population (GP survey).
• Third, results are based on self-reports, making them vulnerable to 
interviewer and social desirability bias. Interviewer bias cannot be ruled out, 
and we are aware that some types of questions (and proposed answers) 
may have forced reply. We tried to limit social desirability bias by conducting 
and handling the surveys under complete anonymous conditions. 
• Fourth, in the questionnaires, the respondents’ choice for diagnostic and 
treatment indicates their practice intentions and intentions to treat in clinical 
case scenarios. The real life setting, however, is much more complex and 
decisions not only depend on physician’s intentions, but are also influenced 
by the individual context, patient comorbidity and patient preferences. 
Nevertheless, well-constructed clinical case scenarios have demonstrated 
to reflect the actual clinical behavior of a group of physicians45-47 and have 
the advantage of being much less time and cost consuming and lead to 
a more straightforward interpretation compared to assessing physician’s 
treatment practices based on medical patient files.48
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as the ENT survey overall compliance with the ARIA recommendations was poor 
and great diversity in treatments and treatment combinations was found, both 
among self-declared guideline users and non-users. 
In both surveys we analyzed whether certain demographic and professional 
physician characteristics influenced compliance with the evidence-based 
treatment recommendations for AR and, consistently, in both the GP as the ENT 
survey, we found that younger age (or less clinical experience) was a significant 
and independent predictor of good compliance. Similar findings of declining 
adherence to clinical practice standards and evidence-based recommendations 
with increasing age and experience have also been reported in other areas of 
medicine.41-43 A possible explanation is that the evolution from opinion-based 
to evidence-based medicine dates from the last 15 years. It is well known that 
physicians not easily change their long-standing prescribing patterns and this 
has been identified as a barrier to the incorporation of scientific evidence and 
guidelines into practice.38 Younger, less experienced physicians on the other hand, 
more often tend to rely on the current scientific knowledge to support their clinical 
practice.
Unfortunately, comparisons between GPs and ENT-specialists concerning 
guideline compliance or adherence to the evidence-based treatment principles 
of AR could not be made because in the interval between the surveys an update 
of the ARIA guidelines7 was published with some modifications in the treatment 
algorithm. Depending on the ARIA guideline version used to score physician’s 
compliance with the ARIA recommendations (and to assess ARIA guideline 
implementation) in the surveys described in chapters 5 and 6 our results would 
differ. Especially the above mentioned immediate combined treatment of a nasal 
steroid and an antihistamine in moderate-severe persistent AR, that is consistent 
with the ARIA 2008 guidelines, but not with the ARIA 2001 guidelines, explains the 
higher overall ARIA compliance scores in the clinical case sections in the GP survey 
(chapter 6, using ARIA 2008 guidelines),  compared to the ENT survey (chapter 5, 
using ARIA 2001 guidelines). 
Similarly, also in chapter 3 , less ‘overtreatment’ would have been reported if 
we would have compared GPs’ prescription habits with the later ARIA 2008 instead 
of the ARIA 2001 guidelines, that were available at the time of the survey. 
However, as defined in the methodology of our surveys, assessment of 
compliance with the ARIA recommendations was performed by strictly comparing 
the physician’s proposed treatments with the recommendations of the ARIA 
guidelines, available at the time of the survey.
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Barriers, however, largely differ between guidelines, but also across recommend-
ations within  guidelines. Furthermore, they vary depending on the healthcare 
setting and analysis of barriers to implementation among the different groups of 
target users is advocated. Every implementation project should therefore be tailor 
made.57 In order to increase the success of implementation, the closely linked 
processes of guideline development, dissemination and implementation should 
not be phased, but should be prepared and proceed together.61 
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Our data are limited to Belgian ENT-specialists and Flemish GPs. Concordant to 
our results, a limited number of studies, conducted in westernized countries, have 
also revealed considerable scope of improvement in the management of AR in 
general and specialist practice38, 49, 50 and have shown that the implementation 
of the ARIA guidelines remains poor.35, 51 Of course, it would be interesting to 
see how GPs, specialists, but also pharmacists in different parts of the world 
manage the prevalent condition of AR and to which extent the evidence-based 
recommendations are disseminated and implemented.
Dissemination and implementation of guidelines are closely linked. The 
dissemination process focuses on educational interventions, that aim at improving 
awareness, knowledge, understanding and skills and influencing attitudes towards 
recommendations. Implementation, on the other hand, is more complex and 
implies strategies to translate changes in knowledge and attitude into changes 
in practice, and aim at the adoption and adherence of recommendations in 
daily routines.52-54 As dissemination is a first step towards implementation, both 
processes are often addressed together, using the terminology of ‘implementation’.
From our research we can conclude that the translation of scientific evidence 
concerning AR management into clinical practice and the implementation of the 
ARIA guidelines is unsatisfactory. It remains to be analyzed, however, why this 
implementation process remains inadequate and how it can be improved.
Cabana et al developed a theoretical framework of the potential barriers 
to physician adherence to clinical guidelines, operating at the level of the 
practitioner, the level of the patient, the organizational context, and the social 
and cultural context. In total, he identified 293 (!) potential barriers that are able 
to influence (or impair) physician’s knowledge, attitudes and behavior.55 The aim 
of identifying barriers is to develop a tailored implementation plan, as it has 
been shown that implementation strategies are more effective when tailored 
to pre-identified barriers.56 Cabana’s model has been applied in qualitative and 
quantitative surveys to analyze barriers towards a (group of) guideline(s), or 
specific guideline recommendations and often resulting in suggested interventions 
to overcome these barriers and improve the feasibility and success of guideline 
implementation.57-60 (TABLE 1)
TABLE 1:  Perceived barriers and suggested interventions in surveys 
addressing barriers to guidel ine implementation 53, 54,  57-60 
Perceived barriers Suggested interventions
Knowledge related barriers 
Lack of awareness/familiarity Inadequate spreading of or 
access to guidelines
Use of clinical practice 
guidelines in professional 
development and continuous 
medical education
Small group, interactive 
educational sessions
Computerization
Reminder systems
Attitude related barriers
Lack of agreement Arguing supporting evidence Detailed and transparant 
information on supporting 
evidence
Lack of self-efficacy Insufficient training or 
experience
Small group education/training
Lack of outcome expectancy Belief that applying guideline 
recommendations will not 
result in patient benefits
Inertia of previous practice/lack 
of motivation
Difficult to overcome habits 
and routines
External barriers
Patient factors Conflicting patient preferences, 
abilities and needs
Use of decision aids to support 
the flexible use of guidelines to 
individual patients in practice
Guideline factors Unclear/ambiguous
Incomplete/not up to date
Not user-friendly/too complex
User-friendly format and 
presentation of guidelines
Choose guidelines that are 
validated according to AGREE
Development of locally adapted 
guidelines
Environmental factors Lack of time/time pressure
Lack of resources/material
Organizational constraints
Lack of reimbursement
Professional incentives, referral 
privileges
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In our studies there are indications that lack of awareness of/familiarity with the 
ARIA guidelines among the GP population, inertia of practice among the seasoned 
GPs and ENT specialists and poor uptake of the ARIA treatment algorithm (due 
to insufficient clarity? Complexity?) are barriers to effective implementation. 
Our questionnaires, however, were not specifically developed to evaluate 
perceived barriers to guideline implementation and our data are insufficient to 
draw firm conclusions.
Finally, it is important to understand that variations in clinical outcomes can not 
only be explained by variations in medical practice process and implementation 
of evidence-based guidelines by healthcare providers, but are largely driven by 
individual responses to treatments and patient compliance. Patients should be 
considered as effective partners in healthcare and the patient’s voice should also 
be heard in the development of guidelines. Patient education and involvement 
is critical in the management of any disease and patient feedback can act as a 
stimulus to health professional change. Adequate patient-doctor dialogue can 
maximize compliance, increase satisfaction and optimize health outcomes.
For many diseases, however, conflicting perspectives are identified between 
patients and physicians.62, 63 The available literature indicates that physicians 
underestimate the impact of AR, leading to inadequate patient-physician dialogue 
and discordant treatment decisions. In CHAPTER 7  we investigated whether a better 
understanding of the burden of AR by physicians, due to personal experience of 
AR, influenced the management of patients suffering from the same disease. We 
found that GPs with AR might better recognize AR patients within their practice and, 
when making treatment decisions, gave a significantly higher ranking to patient 
requests for specific treatment and emotional well-being of the patient, compared 
to their non-AR colleagues. In order to try to optimize healthcare outcomes, further 
inquiry to the decision processes shared by healthcare providers and patients is 
necessary.
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CHAPTER VII I
From our unresolved questions some future research perspectives are prioritized. 
There is an urgent need for a systematic quality appraisal of the Allergic Rhinitis 
and its Impact on Asthma (ARIA) guidelines and other available allergic rhinitis (AR) 
guidelines. The standardized AGREE instrument will be used for this purpose.
Further assessment of the ARIA classification and the modified ARIA classifications, 
proposed by our group and the group of Valero, needs to be performed in large 
groups of AR patients, recruited in different settings: the general population, 
general practice and specialist practice. The different (modified) ARIA classification 
groups will be compared for validated symptom and quality of life scores and 
the presence of well-defined comorbidities. As, at present, least data on the ARIA 
classification are available from the general allergic rhinitis population, the first 
focus lies on this patient group. 
In untreated, but especially also in treated AR patients, we want to compare AR 
control scores, measured by a validated and easy to administer instrument, such 
as the Allergic Rhinitis Control Test (ARCT), with AR severity as defined by the 
(modified) ARIA classification(s) and to analyze potential correlations between AR 
control and severity and  physician-recommended (change in) treatment.
In order to better understand why the implementation of the ARIA guidelines 
remains inadequate, it is necessary to perform a systematic evaluation of 
perceived barriers to the implementation of the ARIA guidelines and suggestions 
to improvement. This work will start by qualitative studies e.g. by conducting focus 
group studies among the different target user groups, and eventually expanding 
to larger quantitative studies. The information resulting from this research 
might provide valuable information to improve the implementation process of 
the current or any future ARIA guideline update or local adaptation, that ideally 
should be accompanied by a simultaneous implementation plan. 
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SUMMARY
Allergic rhinitis (AR) is the most common chronic respiratory disease, affecting 
up to 25% of the population worldwide. The burden of disease goes far beyond 
the nasal symptoms of rhinorrhea, nasal congestion, sneezing and pruritus. AR 
causes significant impairment of the quality of life, is associated with multiple 
comorbidities and has important economic consequences. Nevertheless, the 
disease often remains regarded as trivial, un(der)diagnosed and inadequately 
treated.
In 2001, the first evidence-based guidelines for AR, the ARIA guidelines, were 
published to assist physicians in improving the management of their patients by 
providing them a guide for ‘optimal clinical practices’. The ARIA guidelines propose 
diagnostic recommendations and a stepwise treatment algorithm, based on a 
new classification for AR in terms of the duration of disease (into intermittent and 
persistent) and its impact on quality of life (into mild and moderate-severe).
The main goals of this thesis were to assess the validity and applicability of the 
ARIA classification in a large patient population and the implementation of the 
ARIA guidelines by general practioners (GPs) and ENT-specialists.
In our patient group we confirmed the benefits of classifying AR into intermittent 
or persistent. On the other hand, gradation of severity, into mild or moderate-
severe, showed some important limitations, due to a clear disproportion in the 
distribution of patients, with almost 90% being classified as moderate-severe, and 
the heterogeneity in disease severity within the moderate-severe group. Based on 
these findings, we proposed an adaptation and simplification of the ARIA gradation 
of AR severity, differentiating 3 severity categories: mild, moderate, severe.
To evaluate the implementation of the ARIA guidelines in clinical practice, we 
first performed an exploratory study in Belgian general practice, showing that 
diagnostic and treatment practices for AR often differ from the evidence-based 
ARIA recommendations. Further surveys addressed to Flemish GPs and Belgian 
ENT-specialists confirmed that there remains a lack of influence of clinical 
guidelines on health professional’s behavior. Among the GPs, awareness of the 
ARIA guidelines was very poor. Compliance with the stepwise treatment algorithm 
for AR was poor among both GPs and ENT-specialists, and even among those that 
reported to follow the ARIA guidelines in their daily practice. In both surveys young 
age (and less clinical experience) of the physician was found to be a significant 
and independent predictor for good compliance with the evidence-based AR 
treatment recommendations. 
Further research perspectives will aim at evaluating the original and adapted 
ARIA classification in different patient groups, the additional value of assessing AR 
control in treated patients and the impact of these different instruments on the 
treatment algorithm.
Systematic analysis of perceived barriers to the implementation of the 
ARIA guidelines among the different target user groups is necessary to better 
understand and improve the implementation process.
Finally, the decision processes shared by healthcare providers and patients, 
their impact on patient compliance and clinical outcomes need to be further 
explored.
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Allergische rhinitis (AR) is de meest voorkomende chronische respiratoire 
ziekte, die ongeveer 25% van de wereldbevolking treft. De impact van de ziekte 
gaat veel verder dan de typische neussymptomen, bestaande uit neusloop, 
neusverstopping, niezen en jeuk. AR heeft een significante invloed op de 
levenskwaliteit, is geassocieerd met vele comorbiditeiten en heeft belangrijke 
economische gevolgen. Desondanks wordt de aandoening vaak gebanaliseerd, 
niet- of ondergediagnosticeerd en inadequaat behandeld.
In 2001 werden de  eerste  evidence-based richtlijnen voor AR gepubliceerd, de 
ARIA richtlijnen. De ARIA richtlijnen werden ontwikkeld om artsen/zorgverleners te 
helpen de zorg voor hun patiënten te optimaliseren. De ARIA richtlijnen formuleren 
diagnostische aanbevelingen en stellen een stapsgewijs behandelingsalgoritme 
voor, dat gebaseerd is op een nieuwe classificatie for AR, op basis van  de duur van 
de aandoening (in intermittent en persistent) en de impact op de levenskwaliteit 
(in mild en matig-ernstig).
De belangrijkste doelstellingen van deze thesis waren de evaluatie van de 
validiteit en toepasselijkheid van de ARIA classificatie in een grote  patiëntengroep 
en de implementatie van de  ARIA richtlijnen door huisarten en NKO-specialisten.
De voordelen van een classificatie van AR op basis van de duur van de symptomen, 
met onderscheid tussen intermittent en persistent, werden binnen onze 
patiëntengroep bevestigd.  Anderzijds, vertoonde de classificatie (of gradatie) van 
ernst in de groepen mild of matig-ernstig, toch een aantal belangrijke beperkingen. 
Enerzijds vonden we een duidelijke  disproportie tussen deze 2 groepen, met bijna 
90% van de patiënten die als matig-ernstig werd geclassificeerd, en anderzijds 
was er binnen de matig-ernstige groep toch een belangrijke heterogeniteit in 
ziekte-ernst. Op basis van deze bevindingen stelden we een modificatie en 
vereenvoudiging van de ARIA classificatie voor ernst van AR voor, met onderscheid 
tussen 3 ziekte-ernst categorieën: mild, matig, ernstig.
Om de implementatie van de ARIA richtlijnen in de klinische praktijk te evalueren, 
werd eerst een verkennende studie in de Belgische huisartsenpraktijk uitgevoerd, 
die aantoonde dat de diagnostische en therapeutische aanpak van AR vaak afwijkt 
van de evidence-based ARIA aanbevelingen. In een tweede fase ondervroegen we 
Vlaamse huisarten en Belgische NKO-specialisten en werd de gebrekkige impact 
van klinische guidelines op de praktijkgewoonten van de arts bevestigd. De 
huisartsen bleken bijzonder slecht op de hoogte van (het bestaan van) de ARIA 
richtlijnen. Zowel bij de huisartsen als bij de NKO-artsen was compliance met het 
stapsgewijs ARIA behandelingsalgoritme voor AR zwak, en dit zelfs bij de artsen 
die zelf eerder hadden aangegeven de ARIA richtlijnen te volgen in hun dagelijkse 
praktijk. Zowel bij de huisartsen als specialisten bleek jongere leeftijd (en minder 
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klinische ervaring) van de arts een significante en onafhankelijke predictor 
te zijn voor  goede compliance met de evidence-based aanbevelingen voor de 
behandeling van AR. 
Toekomstige onderzoeksperspectieven zullen gericht zijn op een verdere 
evaluatie van de originele en ‘gemodificeerde’ ARIA classificatie in diverse 
patiëntengroepen, de bijkomende waarde van het meten van ‘controle van AR’ bij 
behandelde patiënten en de  impact van deze  verschillende meetinstrumenten 
op het behandelingsalgoritme van AR.
Een systematische analyse van de barrières tot implementatie van de ARIA 
richtlijnen bij de verschillende groepen eindgebruikers  is noodzakelijk om het 
implementatieproces beter te begrijpen en te verbeteren.
Tot slot is meer inzicht nodig omtrent de impact van gemeenschappelijke 
besluitvorming of ‘shared decision making’ tussen artsen en patiënten op patiënt 
compliance en klinische outcomes.
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November 2012: Basic principles for pediatric care: what ENT professionals should know.  Van 
Hoecke H, Bauters T, Coppens M, Robays H, Van Hoecke E, Dhooge I. Vergadering Belgische 
Vereniging NKO, Wilrijk.
Mei 2011: Bovenste luchtwegobstructie bij het kind. Van Hoecke H, Bonte K. G-ENT Rounds, 
Zwijnaarde.
Oktober 2009: Oor- en gehoorproblemen bij Turner syndroom. Van Hoecke H. Turner 
Symposium, Gent.
Mei 2008: Desctructive otomastoiditis by MRSA from porcine origin. Van Hoecke H, Piette A, De 
Leenheer E, Verschraegen G, Dhooge I. Wetenschappelijke Vergadering Belgische Vereniging 
NKO, Brussel. 
Oktober 2008: Systemic disease mimicking otomastoiditis. Van Hoecke H, De Leenheer E, 
Dhooge I. Vergadering Nederlands-Vlaamse Werkgroep voor Pediatrische Otorhinolayngologie, 
Antwerpen. 
November 2005: Use of ARIA by Belgian ENT-Specialists. Spring Meeting, Koninklijke Belgische 
Vereniging voor NKO, Luik.
Mei 2004: Pathophysiology of pollenosis. Van Hoecke H. Dag van de Allergie, Belgische Vereniging 
Kinderlongartsen, Genval. 
Februari 2004: Expression of innate markers and cytokine profile in nasal polyps from children 
with cystic fibrosis. Van Hoecke H, Claeys S, De Belder T, Holtappels G, Gevaert P, Verhasselt 
B, Van Cauwenberge P, Bachert C. Spring Meeting, Koninklijke Belgische Vereniging voor NKO, 
Brussel.
November 2003: Innate markers in upper airway disease. Van Hoecke H, Claeys S, De Belder T, 
Holtappels G, Gevaert P, Verhasselt B, Van Cauwenberge P, Bachert C. SERIN, Week of Allergy, 
Ghent, Belgium.
POSTERPRESENTATIES
Juni 2008: Burden of allergic rhinitis amongst primary care practitioners and its impact on 
patient management. Van Hoecke H, Van Cauwenberge P, Kardos P, Waserman S, Price D. EAACI, 
Barcelona.
Juni 2006: Dissemination and implementation of the ARIA Guidelines among ENT-specialists. 
Van Hoecke H, Watelet JB, Van Cauwenberge P. EAACI, Vienna.
Februari 2005: Nasal polyps in patients with and without cystic fibrosis: differentiation by 
inflammatory mediators and macrophage phenotype heterogeneity. Claeys S, Van Hoecke H, 
Holtappels G, Van Zele T, Van Cauwenberge P, Bachert C. 3rd EAACI Davos Meeting in Basic 
Immunology in Allergy and Clinical Immunology. 
Januari 2004: Expression of innate markers and cytokine profile in upper airway disease. Claeys 
S, Van Hoecke H, De Belder T, Holtappels G, Gevaert P, Verhasselt B, Van Cauwenberge P, 
Bachert C, Wetenschapsdag Universiteit Gent.
Maart 2004: The Macrophage Mannose Receptor and Toll-likeReceptor 2 and 4 in Chronic 
Sinus Disease. Claeys S, Van Hoecke H, De Belder T, Holtappels G, Gevaert P, Verhasselt B, Van 
Cauwenberge P, Bachert C. AAAAI Annual Meeting, San Francisco.
Juni 2004: Nasal polyps in patients with versus without cystic fibrosis: a differentiation by innate 
and adaptive defence markers. Van Hoecke H, Claeys S, De Belder T, Holtappels G, Gevaert P, 
Verhasselt B, Van Cauwenberge P, Bachert C. EAACI, Amsterdam.

